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Abstract
Cancer cachexia is responsible for one third of cancer–related deaths and
contributes to the death of many others. More than 80% of cancer patients are
cachectic towards the end of life. Despite intensive research, the mechanisms of
cancer cachexia are still poorly understood. It is our hypothesis that identification of
early changes in gene expression in cachexia will lead to an improved
understanding of the mechanism that trigger this important problem in cancer
patients.
Thus, to shed light on the mechanisms involved in the major cachexia target tissues,
we investigated the entire transcriptome in muscle and fat to identify altered
expression of genes in cancer patients with and without cachexia.
Samples of rectus abdominis muscle and visceral fat were collected at surgery from
patients exhibiting 5-10% weight loss prior to surgery, compared with stable-weight
patients. Analysis of all expressed genes was carried out using next generation
sequencing (Illumina HiSeq 2500). Also, selected differentially expressed genes
were confirmed using real time RT-PCR.
In muscle, 30 genes showed highly significant changes in expression (25
downregulated and 5 upregulated: P<0.0005 - P<0.00001, FDR 0.2). Analysis of the
25 downregulated genes involved included 7 that are involved with metabolism (5 of
which are mitochondrial); 4 with signaling; 4 with ubiquitination; and 3 with
intracellular trafficking. There was marked downregulation of multiple genes involved
in glycogen metabolism which correlates with the lack of glycogen, muscle
weakness, and fatigue; characteristic of cachexia. The 5 upregulated genes include
2 involved with calcium signaling and 2 with cell matrix interactions. Expression of
genes previously thought to be important in cachexia, including several inflammatory
cytokines, was not significantly different. FBXO32, which encodes atrogin-1,
upregulated in an in vitro cachexia model, was actually downregulated. No
transcripts for the dermicidin gene, which contains the sequence that codes for the
backbone peptide of proteolysis-inducing factor, were detected. Expression of
myostatin was significantly decreased as was its receptor (ACVR2B), possibly
reflecting end organ adaptation to tumor produced myostatin.
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In visceral fat, expression of 6 genes were downregulated and 10 upregulated with
high statistical significance (P<0.001-0.0002). Several of these encode metabolic
enzymes. Of genes in fat previously implicated in cachexia, such as hormone
sensitive lipase and adipose tissue triglyceride lipase, were unchanged. In contrast,
leptin was significantly downregulated and the zinc-α-2-glycoprotein (lipid mobilizing
factor) was significantly upregulated as expected.
These studies confirmed that for a multifactorial condition, genome wide
transcriptome analysis is the method of choice to explore the disease complexity.
They explain some documented evidence in cachexia pathogenesis, highlight
ambiguous data from animal models, and reveal unexpected changes in gene
expression that underlie the pathophysiology of the cachectic state in cancer. These
results bring reliable, representable, and consistent data from the clinic and back to
the bench with more focused insights to be investigated and verified.
Keywords: Cancer cachexia, wasting, skeletal muscle, adipose tissue, RNA
sequencing, real-time RT-PCR.

viii

)Title and Abstract (in Arabic

تحديد اآلليبت الجزيئية للمرحلة األولية للهزال بدراسة تسلسل كبمل التعبيرات الجينية مه
خزعبت عضلية ودهنية مه مرضى مصببيه ببلسرطبن
الملخص

الهزال أو الدنف المصاحب للسرطان مسإول بشكل مباشر عن ثلث وفٌات السرطان ،وهو أحد
المسببات لباقً الوفٌاتٌ .عانً أكثر من  %80من مرضى السرطان من الهزال فً أٌامهم األخٌرة.
وبالرغم من األبحاث المكثفة ،فإن آلٌات الهزال لمرضى السرطان ال زالت مجهولة .لقد تم بناء هذه
الدراسة على فرضٌة أن تحدٌد متغٌرات التعبٌر الجٌنً فً المراحل األولٌة للهزال ستساهم فً تطوٌر
الفهم لآللٌات المحفزة لهذه المشكلة عند مرضى السرطان.
لذلك ،فإن الهدف من هذه األطروحة هو تسلٌط الضوء على اآللٌات المسببة للدنف فً األنسجة
المستهدفة ،عن طرٌق دراسة كامل التعبٌرات الجٌنٌة "الترانسكرٌبتوم" ( )Transcriptomeفً
األنسجة العضلٌة والدهنٌة ،بهدف تحدٌد الجٌنات المتماٌزة تعبٌرٌا لمرضى السرطان اللذٌن ٌعانون
من الهزال ،ومقارنتهم بمرضى سرطان ال ٌعانون منه.
تم جمع عٌنات من العضالت القطنٌة ( (rectus abdominisوالدهون الحشوٌة ( )visceral fatأثناء
العملٌات المجدولة للمرضى الذٌن خسروا  %10-5من أوزانهم قبل إجراء العملٌة ،وتمت مقارنتها
بآخرٌن من الذٌن بقٌت أوزانهم ثابتة .تم تحلٌل مستوى التعبٌر الجٌنً بدراسة تسلسل كافة الجٌنات
بواسطة تقنٌات عالٌة اإلنتاجٌة ( )Next generation sequencingباستخدام جهاز ( Illumina
 .)HiSeq 2500كما وتم تؤكٌد النتائج على مجموعة مختارة من الجٌنات باستخدام تفاعل البولٌمٌراز
المتسلسل اللحظً ).(Real-time RT-PCR
أظهرت نتائج الدراسة فً األنسجة العضلٌة تغٌرات هامة للغاٌة فً التعبٌرات ل  30جٌن ( 25منها
مثبط ،بٌنما  5منها مفعل :القٌمة االحتمالٌة ) .)FDR 0.2, P˂0.0005-0.00001تحلٌل ال  25جٌن
المثبط أظهر أن 7 :منها ٌساهم فً عملٌات األٌض ( 5( )metabolismمن هذه السبعة عملٌات أٌض
فً المٌتوكوندرٌا) 4 ،فً تؤشٌر الخلٌة ( 4 ،)signalingفً عملٌات التحلٌل البروتٌنً
( ،)ubiquitinationو  3فً حركة سٌر البروتٌنات داخل الخالٌا ( .)intracellular traffickingكما
أظهرت الدراسة تثبٌطا واضحا للعدٌد من الجٌنات المشاركة بؤٌض الجالٌكوجٌن ،والتً بدورها تفسر
سبب نقص الجالٌكوجٌن بالعضالت وما ٌصاحبه من ضعف وإنهاك ،وهً أعراض أساسٌة مصاحبة
للهزال .فً المقابل ،فإن تحلٌل ال  5جٌنات المفعلة أظهر أن 2 :منها ٌساهم فً تؤشٌر الكالسٌوم ،و 2
بتفاعالت نسٌج الخلٌة الخارجً.
من ناحٌة أخرى ،فإن بعض التعبٌرات الجٌنٌة للسٌتوكٌنات المسببة لاللتهاب – والتً كان ٌُعتقد
حسب دراسات سابقة أن لها تؤثٌرا فً الهزال – لم تظهر أي تغٌٌر ٌُذكر .كما أن الجٌن المالحظ
تفعٌله بالعدٌد من الدراسات المختبرٌة ( )in vitroوهو ( )FBXO32; atrogin-1وجد مثبطا .كما لم
ٌتم الكشف عن أي تعبٌر جٌنً لجٌن ال ( .)dermicidinكما أن التعبٌر الجٌنً لجٌن ال ()myostatin
باإلضافة للمستقبل الذي ٌعمل علٌه ( ،)ACVR2Bوجدا مثبطٌن على غٌر المتوقع ،مما قد ٌعكس
احتمالٌة وجود تكٌف من األنسجة العضلٌة لتؤثٌر ال ( )myostatinالمنتج من الورم السرطانً.
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أما بخصوص النسٌج الدهنً الحشوي  ،فقد أظهرت نتائج الدراسة تغٌرات هامة للغاٌة فً التعبٌرات
ل  16جٌن ( 6منها مثبط ،بٌنما  10منها مفعل :القٌمة االحتمالٌة ) .)P˂0.001-0.0002تحلٌل هذه
الجٌنات أظهر مشاركتها اإلنزٌمٌة فً العملٌات األٌضٌة .مقارنة نتائج هذه الدراسة بدراسات الهزال
السابقة أظهر عدم ظهور أي تغٌٌر على إنزٌمات اللٌباسٌس ( hormone sensitive lipase and
 .)adipose triglyceride lipaseبالمقابل فإن هرمون اللٌبتٌن ( )leptinكان مثبطا ،بٌنما بروتٌن
( )zinc-α-2-glycoproteinكان مفعال بشكل واضح ،كما هو متوقع.
أثبتت نتائج هذه الدراسات أن الهزال متعدد األسباب .كما أظهرت أن الطرٌقة المثلى لدراسة
واستكشاف تعقٌدات األمراض هً عن طرٌق دراسة تسلسل كامل التعبٌرات الجٌنٌة .هذه الدراسة
شرحت بعض الدالئل الموثقة بدراسات سابقة ،وألقت الضوء على بعض الغموض فً نتائج الدراسات
على حٌوانات التجارب .كما وأظهرت نتائج غٌر متوقعة لتطور مرض الهزال لمرضى السرطان.
هذه النتائج هً بمثابة نموذج ٌمكن االعتماد علٌه نظرا لثبات بٌاناته وتناسقها ،والتً تعكس الصورة
السرٌرٌة لهإالء المرضى بشكل أدق ،لٌتم بحثها و التحقق منها بشكل أفضل مخبرٌا.

مفاهيم البحث الرئيسية :الهزال لمرضى السرطان  ،الدنف  ،العضالت الهٌكلٌة  ،النسٌج الدهنً ،
تسلسل الرنا ( ، )RNAتفاعل البولٌمٌراز المتسلسل اللحظً ).(Real-time RT-PCR
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Chapter 1: Introduction
1.1

Overview
1.1.1

History, Etymology, and Definition

Cachexia is known for centuries. The earliest link of cachexia to chronicity of ailment
dates back 2400 years to the classical Greece and the school of medicine of
Hippocrates [1]. It was described by Hippocrates as:
"The flesh is consumed and becomes water,... the abdomen fills with
water, the feet and legs swell, the shoulders, clavicles, chest, and
thighs melt away... The illness is fatal." [1].
Hippocrates, 460-377 BC
The first time cachexia was used to describe involuntary weight loss in the context of
chronic illness is unknown. However, "cardiac" cachexia was first documented by
Charles Mauriac, a French physician, back in 1860 when it was described as a:
“commonly observed secondary phenomenon in patients affected with
diseases of the heart... a peculiar state of cachexia which is...
conventionally designated cardiac cachexia” [2].
Cachexia was also acknowledged by Herta Müller, a 2009 Nobel Prize winner for
literature, who wrote in her novel "Atemschaukel", which was translated to English
"The Hunger Angel"[3] as:
"…once the flesh has disappeared from the body, carrying the bones
becomes a burden; it draws you down into the earth”
Müller, 2009
Cachexia is a term originating from the Greek " kakós" and "hexis"; meaning "bad
condition or appearance" [2]. Cachexia or the "Wasting Syndrome" is evident in
many diseases and conditions such as: cancer, chronic heart failure, chronic kidney
disease, chronic obstructive pulmonary disease, cystic fibrosis, rheumatoid arthritis,
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multiple sclerosis, Alzheimer's disease, infectious diseases such as acquired
immune deficiency syndrome, and tuberculosis, familial amyloid polyneuropathy,
gadolinium poisoning, mercury poisoning, hormonal deficiency, and many other
chronic illnesses [4].
Definition of cancer cachexia has changed several times in the last few years
despite the slow-paced understanding of its etiopathogenesis. Up till 2008, cachexia
had no operational definition that can adequately and reasonably validate it in terms
of its existence and pathological processes. This had hindered, for years, properly
designed and conducted clinical and basic sciences research. Thus, many efforts
were taken to reach a consensus definition for the syndrome [5-7]. However, many
cachexia definitions share two main themes; weight loss and inflammation [8] with
many other associated symptoms: anorexia, fatigue, insulin resistance, and
increased muscle protein breakdown. Cachexia is different from starvation, agerelated loss of muscle mass, primary depression,malabsorption, hyperthyroidism,
and all other metabolic diseases and conditions. The latest definition of cancer
cachexia states that it is a:
"multifactorial syndrome characterized by an ongoing loss of skeletal
muscle mass (with or without loss of fat mass) that cannot be fully
reversed by conventional nutritional support and leads to progressive
functional impairment" [7].
None of the definitions of cachexia suggested so far are final. However, the most
recent systemic review indicated that in clinical practice, muscle wasting is assumed
in relation to weight loss in cancer patients, provided the patients have no fluid
retention or a large tumor mass [9]. Keeping in mind that this thesis wishes to
identify mechanisms of early cachexia, we operationally defined early cancer
cachexia to guide our patients' selection as: cancer patients with documented or
self-reported weight loss of 5-10% of total body weight in the past 6 months.
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1.1.2

Epidemiology

Cachexia is one of the most serious and highly prevalent, however, underestimated
and under-diagnosed syndrome. Cachexia is a major unmet health challenge.
Despite of the scarce resources about the extent of cachexia, it is believed that the
overall prevalence of cachexia is growing worldwide. It is estimated to constitute
around 1% of the total population in the developed world [4] and a possibly
comparable number in the rest of the world. Cachexia prevalence is generally high
and variable amongst different pathological conditions. For example, it ranges from
5% to 15% in congestive heart failure and chronic obstructive pulmonary disease
[4], while it reaches 60% to 80% in advanced cancer [4, 10]. Data about prevalence
of cachexia in the cancer patients varies considerably depending on the cancer type
and stage, and also differed depending on the criteria used for its diagnosis [11].
The incidence of cachexia among cancer patients is very high, but it is dependent
on tumor type and the stage of the disease. For example, the incidence in patients
with gastric or pancreatic cancer is more than 80%, while it is around 50% in lung,
prostate or colon cancer patients, and approximately 40% of patients with breast
cancer or some leukemias [12, 13]. However, tumor type was not found to have a
direct correlation to extent of cachexia. For example, some lymphomas can weigh
several kilograms and cause no cachexia, while pancreatic tumors as small as ˂2
cm3and weighing one or two grams may cause profound cachexia.
1.1.3

Classification of Cancer Cachexia

Cancer cachexia is classified to three clinical stages; precachexia, cachexia, and
refractory cachexia. Each of these stages has distinguishing clinical features agreed
on via consensus panel of experts in the field [7]. Stages are distinguished primarily
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on body mass index (BMI) as an indication of body energy stores in addition to the
general overall condition. In precachexia, patients demonstrate substantial
involuntary weight loss (i.e. ≤5%) in addition to early clinical and metabolic signs
(e.g. anorexia). In cachexia stage, weight loss exceeds 5% of stable body weight
over the past 6 months, or a body mass index (BMI) less than 20 kg/m² and ongoing
weight loss of more than 2%. On the other hand, refractory cachexia is a stage
reached at the very advanced cancer when patients are clinically "terminal" (life
expectancy of less than 3 months) and it is distinguished by the presence of rapidly
progressive cancer unresponsive to antineoplastic therapy, active catabolism,
and/or the presence of factors that render active management of weight-loss no
longer possible or appropriate [7]. In refractory cachexia, patients also demonstrate
low performance status. While there are three identifiable stages of cachexia,
patients will not necessarily exhibit the all three phases.
The risk of developing cachexia, the stage of cachexia, and the rate of progression
of cachexia varies depending on the cancer type and stage, the presence of
systemic inflammation, food intake, and response to anticancer therapy [7]. Cancer
cachexia is further complicated by anticancer treatment (e.g. chemotherapy and
radiotherapy) which themselves induce anorexia, and malabsorption that exacerbate
the effects of the cancer itself. Also, obstruction of the gastrointestinal tract by the
tumor will also cause anorexia, nausea and vomiting and reduction in digestion and
absorption. All these can even further complicate cachexia.
1.1.4

Significance of Weight Loss in Cancer Patients

Cachexia is known since ancient Greek times as a label for 'signummaliominis'
(indicating end stage and poor quality of life) in various, mostly fatal, diseases.
Weight loss (the most prominent feature of cachexia) is a positive risk factor for
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death for cancer patients. Its presence is always associated with high-mortality and
diminishing quality of life [14]. Mortality rates of patients with cachexia are highest in
cancer patients. More than 30% of cancer patients die due to cachexia and it
reaches around 80% in some cancer cases, and more than 50% of patients with
cancer die with cachexia being present [4, 15]. In cancer patients, death normally
happens when weight loss exceeds 30% of total body weight [16]. While in
starvation, weight loss exceeding 40% of body weight usually leads to death [17].
Considering cancer as a disease of old age, weight loss is a well-documented factor
for a significant increasing mortality among elderly patients whether they are
discharged home [18] or residing at nursing homes [19].
On the other hand, weight loss as a primary measure of cachexia is important due to
unavailability of data on body composition. Attainment and accurate measurement
of baseline data on body composition is clinically hard to perform and isn’t yet
considered as an acceptable clinical standard. Also, changes in body weight can be
accurately and easily assessed and followed up.
On the other hand, however, weight loss is still debated as a mono measure of
diagnosing the cachectic state. Weight loss alone cannot fully explain the associated
physical symptoms that accompany cachexia. Nevertheless, the preponderance of
evidence is in favor for the importance of weight loss as the main clinical
manifestation of cachexia and that it is highly predictive of morbidity and mortality in
cachectic patients.
1.1.5

Diagnosing Cancer Cachexia

Cancer cachexia is rarely screened and always under-diagnosed due to its
complexity in nature, and the lack of generally acceptable definition or diagnostic
guidelines. However, clinically, multiple definitions of cachexia been utilized to
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examine the presence or absence of cachectic state in cancer patients. Fox et.al.
(2009) conducted a study to estimate the cachectic state amongst cancer patients
based on four different cachexia definitions; ICD-9 diagnostic code of 799.4
(cachexia), ICD-9 diagnosis of cachexia, anorexia, abnormal weight loss, or feeding
difficulties, prescription for megestrol acetate, oxandrolone, somatropin, or
dronabinol, and ≥5% weight loss in patients with different malignancies [11]. The
eye opening findings of the study was the huge discrepancy in cachexia prevalence
in cancer patients under each of these categories depending upon the employed
definition. For example, in breast cancer patients, prevalence of cachexia was 8.8%,
13.9%, 20.5%, and 31.3% for the four categories respectively. That is around 3.6
fold increase between the first and the forth definition [11]. Thus, unless we
operationally define cachexia based on more educated insights about its
etiopathogenicity, developing a specific/sensitive/accurate diagnostic measure/s is
an unattainable goal.
The two gold standard measures for diagnosing cachexia should be computed
tomography and the magnetic resonance imaging. The two measures are expensive
and not used routinely. However, since cachexia is a time-dependent process, it is
highly unlikely that these methods could be routinely applied to the clinical diagnosis
of cachexia, because of the absence of a baseline comparison.
1.2

Management of Cancer Cachexia

Patients with cancer cachexia have limited treatment options. Current available
options basically treat symptoms of cachexia, such as anorexia, and not cachexia
itself.
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1.2.1

Nutritional Treatment

Many attempts were made to reverse cachexia via nutritional management (i.e.
enteral, parenteral, and nutritional supplements). However, none of these achieve
improvement in lean body mass [20]. A meta-analysis evaluating the effect of
enteral nutritional supplementation failed to demonstrate any survival benefit in
cancer patients but was able to decrease some post operatively risks and to
reduces the overall hospital stay [21]. Furthermore, parenteral nutrition was found to
be associated with net negative consequences in cancer patients [22] and does not
alone affect the overall survival or quality of life [23].
Supplements tested in cachexia include minerals, vitamins, omega-3fats, proteinenriched nutrition, and antioxidants [24]. Omega-3fats, have been extensively
investigated in cachexia and found to have a minimal positive effect on weight,
appetite and quality of life in advanced cancer patients[25]. Taken together, the
complex mix of different mediators involved in the pathophysiology of cancer
cachexia renders nutritional intervention a strategy unlikely to succeed completely,
although of course overall nutrition needs to be adequate [26].
1.2.2

Non-Pharmacological Treatments

Non-pharmacological

treatments

include

different

measures

such

as:

counseling/education, psychotherapeutic interventions, and physical training (or
therapeutic exercise). Psychotherapeutic interventions such as the creation of a
pleasant environment for meals, encouraging patients to eat with adequate attention
to the food preferences of the patient show some promise [27]. The
pathophysiologic changes in cachexia include: insulin resistance, a decrease in the
rate of protein synthesis, and a systemic inflammatory response. Physical exercise
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exerts beneficial documented evidence in increasing insulin sensitivity, protein
synthesis rate, and suppression of the inflammatory response [28]. However, most
research has not found a conclusive evidence for its effectiveness [29].
1.2.3

Drug Therapy

Many drugs have undergone clinical trials that attempt to reverse cachexia.
Thalidomide was used in clinical trial with advanced pancreatic cancer patients and
found to be well tolerated and effective at attenuating loss of weight, arm muscle
mass and physical function [30]. Nevertheless, no study has provided information on
long-term weight gain in a larger trial, or in end stage disease, or in advanced
cachexia. On the other hand, cannabis extract of tetrahydrocannabinol did not result
in any differences in appetite or quality of life in patients with cancer cachexia [31].
While cannabinoids may increase appetite in selected patients, there is not enough
evidence to support their use. In a systematic review, megestrol; an appetite
stimulant, was found to improve appetite and weight gain in cancer cachexia [32],
but it increased mortality without a significant increase of body-weight [33].
Short-term treatment with steroids improved appetite and activity in terminally ill
cancer patients [34] while in longer treatment duration did not result in weight gain
[35-37]. On the other hand, the long-term use of non-steroidal anti-inflammatory
drugs showed reduction in the resting energy expenditure and preservation of total
body fat, while lean body mass was not influenced [38]. Finally, prokinetics did not
improve the nutritional status of patients with cachexia [39].

1.2.4

Multimodal Therapy

Considering the multi-factorial nature of cancer cachexia pathogenesis, treating the
underlying neoplasm that trigger its initiation is the treatment gold standard. The
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best way to treat cancer cachexia is to cure the cancer. Anticancer treatment will
not, per se, alleviate cachexia through targeting the metabolic changes and the
other documented etiologies. Metabolic changes such as reduced energy intake, in
turn, can be supported by targeting more than one of the contributing factors despite
the absence of properly tested combination therapy in cancer cachexia. For
example,

combination

of

megestrol

with

tetrahydrocannabinol

[40]

and

eicosapentaenoic acid [41] did not provide any benefits compared with megestrol
alone but was more effective when combined with ibuprofen [42]. Another large
study comparing medroxyprogesterone, megestrol acetate, eicosapentaenoic acid,
L-carnitine and thalidomide found that the combination of all drugs was superior to
any of the other treatment arms with single drug treatment leading to increased lean
body mass, decreased resting energy expenditure and improved appetite [43].
Therefore, multimodal therapy for cancer cachexia should be presented as opposed
to monotherapy. Also, early palliative care should be initiated to manage the
individual symptoms associated with refractory cachexia and that research in this
domain should be promoted.
1.3

Prevention of Cachexia

Many intervention been tested for likelihood to prevent cachexia. Relaxation training
with deep abdominal breathing, autosuggestion, controlled tension and relaxation of
body parts and voluntary image control are some of these tested interventions.
Relaxation, for example, was found to have positive effects on body weight and
performance status in a group of cancer patients [44]. However, this study did not
separate the cachectic from the non-cachectic patients and its results have not been
reproduced.
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1.4

Etiopathogenesis of Cancer Cachexia

Cancer cachexia is a multifactorial, so far, irreversible syndrome. Symptoms of
cachexia involve loss of muscle, with or without fat, frequently associated with
anorexia, inflammation and insulin resistance. Cachexia has its unique pathology
that sets it unique compared to starvation. Cachexia has a preferential muscle loss
for an equivalent amount of weight loss compared to starvation [45]. In cachexia, the
visceral protein compartments are preserved [46]. Muscle loss occurs predominantly
in skeletal muscles rather than visceral muscle [47]. Even more interestingly, the
volume of the liver and other viscera may increase in cancer cachexia as opposed
to the decrease observed in starvation [45]. However, the mechanisms of that
increase are unknown. As in sepsis, patients with advanced cancer have an
elevated rate of whole-body tracer flux and depressed non-export (structural)
hepatic protein synthesis rate [46]. This brings cancer cachexia in proximity to
sepsis. Yet, cancer cachexia develops slowly and is not associated with the
tremendous increase in basal metabolism due to the surge of different inflammatory
cytokines in sepsis [48].
On the other hand, patients with anorexia have the majority of weight lost from fat
compared to lung cancer patients, who lose weight from both, total body fat and
skeletal muscle protein mass [49]. In summary, the changes in body composition
seen in cachexia resemble those found in infection and injury rather than those in
starvation. During prolonged starvation, ketone bodies produced by fat metabolism
in the liver replace glucose as an energy source for the brain, thus preventing loss of
muscle through glucogenesis from amino acids. However in cachexia, this does not
occur, probably because the energy demands on the host are sufficiently high to
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prevent the buildup of acetyl CoA in the liver and its subsequent conversion to
acetoacetate and -hydroxybutyrate [50].
1.4.1

Energy Balance and Energy Expenditure

Body mass is controlled by the balance between the amount of energy intake and
energy expenditure. Therefore, a major contributor to the cachexia can be attributed
to the increased energy expenditure. Since the majority of energy intake is spent on
the resting energy expenditure (REE), determining the level of REE in cancer patient
can be the starting point to uncover the etiology of cancer cachexia. The rate of REE
in cancer patients is strongly determined by the type of tumor. For example, patients
with lung [38] and pancreatic [51] cancer have an elevated REE, while gastric and
colon cancer patients have no increase in REE [38]. This can, at least in part,
explain the higher mortality rates of lung and pancreatic cancer patients. In
pancreatic cancer patients, for example, the increase in REE is proportional with the
increase in the acute phase response (APR) [51]. APR proteins have long been
known to be a measure of underlying tissue injury, infection, or inflammation. In
APR, the liver redirects protein synthesis from albumin to acute phase proteins
(APP), such as C-reactive protein (CRP), fibrinogen, serum amyloid A, α-2macroglobulin, and andα1-antitrypsin. Elevated levels of APP, in turn, are correlated
with shorter survival in pancreatic cancer patients [51]. The link between the
development of an APR and the rate of loss of body mass is also established in lung
and gastrointestinal cancers [52]. Furthermore, serum levels of interleukin6 (IL-6)
was found to correlate with level of CRP in patients with non-small cell lung [53].
Despite of the above evidence, pancreatic cancer patients were found to have
reduced total energy expenditure (TEE) due to a reduction in their physical activity
level (PAL) [54].
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Recently, research on the link between brown adipose tissue (BAT) and cachexia
has been brought to the surface. The history of this link goes back to the study
which examined autopsy samples of peri-adrenal tissue that showed BAT to be
present in 80% of cachectic cancer patients, compared with only 13% of age
matched controls [55]. BAT has a well-established role in controlling body
thermostasis and energy balance despite its scarcity in adult

humans.

Thermogenesis in BAT and its possible link to cachexia was studied in the context of
REE. Thethermogenic effect of BAT and skeletal muscle is probably due to the
function of uncoupling proteins (UCP). UCPs are mitochondrial inner membrane
proteins that can dissipate the proton gradient before it can be used to provide the
energy for oxidative phosphorylation by decreasing the level of coupling of
respiration to ADP phosphorylation [56]. There are five types of UCPs: UCP1 found
only in BAT, UCP2 found in most tissues, UCP3 found only in BAT and skeletal
muscle, UCP4 found in brain tissue, and UCP5 found in brain, testis and others
[57].Of these five, UCP1 is considered to be most important, although UCP3 also
plays an important role in energy balance and lipid metabolism. In a murine model of
cachexia, mRNA expression levels of UCP1, but not UCP2 and 3, in BAT was
significantly elevated over controls [58]. However, expression of UCP2 and 3 were
significantly increased in skeletal muscle [58]. In cachectic cancer patients, UCP3
expression level in rectus abdominis muscle was five times higher than controls [59].
This increased expression level might be the mechanism by which REE is increased
in skeletal muscles of cachectic patients. Therefore, the increase in REE is not
merely the main cause of cachexia.
Another way of which energy balance can be a cause of cachexia is the "futile
energy cycle". This futile cycle, a phenomenon termed "Warburg effect", is used by
most cancer cells to generate ATP. Warburg effect utilized glycolysis followed by

13

lactic acid fermentation in the cytosol, rather than by a comparatively low rate of
glycolysis followed by oxidation of pyruvate in mitochondria in most normal cells as
the principal method to generate energy [60]. Malignant cells typically have
glycolytic rates up to 200 times higher than those of their normal tissues of origin
even with the presence of oxygen.Several reasons are attributed to this
phenomenon. However, regardless of the possible reasons, the Warburg effect
results in a net yield of two ATP molecules as opposed to oxidative phosphorylation
that yields a total of approximately 30-32 ATP molecules. Thus, the conversion of
glucose into lactic acid is an energy-inefficient process, which means that growth of
tumors requires 40 times more glucose than if it was fully oxidized through the
tricarboxylic acid cycle. In order for the lactate to be recycled by liver, a net of 4 ATP
molecules are needed. Hence, the Warburg effect results in a negative balance of 2
ATP molecules; which is another energy inefficient process [61]. In weight losing
colorectal cancer patients, the rates of glucose production and recycling were
significantly higher than that in controls [62]. This complete futile process account for
an approximately additional loss of energy in cancer patients of 300 kcal/day [63].
Regardless of these evidence, fast progressing cachexia such that evident in
pancreatic cancer patients, cannot be attributed merely to this futile cycle.
Pancreatic tumors are relatively small in size and require a long period to develop
which is disproportional to the degree and intensity of weight loss observed in these
patients.
1.4.2

Anorexia and Cachexia

Anorexia, or loss of appetite, is one of the symptoms of cachexia and is common in
cancer patients. Cancer patients report early satiety. This may be the result of many
factors such as: the mechanical obstruction of the gastrointestinal tract which may
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hinder the passage of food, the functional abnormalities of the gastrointestinal
mucosa resulting in malabsorption, or chemical triggers that suppresses appetite
center in the brain. If anorexia, regardless of the cause, is the main reason of weight
loss in cancer patients, one should expect a direct correlation between reduced food
intake and the degree of weight loss. Surprisingly, the opposite is true! A large study
of 297 cancer patients found that weight loss could not be accounted for by a
diminished dietary intake, since the absolute amounts of energy intake did not differ,
and the intake per kilogram of body weight was actually higher in the weight-losing
patients compared with the weight-stable patients [64].
Also, if anorexia is a direct and essential etiology for cachexia, nutritional
supplementation to compensate for the deficiency in caloric intake would be
expected to promptly reverse cachectic state. However, clinical trials showed that
the wasting process in cancer patients cannot be reversed by all means of
nutritional supplementation such as dietary counseling [65], total parenteral nutrition
[66], or appetite stimulants such as cryoheptadine [67], or dronabinol. In addition,
weight gain due to the total parenteral nutrition was transient and translated into an
increase in fat and water rather than lean body mass [66]. This effect is not only
limited to weight loss in cancer patients, but was also observed in patients with
human immunodeficiency virus [68], and sepsis [69]. However, nutritional
supplementation in pancreatic cancer patients has some survival advantage despite
of its inability to reverse body weight loss [70]. These results show that anorexia is
an important symptom of cachexia but is not the sole suspect for the loss of body
mass.
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1.4.3

Cachexia as a Catabolic State

In the absence of stimuli, adult muscle mass remains constant with relatively equal
rates of protein synthesis and degradation. However, an imbalance via depression
in protein synthesis, an increase in protein degradation, or a combination of both
should occur for cachexia to develop; research evidence is available for all the
possibilities. For example, one study suggested that cachexia is primarily a result of
alterations in protein synthesis rather than protein degradation [71]. Other study
suggested the high protein turnover rates in patients with hepatocellular carcinoma
to be the result of an elevated rate of protein breakdown, with oxidation of the
released amino acids [72]. However, the majority of studies suggest that both
processes are occurring simultaneously. There are three major proteolytic pathways
responsible for the degradation of proteins in skeletal muscle; the lysosomal system,
the calcium-activated system, and the ubiquitin-proteasome pathway [73].
The lysosomal system includes the acid optimal cysteine proteases cathepsins B, H,
and L as well as the aspartate protease cathepsin D. This system is mainly
responsible for the degradation of extracellular proteins, cell receptors, endocytosed
proteins, and phagocytosed bacteria rather than influencing the normal turnover of
cytosolic proteins [74, 75]. This degradation system is accelerated by glucagon in
the liver and the lack of insulin or essential amino acids [76]. The second
degradation system is the ATP-independent, calcium-activated, cytosolic cysteine
proteases system that are activated by an increase in cytosolic calcium which is
mainly involved in tissue injury, necrosis, and autolysis. These proteases include
calpains I and II [77-79]. The third degradation system is the ATP- and ubiquitindependent proteasome pathway. The function of the ubiquitin-proteasome pathway
is to degrade defective protein products produced from errors in translation or from
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oxidative stress [80, 81]. It works in harmony with the calpain system to disassemble
and degrade muscle myofilaments [82]. The defective protein is targeted by the
addition of multiple ubiquitin molecules and the subsequent recognition and
degradation by the 26S proteasome [83]. Polyubiquitination of the protein is a
process that not only tag proteins for degradation, but also ensures the specificity of
the process that is normally handled by the proteasome. For polyubiquitination to
occur, ubiquitin is activated by an activating enzyme (E1) in two steps. Firstly, an
intermediate is formed by ATP hydrolysis connecting adenosine monophosphate
(AMP) with the carboxy-terminal carboxyl group of glycine in ubiquitin. Secondly, a
thioester linkage with a cysteine residue in E is formed [81]. Then, the ubiquitin
carrier protein (E2) accepts this ubiquitin to its active site at a cysteine residue. This
is followed by E2 carrier protein recognizing the ubiquitin protein ligase (E3). Then,
the E3 ligase transfers ubiquitin from the E2 thioester intermediate either to a
specific ubiquitin binding site or to an isopeptide linkage with some degree of
substrate specificity [73]. After multiple rounds of E3, ubiquitin ligation creates a
polyubiquitin chain on the target protein. Once the proteins are marked with a
polyubiquitin chain, they are degraded into oligopeptides (peptides containing six to
nine amino acid residues) by the 26S proteasome [84]. These are then degraded by
the giant protease tripeptidyl peptidase II (TPPII) and various aminopeptidases.
TPPII cleaves peptides generated by the proteasome into tripeptides [85]. In normal
situations, this process is not rate-limiting for proteolysis. However, it is important
because the accumulation of abnormal peptides may be injurious to the cell.
1.4.3.1 Ubiquitin Proteasome Pathway System and Cachexia
The ubiquitin proteasome pathway system is responsible for the majority of skeletal
muscle protein catabolism [73] and has been extensively reviewed [86]. This
pathway is activated in catabolic states resulting in muscle atrophy. Thus, it more
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likely accounts for the advanced proteolysis seen in wasting conditions such as
fasting, sepsis, metabolic acidosis, acute diabetes, weightlessness and cancer
cachexia [87].
In vitro studies of atrophying muscles have demonstrated no involvement of the
lysosomal proteases or calcium-activated proteases systems. Yet, inhibiting ATP
production decreased the rate of proteolysis to that of control muscles indicating that
the ATP-dependent ubiquitin proteasome pathway is primarily responsible for
skeletal muscle degradation [88, 89].
In mice bearing the cachexia-inducing MAC16 tumor, both proteasome proteolytic
activity and TPPII activity increase in parallel with weight loss reaching a maximum
at 16% weight loss, after which there was a progressive decrease in activity for both
proteases with increasing weight loss [90]. In other animal models of cancer
cachexia and in cancer patients, the ubiquitin proteasome pathway found to play the
predominant role in the degradation of myofibrillar proteins especially in patients
with ˃10% weight loss [91]. In yoshida ascites hepatoma (YAH)-bearing rats,
removal of calcium or blocking the calcium-dependent proteolytic system did not
inhibit muscle protein degradation, while inhibition of the lysosomal function reduced
proteolysis by 12% in muscles [92].

Nevertheless, when ATP production was

inhibited, proteolysis in muscles was similar to that of controls [92]. The same study
showed a significant increase in ubiquitin mRNA (590-880%), the level of ubiquitinconjugated proteins, and of mRNA for multiple proteosome subunits (100-215%)
[92]. These findings indicate that the ubiquitin pathway is the predominant
degradation system in animal models of cachexia.
Normally, the majority of cellular proteins are degraded by the proteasome pathway.
However, for patients with a low weight loss (i.e. 2.9%), muscle biopsies showed no
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change in components of the ubiquitin proteasome pathway, but rather an increase
in the expression of cathepsin B mRNA [93]. Another study also showed an increase
in lysosomal activity, as measured by cathepsin D and acid phosphatase, in skeletal
muscle of cancer patients which in part of the subjects appears to correlate with
weight loss [94]. Myofibrillar protein constitutes half of the total muscle protein and is
lost at a faster rate than other proteins during atrophy. In a murine model of
cachexia, myosin heavy chain was selectively targeted by the ubiquitin proteasome
pathway in the cachectic state, while other core myofibrillar proteins including
troponin T, tropomyosin (α- and β-forms), and α-sarcomeric actin remain unchanged
[95].
With increasing evidence of the involvement of the ubiquitin proteasome pathway in
regulating the skeletal muscle degradation in cancer cachexia, it is important to
understand its triggers and how it gets activated.
1.4.4

Tumor and Host Factors Influencing Muscle Mass in Cachexia
1.4.4.1 Tumor Necrosis Factor-α

Animal studies provide a considerable evidence for the importance of tumor
necrosis factor-α (TNF-α) in triggering muscle wasting in cancer cachexia.
Transplantation of Chinese hamster ovary cells that is transfected with the human
TNF-α gene in mice resulted in a syndrome resembling cachexia, with progressive
wasting, anorexia, and early death [96]. Also, genetically engineered mice deficient
in the TNF-α receptor protein type I which are transplanted with Lewis lung
carcinoma showed reduced wasting of skeletal muscle compared with wild-type
mice, despite the equal levels of serum TNF-α in both groups [97]. In addition, acute
treatment of rats with recombinant TNF-α enhanced protein degradation and
decreased protein synthesis in soleus muscle [98]. The mechanism of which TNF-α-
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induced muscle wasting has also been studied. TNF-α has been shown to induce
oxidative stress and nitric oxide synthase in murine skeletal muscle causing
decrease in body weight, muscle wasting, and skeletal muscle molecular
abnormalities, all of which are prevented by treatment with antioxidants or nitric
oxide synthase inhibitors [99].
In humans, recombinant human TNF-α administered to patients as part of an
antineoplastic regimen, caused a dose-related metabolic effects of enhanced energy
expenditure with elevated CO2 production, increased protein catabolism, peripheral
efflux of amino acids, decreased total arterial amino acid levels, an increase in
plasma cortisol level, elevated serum triglycerides, as well as increased glycerol and
free fatty acid turnover [100]. These metabolic effects (both; muscle and fat)
resemble those seen in refractory cancer cachexia, although its role in the human
condition is questionable.
1.4.4.2 Interleukin-6
IL-6 decreased the half-life of long-lived proteins in in vitro studies in murine
myotubes by increasing the activity of the proteasome, together with cathepsins B
and L [101]. However, most research on IL-6 in cancer cachexia is in in vivo models
with variable results. Inhibition of IL-6 secretion and binding to its cellular receptor by
suramin, reduces the catabolism seen in colon-26 (C26( adenocarcinoma-bearing
mice [102]. Also, muscle atrophy is seen in IL-6 transgenic mice that overexpress IL6, which is completely reversed by IL-6 receptor antibody and is associated with
increased mRNA levels for cathepsins (B and L) and ubiquitins [103]. On the other
hand, wasting was not induced by administration of recombinant IL-6 in mice, even
with repeated administration [104]. In contrast, using an ApcMin/+ mouse, an
established model of colorectal cancer and cachexia, to determine the role of
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circulating IL-6 on the development of cachexia. Mice with the highest circulating IL6 levels had the most severe cachectic symptoms [105]. Similarly, administration of
IL-6 to rats acutely activated both total and myofibrillar protein degradation in muscle
[106]. Unlike TNF-α, however, IL-6 produced no change in the expression of
ubiquitin when administered intravenously to rats [107]. Thus, further research is
needed to verify the role of IL-6 in cancer cachexia.
1.4.4.3 Interleukin-1ß
The data for the role of interleukin-1ß (IL-1ß) in cancer cachexia is controversial.
Alike TNF-α, IL-1 can induce body weight loss and anorexia in mice [108]. Also,
chronic treatment of rats with recombinant IL-1ß resulted in redistribution in body
protein and a significant decrease in muscle protein content associated with a
coordinated decrease in muscle mRNA levels of myofibrillar proteins [109].
1.4.4.4 Interferon-γ
In mice bearing Lewis lung tumors, administration of anti-interferon-γ (IFN-γ)
monoclonal antibodies markedly decreased cachexia [110]. Also, nude mice
inoculated with CHO-IFN-γ cells exhibited severe cachexia that was prevented in
mice given anti-INF-γ monoclonal antibodies prior to injection of tumor cells [110].
Expression of ubiquitin gene in rat skeletal muscle was also up-regulated by IFN-γ in
a similar manner to TNF-α and IL-1ß [107].
Studies have investigated individual key players in triggering the main degradation
pathway in cancer cachexia (i.e. ubiquitin proteasome pathway), but also it looked at
the effect of combining these elements together. For example, myotubes and mouse
muscles treated with TNF-α together with IFN-γ resulted in a significant reduction in
myosin expression through an RNA-dependent mechanism which indicates that
these two cytokines are complementary in the progression of muscle degradation
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[95]. Nevertheless, murine colon-26 adenocarcinoma treated with antibodies to IL-6,
but not TNF-α or IFN-γ, attenuated the development of weight loss and other key
parameters of cachexia [111]. However, serum levels of cytokines, including IFN-γ,
TNF-α, IL-1ß, and IL-6 are poorly correlated, so far, with weight loss and cachexia in
cancer patients [112].
1.5

Gene Expression Profiling as a mean of Understanding Pathology

The transcriptome is the total set of RNA molecules (i.e. transcripts) and their
quantity in a given cell, tissue, organ, or a whole organism [113]. Unlike genome,
which is relatively static, transcriptome varies from place to place and time to time in
response

to

developmental,

environmental,

or

pathological

stimuli

[114].

Understanding the transcriptome is essential for interpreting the functional elements
of the genome and revealing the molecular constituents of cells and tissues, and
also for understanding development and disease [113, 114]. One way for the
characterization of a physiologic and/or pathological condition in a given tissue can
be determined by its differentially active genes [114]. "Gene expression profiling" is
a molecular biology technique that measures and reflects on the activity of many to
all of the expressed genes between two (pairwise comparison) or more sample
types (i.e. case/s vs. control/s) at a given time.
After passing the era of "Human Genome Project", it was necessary to bridge the
gap between gene sequence and function. A novel technology called "DNA
Microarray" was introduced which enabled simultaneous measurement or a whole
transcriptome analysis of the activity of virtually all genes in the genome. Whole
transcriptome analysis can be done in two main methods; the hybridization- or the
sequence-based

approaches.

The

hybridization-based

approach

utilizes

differentially fluorescently labeled cDNA molecules from the desired sample versus
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its control. The mixed equal quantities of cDNA are then incubated on a microarray
plats that contain spots with probes targeting the desired genes. Gene activity based
on microarray technology relies on spots brightness captured through these probes
that hybridize to the differentially fluorescently labeled groups of samples. The
intensity of brightness varies from gene to gene and correlates to the transcriptional
activity of the examined genes. This technology was an enabler in many aspects of
cancer biology; we can differentiate between tumor and non-tumor, different tumor
grades, risk of tumor metastasis, etc. It even enabled clinicians make decisions
about the optimal treatment of cancer patients. However, the technology did not stop
there! Thus, understanding the transcriptome plays a pivotal role in interpreting the
functional elements of the genome and revealing the molecular constituents of cells
and tissues, and also for understanding development and disease.
The sequence-based approaches uses high-throughput next generation sequencing
techniques that were developed based on DNA microarray technology. The use of
next-generation sequencing technology to study the transcriptome at the nucleotide
level is known as RNA Sequencing (RNA-Seq). RNA-Seq, also called Whole
Transcriptome Shotgun Sequencing [115], is a technology that uses next-generation
sequencing capabilities to reveal an overview of RNA expression and quantity from
a genome at a given moment in time [116].
Despite being a yet evolving technology that is yet under active development, RNASeq is expected to revolutionize our understanding of science [113]. It is a
technology that outweighs all its counterparts in its advantages. Yet, a major
exclusive setback is the bioinformatics challenges in assuring the righteous and in
managing these tremendous representations of data [113].
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Chapter 2: Research Aim, Hypothesis, and Specific Objectives

Given the fact that cancer cachexia has been known for such a long time, our
understanding of the mechanisms of cancer cachexia lag way behind our knowledge
of other aspects of tumor biology. This is despite the increase of the prevalence and
significance of the syndrome. Exploratory clinical research into the basic
etiopathological causes of cancer cachexia is lacking and we don’t currently have
any approved effective treatment for the involuntary weight loss in cancer patients.
The main aim of this thesis was to explore early differential changes in gene
expression in cancer patients with or without cachexia using state-of-the-art whole
expression profiling technology (RNA-Seq) in order to identify the mechanistic
pathway/s responsible for early development of cancer-associated cachexia. This
can bring reliable, representable, and consistent data from the clinic and back to the
bench with more focused insights to be investigated and verified.
It is our hypothesis that identification of early changes in gene expression using
whole transcriptome analysis in cachexia will lead to an improved understanding of
the triggering mechanism in cancer patients. Also, understanding cancer cachexia
can be best achieved through studying representative clinical muscle and fat
samples.
Our research specific objectives were to:
1. Collect representative muscle and fat biopsies from cancer patients with
cachexia and match them with non-cachectic weight-stable cancer controls.
2. Conduct global gene expression assays from high quality representative muscle
and fat biopsies from cancer patients with early cachexia and compare them to
non-cachectic weight-stable cancer controls.
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3. Identify differential up and downregulated pathways involved in each of the two
tissues.
4. Identify and analyze the highly significantly up and downregulated altered genes
in each of the two tissues.
5. Verify expression data from clinical and preclinical models of cancer cachexia
against the global gene expression results.
6. Identify and analyze the overlapping differentially expressed genes between
cachectic skeletal muscles and cachectic adipose tissues.
7. Confirm increased or decreased expression of a selected genes using real-time
RT-PCR.
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Chapter 3: Materials and Methods
3.1

Ethical Approval

The ethical approval request was submitted to "Al Ain Medical District Human
Research Ethics Committee (AAMDHREC)" at the College of Medicine and Health
Sciences (CMHS) in the United Arab Emirates University (UAEU). AAMDHREC is
accredited by the Federal Wide Assurance (FWA) under the number 00007109.
Research ethical proposal and protocol obtained under approval number
AAMDHREC 11/49. Written informed consents were obtained from each subject and
each subject was also given “Patient Information Sheet” in the language of
preference (i.e. Arabic or English) as per the committee recommendation.
3.2

Subjects

A total of 24 biopsies were obtained; 12 skeletal muscles and 12 visceral adipose
tissue. Each set of the two tissues contains 6 biopsies from cachectic cancer cases
and 6 weight-stable controls. All subjects (cachectic and weight-stable) were with
diagnosed malignancies. All samples were obtained through elective surgeries.
Inclusion and exclusion criteria were as following:
Inclusion Criteria: Cancer patients of any race, sex, and age equal or above 21 yearold with histologically proven malignancy and under active treatment. All cases
should have documented or self-reported weight-loss (cachexia) that is measured
by 5-10% involuntary weight loss of the total body mass in the past 3-6 months who
are undergoing elective abdominal surgery who agreed to sign an informed consent.
Exclusion criteria: Subjects who are under 21 year-old. Any subject with any
autoimmune and/or muscular disease, uncontrolled diabetes or thyroid disorder,
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history of treatment with any anabolic/catabolic agents for the past 6 months, or
history of physical impairment that affects mobility was excluded.
Control subjects were matched for age and diagnosis (as possible) and with no
documented or self-reported weight loss or gain in the past 3-6 months prior to
surgery (see Figure 1 for study flow diagram).
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Surgical cancer patients from clinic visits and OR lists

Record screening for eligibility

Cachectic patients with 5-10% weight loss;
and weight stable controls in thepast 6 months

Excluded:
• Age below 21
• Autoimmune and/or muscular
disease
• Diabetes or thyroid disorder
• Recent history of treatment
with any anabolic/catabolic
agents for the past 6 months
• History of physical impairment
affecting mobility

Consented Patients

Rectus abdominismuscle and
visceral fat biopsies obtained

Extracted RNA and Protein

RNA-Sequencing

Excluded:
• Weight loss ˂5% or ˃10%
• Controls with fluctuating weight

Real-Time RT-PCR

Excluded:
 Poor quality RNA samples

Figure 1: Study Flow Diagram.
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3.3

Clinical Parameters

Body weights were measured with participants in light clothing using a beam scale
(Seca). Heights were measured using a standard wall mounted measure and body
mass indices (BMI) were calculated. All current available nutritional and
inflammatory clinical parameters were recorded. History of weight changes from
patients' records and/or self-reported weights were also recorded.
3.4

Collection of Muscle and Adipose Tissue Biopsies

All biopsies were taken at the start of either open or laparoscopic abdominal
surgeries. Specimens of approximately 0.5-1.0 cm3 from the rectus abdominis
and/or visceral fat were removed. The biopsies were washed with normal saline
solution, blotted, and immediately placed in RNALater (AM7021; Applied
Biosystems, Carlsbad, CA, USA) and kept overnight at 4ºC to allow thorough
penetration of the tissue. Tissue samples were then frozen at –80ºC until further
processing.
3.5

Sample Labeling and Subject Confidentiality

Collected samples were given identification labeling composing of two letters to
denote origin (i.e. "M" for muscle, and "F" for fat) and group (i.e. "S" for cachexia
cases, and "C" for weight-stable controls). Each sample is then followed by a unique
identification number. To ensure confidentiality, all other subject identifications were
removed and never communicated in downstream sample processing. For future
possible reference to subject data, the link of these labeling and actual medical
record numbers is kept under the access of the leading experimenter and the
principle investigator only.
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3.6

Samples Preparation for RNA and Protein Extraction

Samples of muscle (45-59 mg) adipose tissue (95-173 mg) were homogenized in ice
in 1.2 ml of trizol Reagent (15596-026, TRIzol® Reagent, Life Technologies, Thermo
Fisher Scientific, USA) using the polytron homogenizer (POLYTRON® PT 2100
Homogenizers, Kinematica, Switzerland). Sample homogenizations were done at
intermittent intervals with samples kept in ice in between to avoid RNA and protein
degradation. Intermittent homogenization was the best method to ensure complete
retrieval of RNA and protein from samples that are difficult to homogenize (e.g.
muscle) or those who have low RNA and protein yield (i.e. fat) [117-119].
Homogenization was done in batches of 6 samples or less at 1500-2000 rpm.
Completion of each batch took 3 hours (fat) and 4-5 hours (muscle) till no clear
visible homogenate particles were observed. Polytron generator was cleaned in
between samples in the following sequence; DNase/RNase free distilled water, 70%
ethanol in DNase/RNase free distilled water, followed by DNase/RNase free distilled
water. To ensure proper removal of tissue sticking on the generator, a solution of
1% of sodium dodecyl sulfate in DNase/RNase free distilled water was used every
1-2 hours and as needed to clean the probe.
3.6.1

RNA Extraction

Once a complete tissue homogenization had been achieved, RNA extraction was
carried out using a combination of the liquid-liquid extraction technique; the acid
guanidiniumthiocyanate-phenol-chloroform extraction (AGPC) [120, 121], and the
column-based system. The AGPC method was used to separate the aqueous phase
(RNA containing phase). This step was preceded with an additional centrifugation
for fat samples only in order to remove the floating fat layer before the addition of
the chloroform. The total RNA was then precipitated using ethanol and processing of
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RNA isolation was completed using the SV Total RNA Isolation System® (Promega,
Madison, USA) according to manufacturer’s instructions. The concentration and
purity of the RNA samples were determined by measuring the absorbance at 260
nm and the ratio of the absorbance at 260/230 and 260/280 nm using
spectrophotometer (ND-1000 NanoDrop, Thermo Scientiﬁc, Wilmington, DE, USA).
Only ratios ≥ 1.8 were accepted or else, extractions were repeated till the required
purity was achieved. RNA samples were kept on ice during processing and quality
check and then stored at -80º C pending further processing.
3.6.1.1 RNA Concentration
Sample yields below 20 ng/µl were concentrated using a cold vacuum centrifuge.
This was followed by another check for RNA concentration and purity using
spectrophotometer (ND-1000 NanoDrop, Thermo Scientiﬁc, Wilmington, DE, USA).
3.7

Reverse Transcription

Total RNA was converted into cDNA using a High Capacity cDNA Reverse
Transcription Kit® (High Capacity cDNA Reverse Transcription Kit; 4374966;
Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Total RNA (420ng) was converted into cDNA in a 30μl reaction volume
using the following reaction (Table 1) and was repeated whenever needed:
Table 1: Reverse Transcription Reaction.
Reverse Transcription Master Mix Components
10 x RT Buffer
25 x dNTP Mix
10 x RT Random Primers
Multiscribe™ Reverse Transcriptase
RNASE Inhibitor
RNase Free H2O
Total Volume Reaction

Volume (1x)
3.0 µl
1.2 µl
3.0 µl
1.0 µl
1.0 µl
= (30 - 9.2 - vol of 420ng
template) µl
30.0 µl
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The above reaction gives a final cDNA concentration of = 420ng/30µl = 14ng/µl.
Each cDNA sample were then diluted to 4ng/µl and stored in -20º C. The reverse
transcription reaction was carried out in a Veriti thermal cycler (Life Technologies,
Applied Biosystems, USA) using the following parameter values (Table 2):

Table 2: Parameters of the Thermal Cycler for Reverse Transcription.

Temp ºC
Time

3.8

Step 1

Step 2

Step 3

Step 4

25 ºC
10 minutes

37 ºC
120 minutes

85 ºC
5 minutes

4 ºC
∞

Real-Time Reverse Transcription Polymerase Chain Reaction

The expression levels of mRNA were analyzed using target specific TaqMan® gene
expression assays using real-time reverse transcription polymerase chain reaction
(RT–PCR) and performed in a 7900HT Fast ABI Prism 7900HT Sequence Detection
System (Applied Biosystems, USA). The following TaqMan® primers and probes
kits were purchased from Applied Biosystems (Table 3):

Table 3: List of the TaqMan® Primers for Real-Time RT-PCR.
Assay ID

Gene Symbol

Assay ID: Hs01098873_m1
Assay ID: Hs00373339_m1
Assay ID: Hs00394748_m1
Assay ID: Hs01062014_m1
Assay ID: Hs00373136_m1
Assay ID: Hs00192297_m1

Gene Symbol: COL4A2, hCG33042
Gene Symbol: NRXN2, hCG1810991
Gene Symbol: AGRN
Gene Symbol: NOTCH1, hCG1818285
Gene Symbol: PTPRR, hCG25410
Gene Symbol: NDUFS1, hCG17250

Assay ID: Hs00174877_m1
Assay ID: Hs00223332_m1
Assay ID: Hs00896336_m1
Assay ID: Hs04187682_g1
Assay ID: Hs02800695_m1, #4326321E
Assay ID: Hs02758991_g1, #4326317E

Gene Symbol: LEP, hCG33000
Gene Symbol: TNMD, hCG20191
Gene Symbol: LHCGR, hCG16776
Gene Symbol: CXCL11, hCG23841
Gene Symbol: HPRT1
Endogenous
Gene Symbol: GAPDH
Controls
Gene Symbol: ACTB

Assay ID: Hs01060665_g1, #4326315E

32

The reaction mix of 10µl containing a total cDNA of 4ng/reaction was prepared using
TaqMan® H Fast Universal PCR Master Mix, No AmpErase H UNG (Life
Technologies #4352042, Applied Biosystems, USA) as follow (Table 4):
Table 4: Real-Time RT-PCR Reaction.
Real Time PCR Master Mix Reaction

Volume (1x)

DNase/RNase free H2O
cDNA (stock concentration 4ng/µl)
2 X TaqMan H Fast Universal PCR Master Mix
20 X Gene of Interest (GOI)

3.5 µl
1 µl
5 µl
0.5 µl

Quantitative real-time PCR assay for the gene of interest was performed in
duplicates and in a singleplex PCR reaction. The PCR thermal cycling parameters
were run in fast mode as follow (Table 5):

Table 5: Parameters of the Thermal Cycler for Real-Time RT-PCR.
Step 1

Step 2

Step 3

Step 4

Temp ºC

50º C

95 º C

60 º C

Time

2 minutes

20 seconds

40 cycles of
95 º C
1 second

20 seconds

Results were initially analyzed with the ABI Prism 7900HT SDS program v2, 4, all
remaining calculations and statistical analysis were performed by the SDS RQ
Manager 1.1,4 software using the 2-∆∆Ct method with a relative quantification
RQmin/RQmax confidence set at 95%. Three different endogenous controls were
tested; human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), human
Hypoxanthine phosphoribosyltransferase (Hprt1) rRNA, and human β-actin. Hprt1
was found to be the best and used to normalize expression results. Other
expression related guidelines were followed from the MIQE guidelines [122].
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3.9

Statistical Analysis

Preliminary statistical analysis of the next generation sequencing was carried out by
our collaborator in Qatar. Confirmation of changes in gene expression by real-time
RT-PCR was done using Student's t-test and analysis was done using the
GraphPad Prism Software (version 5).
3.10

Bioinformatics Tools

Much freely available databases and software were used check gene functions,
expression pattern, protein interaction, and functional pathways. These databases
and software are:


The

US

National

Library

of

Medicine

National

Institutes

of

Health:

http://www.ncbi.nlm.nih.gov/pubmed


UCSC Genome Bioinformatics: http://genome.ucsc.edu/



Ensembl: http://www.ensembl.org/index.html



KEGG database: http://www.genome.jp/kegg/kegg1.html



String: http://string-db.org/



Biological General Repository for Interaction Datasets: http://thebiogrid.org/



ExPASy Bioinformatics Resource Portal:
http://www.expasy.org/proteomics/protein-protein_interaction

3.11

RNA Sequencing

Muscle and fat RNA samples (600ng) were sent in dry ice to our collaborators in
Weill Cornel Medical College in Qatar for RNA Sequencing (RNA-Seq). RNA-Seq is
a revolutionary transcriptomic technique that uses deep-sequencing technologies.
The technique utilizes a population of RNA that is reversed transcribed into a library
of cDNA fragments.
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All samples underwent quality check prior to sequencing by measuring the RNA
Integrity Number and ensuring that all samples are with a RNA Integrity Number
value of at least 7. Samples were then reversed transcribed into cDNA. RNA-Seq
was then performed on the Illumina HiSeq 2500 System.
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Chapter 4: Results and Discussions – Muscle
4.1

Demographic and Biochemical Characteristics of Subjects
4.1.1

Results

Demographic and biochemical details of patients for muscle cachexia cases (MS)
and muscle weight-stable controls (MC) are shown in bellow tables. The table
shows the data after excluding two samples (one of each group) since they were
outliers from the RNA-Seq data. The cause of these two samples as outliers was
investigated. Data on the excluded cachexia sample was obtained through patients
self-report of weight changes in the past six months with the complete absence of
baseline data in patient's record. The patient was a referral to the hospital from a
different city just to be operated. On the other hand, further investigation of the
excluded control sample in patient's extended electronic records in different health
institutions found to have obvious fluctuation of patients weight in between the two
time points that our study has initially selected patients on. All samples were then
analyzed based on weight, BMI, some nutritional parameters, inflammatory markers,
and other related demographics.
Table 6 shows subjects' oncological diagnoses for muscle biopsies. All patients
were with histologically confirmed malignancies. Age and gender distribution were
not significantly different between cachexia muscle cases (MS) and weight-stable
muscle controls (MC) (Table 7). All biochemical nutritional parameters (i.e.
hemoglobin, total protein, albumin, urea, and creatinine) and inflammatory markers
(i.e. WBC and CRP) were not significantly different between both groups (Table 7).
Baseline weights and BMIs in the cachexia group did not differ significantly from the
control. The time range between current (at time of biopsy) and baseline weights
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(preceding date of biopsy) was 3-6 months. Mean weight loss from baseline in the
cachexia group was 4.6 kg which is 6.5% of baseline body weight (i.e. 3-6 months
before the date of sample collection). Amount and percentage of weight loss was
significantly different from controls that had stable weights; P-value of 0.0014 and
0.0003, respectively.

Table 6: Subjects' Diagnoses for Skeletal Muscle Biopsies.
Cachectic Muscle Cases (MS)

Weight-stable Muscle Controls (MC)

MS1: Malignant Neoplasm of Rectum
MS2: Malignant Neoplasm of Stomach
MS3: Malignant Neoplasm of Rectum
MS4:Malignant Neoplasm of Duodenum

MC1: Malignant Neoplasm of Rectum
MC2: Malignant Neoplasm of Rectum
MC3: Malignant Neoplasm of Colon
MC5: Malignant Neoplasm of Connective
and Soft Tissue
MC8: Malignant Neoplasm of Colon

MS6: Malignant Neoplasm of Pancreas
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Table 7: Demographic Data for Cachectic Muscle Cases and Weight-Stable Muscle
Controls.
Gender (M/F)
MS: 4/1; MC: 3/2
Characteristics
Age
Hemoglobin
Creatinine
Urea
Total protein
Albumin
WBC
CRP
Baseline BMI
Current BMI
Baseline weights
Current weights
Amount of weight
loss
% of weight loss

MS:
N=5
MC:
N=5
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.

Mean

SEM

Median

Range

P-Value

61.40
53.40
114.0
114.6
65.75
61.60
6.650
3.480
52.75
51.60
27.50
30.00
8.900
8.640
12.50
14.67
23.58
29.86
21.95
29.79
67.92
81.20
63.38
81.00
4.540
0.2000
6.552
0.2740

7.461
6.447
4.669
8.583
10.23
3.385
1.735
0.3980
4.535
3.516
4.349
2.280
1.307
1.613
7.331
2.333
2.378
1.765
2.030
1.811
5.738
2.653
5.213
2.811
0.8818
0.2000
0.9994
0.2740

67.00
59.00
111.0
122.0
69.00
63.00
6.300
3.900
49.50
49.00
25.00
29.00
9.000
9.600
7.500
14.00
23.02
30.46
21.98
30.46
73.00
84.00
67.90
84.00
4.000
0.0000
5.479
0.0000

44-83
36-66
103-125
90-135
41-84
52-72
2.9-11.1
1.9-4.0
46-66
42-63
20-40
23-37
6.0-13.3
4.4-12.1
1-34
11-19
15.57-92.92;
25.26-35.38
14.81-26.44;
24.91-35.38
45.00-74.60;
73.00-87.00
42.80-71.20;
72.00-87.00
2.200-7.000
0.0000-1.000
4.558-9.589
0.0000-1.370

0.4406
0.9525
0.6837
0.0863
0.8441
0.6047
0.9034
0.8172
0.0667
*0.0205
0.0689
*0.0177
**0.0014
***0.0003
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Table 8 compares weight and BMI changes between current and baseline within
each group (paired t-test). The cachectic muscle cases (MS) had a significant
difference between current and baseline data while weight-stable controls (MC) had
no significant change.

Table 8: Paired t-Tests for Weight and BMI Changes for Muscle Biopsies.
Characteristics
Weight MS
(cachectic)
BMI MS
(cachectic)
Weight MC
(weight-stable)
BMI MC
(weight-stable)

4.1.2

N=MS/MC;
5/5
Baseline
Current
Baseline
Current
Baseline
Current
Baseline
Current

Mean

SEM

Median

Range

P-Value

67.92
63.38
23.58
21.95
81.20
81.00
29.86
29.79

5.738
5.213
2.378
2.030
2.653
2.811
1.765
1.811

73.00
67.90
23.02
21.98
84.00
84.00
30.46
30.46

45.00-74.60;
42.80-71.20
15.57-29.24;
14.81-26.44
73.00-87.00
72.00-87.00
25.26-35.38
24.91-35.38

** 0.0068
* 0.0140
0.3739
0.3739

Discussion

In the above demographic analysis, patients included in the study were chosen
meticulously to be at the early stages of cachexia (i.e. 5 - < 10% weight loss).
Consensus definition had identified early cachexia as weight loss >5% or BMI
<20kg/m2 and weight loss >2% or sarcopenia and weight loss >2% with often
reduced food intake or systemic inflammation [7]. Our subjects had a mean
percentage of weight loss of 6.5% (range 4.6-9.6 %). Since systemic inflammation
measured via serum CRP may or may not be present in patients with cachexia [7],
our subjects were included regardless of their CRP values (range 1-34, Table 6).
However, the CRP values between cachectic cases (MS) and weight-stable controls
(FC) were ensured to be not statistically significant; P= 0.325 in muscle.
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Nutritional and nutrition-related biochemical markers were all ensured to be
comparable in both groups to objectively exclude the possibility of malnutrition as
the primary cause of weight loss.
4.2

Heat Map of RNA Sequencing Data
4.2.1

Results

Figure2shows the heat map of differentially regulated genes between cachectic
muscle cases (MS) and weight-stable controls (MC). The figure shows a complete
and clear cut separation between both groups. The heat map shows a total of 238
significantly upregulated genes and 235 downregulated genes (P-value < 0.05; and
FDR < 0.5).
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Figure 2: Heat Map Representation of the Differentially Expressed Genes in Skeletal
Muscle Tissue.
Gene expression is shown for the cachectic muscle cases (MS; purple bars; upper
panel) and weight-stable controls (MC; green bar; lower panel). Colors represent
scaled and centered expression values; red represents higher expression, blue
represents lower expression.

4.2.2

Discussion

The heat-map provides a graphical visualization of the matrix dataset by
representing individual values with different colors. This necessity stems from the
increasing data volumes generated by scientific studies. Effective data visualization
enables understanding data at both broad and detailed levels. Recent progress in
high-throughput techniques, such as RNA-Seq, has increased the demand for the
visualization of multi-dimensional in addition to the numeric data [123]. This simple
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hierarchical cluster analysis revealed a clear visual distinction of gene expression
signature between cachexia muscle cases (MS) from those with weight-stable
controls (MC).
4.3

Analysis of Differentially Expressed KEGG Pathways
4.3.1

Introduction to Pathways Analysis

Even for the simplest biological function, single-gene expression analysis has its
own limitations for understanding the biological mechanism of a disease/syndrome.
Complicated biological and pathological processes are a function of hundreds of
differentially expressed genes. These genes never work independently. Whole
genome expression analysis draws attention for discovering the hidden links
disregarded by the single-gene analysis.
The introduction of high throughput technology, like microarray, enabled
simultaneous quantification of thousands of genes to the full genome expression.
However, “next generation sequencing” is much more powerful than microarray in
identifying a more quantitative expression of genes of the whole transcriptome from
cells or tissues.
4.3.1.1 Why Pathways Analysis?
Pathways analysis has emerged as one of the most important methods to gain
insight into the underlying biology of differentially expressed genes. It is a logical
next step in any high-throughput experimentation. Basing the massive quantity of
data generated through full genome expression assays on pathways analysis
reduces the complexity of single gene analysis. Also, high-throughput experiments
do not produce biological findings. Since gene products do not work alone, but in an
intricate network of interactions, pathways analysis helps interpret the data in the
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context of biological processes; pathways and networks. Thus, it gives a global
perspective on the data and the problem in hand.
Pathways analysis also provides in-depth and contextualized findings to help
understand the mechanisms of disease/conditions in question. It helps in
identification of genes and proteins associated with the etiology of a specific
disease. Also, it helps to understand how to intervene therapeutically in disease
processes by prediction of drug targets. It aids in data integration from diverse
biological information and hence the discovery of the function of unknown genes.
Many pathways analysis approaches and resulting software/tools are available.
These tools have evolved in, so far, three generations of algorithms of increasing
complexity and hence, comprehensiveness [124]. "KEGG pathway analysis" is one
of the third generation tools that is widely used [124]. Tools in the first and the
second generations consider only the number of genes in a pathway or gene
coexpression to identify significantly altered pathways. Thus, they always produce
the same results no matter how they are analyzed [124]. However, the third
generation pathways analysis utilizes additional information available from these
knowledge bases [124]. It is important to understand this concept during data
analysis since variations in statistical significance is highly likely [125]. For example,
statistical significance of cytokine-cytokine receptor interaction pathway calculated
by three different methods resulted in P-values of 8.08×10-6, 0.72, and 6.19×10-2
[125]. This huge difference should be always considered during data analysis.
However, the real value of pathway analysis is to generate hypothesis, inferences,
and

explore

the

overall

diseases/conditions/syndromes.

picture

of

a

complex

unknown
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4.3.1.2 KEGG Pathways
The Kyoto Encyclopedia of Genes and Genomes (KEGG) database is a project that
was initiated back in 1995 under the then ongoing Japanese Human Genome
Program [126]. It is a collection of databases (seventeen main databases) that are
broadly categorized into 4 broad categories that deals with genomes, biological
pathways, diseases, drugs, and chemical substances. In our study, our collaborator
in Qatar has initially utilized it to generate a computer representation from our
molecular-level information (RNA Sequencing results) to explore differentially
involved pathways in cachexia pathogenesis [126, 127]. The outcome of this
analysis is the "KEGG pathway mapping", whereby the gene content in the genome
is compared with the "KEGG PATHWAY" database to examine which pathways and
associated functions are likely to be differentially encoded in the genome.
Several pathways were found to be differentially expressed; up- or downregulated,
when expression data was analyzed using KEGG pathways analysis. Each of these
pathways has several genes that are significantly altered and will be discussed
below.
4.3.2

Upregulated KEGG Pathways in Cachectic Skeletal Muscle
4.3.2.1 Results

Four KEGG pathways are differentially upregulated in cachectic muscles cases vs.
weight-stable control muscles; notch signaling pathway, cell adhesion molecules
(CAMs), acute myeloid leukemia, extracellular matrix (ECM)-receptor interaction.
These pathways have 4, 6, 4, and 4 significantly upregulated genes respectively
(Table 9).Figure 2shows the individual genes in each pathway and the overall
statistical significance for each of these pathways. Table 10 shows a summary of
the full gene name, fold change, and P-value for individual genes in each pathway.

44

Table 9: Differentially Upregulated KEGG pathways in Cachectic Skeletal Muscle.
KEGG
Pathway
Notch
signaling
pathway
Cell
Adhesion
molecules
Acute
myeloid
leukemia
ECMreceptor
interaction

Gene

Gene

Gene

Gene

NOTCH1

NOTCH4

MFNG

DTX2

F11R

CLDN11

ESAM

HLA-A

RARA

STAT5A

TCF7L2

AGRN

COL4A2

HSPG2

Gene

Pvalue
0.021

FDR

0.025

0.70

RELA

0.036

0.70

VWF

0.088

0.90

HLA-C

Gene

NRXN
2

0.87
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Table 10: Data of Individual Genes in the Upregulated KEGG Pathways in Cachectic
Skeletal Muscle.
Gene
Gene Full Name
Symbol
Muscle-Up / Notch Signaling Pathway
MFNG

PValue

2.99

0.0022

5.69
3.69

0.0143
0.0040

DTX2
deltex homolog 2 (Drosophila)
Muscle-Up / Cell adhesion molecules (CAMs)

3.70

0.0155

F11R
CLDN11
ESAM
HLA-A

2.59
6.76
3.39
2.92

0.0160
0.0158
0.0004
0.0162

3.56

0.0173

11.83

0.0148

3.06

0.0134

signal transducer and activator of transcription 5A
transcription factor 7-like 2 (T-cell specific, HMG-box)
v-relreticuloendotheliosis viral oncogene homolog A
(avian)
Muscle-Up / ECM-receptor interaction

3.33
2.36
2.29

0.0150
0.0169
0.0069

AGRN
COL4A2
HSPG2
VWF

2.75
8.54
7.79
3.22

0.0161
0.0184
0.0189
0.0167

NOTCH1
NOTCH4

MFNG O-fucosylpeptide 3-beta-Nacetylglucosaminyltransferase
Notch homolog 1, translocation-associated (Drosophila)
Notch homolog 4 (Drosophila)

Fold
Change

F11 receptor
claudin 11
endothelial cell adhesion molecule
major histocompatibility complex, class I, A

HLA-C

major histocompatibility complex, class I, C; major
histocompatibility complex, class I, B
NRXN2
neurexin 2
Muscle-Up / Acute myeloid leukemia
RARA

retinoic acid receptor, alpha

STAT5A
TCF7L2
RELA

Agrin
collagen, type IV, alpha 2
heparan sulfate proteoglycan 2
von Willebrand factor

4.3.2.2 Discussion
Notch Signaling Pathway
Notch signaling is an evolutionarily conserved intercellular pathway that regulates
interactions between physically adjacent cells and is a well-documented pathway in
skeletal muscle development and regeneration [128]. Normally, Notch pathway in
skeletal muscles regulates proliferation and commitment of activated satellite cells to
myogenic lineage. Also, activation of Notch signaling is a prerequisite for the
expansion of postnatal satellite cells and to prevent the premature differentiation of
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myogenic progenitor cells precursors in injured myofibers into mature muscle [129,
130]. These two processes ensure muscular homeostasis. Muscle injury, which is
the early cachexia in our case, is known to activate Notch pathway. Two known
notch receptors NOTCH1 and NOTCH4 were upregulated. In addition, two known
activators of the pathway [131, 132] were upregulated; MFNG, which encodes for
manic fringe (a protein family that also includes the radical and lunatic fringe) which
fucosylates and thereby modulates notch, and DTX2, which encodes for deltex-1 an
E3 ubiquitin ligase which is positive regulator of downstream, were upregulated
[133, 134].
Cell adhesion molecules and ECM-receptor interaction pathways
It is well-know that further activation of Notch pathway require more cell-cell
contacts [135]. Thus, no wonder that two other supportive pathways; cell adhesion
molecules (CAM),

and extracellular

matrix-receptor

interaction, were

also

upregulated with multiple genes involved at different levels.
On a different note, elements in the extracellular matrix-receptor interaction pathway
were also correlated to documented literature in muscle wasting. For example, agrin
(AGRN) fragments are under investigation as a possible biomarker for sarcopenia
[136] and was also found to be upregulated in cachectic muscles. Also, expression
of collagen type 4 alpha 1 (COL4A1, from original data) and collagen type 4 alpha 2
(COL4A2) genes; which are components of the myocyte basal lamina [137], are
significantly upregulated. The matrix metalloproteinase genes (MMP2 and MMP9)
code for abundant gelatinases in muscle that hydrolyze fibrillar collagens [138]. The
two genes which are normally expressed in quiescent satellite cells [139]. MMP2 is
activated by MMP14 at the sarcolemma [138]. MMP2, its activator; MMP14 and
MMP9 are massively upregulated (but not statistically significant) in the cachectic
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muscles. This signature molecular changes in our cachectic muscles reflects the
quiescent state of the satellite cells which are, possibly, at its borderline activation
once the degrading forces for the type IV collagens (i.e. COL4A1 and 2) exceeds
cellular degradation resistance threshold.
Acute myeloid leukemia pathway
Another upregulated pathway in cachectic muscles is the acute myeloid leukemia.
One gene is of a particular and a justified importance in the cachexia context; the
transcription factor 7-like 2 (TCF7L2) gene. This gene was found in a genome-wide
association scans to be the most important locus predisposing and consistently
involved in type 2 diabetes [140]. Insulin resistance is an important common feature
between cancer cachexia and type 2 diabetes and patients with cancer cachexia
have profound insulin resistance [141, 142].
A certain polymorphism that increases TCF7L2 gene expression is associated to
type 2 diabetes [140] and it could be that the same gene involved in muscles
contributing to insulin resistance in cachectic patients. Not only TCF7L2, but also
another gene in the same pathway; the signal transducer and activator of
transcription 5A (STAT5A) gene, plays an important role in insulin resistance.
STAT5A is a physiological substrate of the insulin receptor that is independent of
JAK [143]. Insulin activates STAT5A (along other stats) [143]. Prolonged insulin
exposure in skeletal muscle cells increases STAT5 expression which may play an
important role in the manifestation and/or progression of insulin resistance in
muscles [144]. RELA, which is a member of the NFkappaB family, forms a
heterodimer with p65-c-Rel to from a transcriptional activator. Expression of RELA
gene, on the other hand, was increased in human and mouse model of Huntington's
disease [145].
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4.3.3

Downregulated KEGG Pathways in Cachectic Skeletal Muscle
4.3.3.1 Results

Eleven KEGG pathways are differentially downregulated in cachectic muscles cases
vs. weight-stable muscles. Several of these pathways share many of the same
genes (Table 11). We decided to collectively call these pathways (i.e. hypertrophic
cardiomyopathy,

dilated

cardiomyopathy,

arrhythmogenic

right

ventricular

cardiomyopathy, and cardiac muscle contraction); the cardiac muscle contraction
and cardiac myopathy pathway. Also, via studying the nature of the genes involved
in the insulin signaling pathway, we decided to call it glycogen metabolism pathway.
Table 11 shows the individual genes in each pathway and the overall statistical
significance for each of these pathways. Table 12 shows a summary of the full gene
name, fold change, and P-value for individual genes in each pathway.
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Table 11: Differentially Downregulated KEGG Pathways in Cachectic Skeletal
Muscle.
KEGG
Pathway

Gene

Gene

Gene

Gene

Gene

ATP2A2 CACNA2D1 CACNA2D3

ITGB6

SGCD

TTN

TPM2

PRKAB2 0.0001

0.01
2

Dilated cardioATP2A2 CACNA2D1 CACNA2D3
myopathy

ITGB6

SGCD

TTN

TPM2

0.001

0.06
3

Arrhythmogenic right
ventricular
cardiomyopathy

ITGB6

SGCD

CTNNA3 0.003

0.06
4

ATP1B4

0.07
8

ATP2A2 CACNA2D1 CACNA2D3

Cardiac muscle
ATP2A2 CACNA2D1 CACNA2D3
contraction
Insulin signaling
PHKA1
pathway
Valine, leucine
and isoleucine
degradation

AUH

Parkinson’s
disease
Calcium
signaling
pathway

Alzheimer’s
disease

PPP1R3A PPP1R3B PPP1R3C

PRKAB2 0.002 0.33

ACADSB

DLD

NDUFB5

NDUFS1

ATP5B

PINK1

PARK2

UBE2G1

0.028 0.33

PHKA1

PHKB

PLCB1

PPP3CB PHKG1

0.029 0.31

PLCB1

PPP3CB

0.062 0.51

SOS2

PTPRR

PPP3CB MEF2C

0.064 0.48

SOS2

PLCB1

PPP3CB

0.066 0.46

CAMK2G
EGF

0.02

ACADM

ATP2A2 CAMK2G

Long-term
potentiation
MAPK signaling
pathway

PHKB

TPM2

Gene

PFDR
value

Gene

Hypertrophic
cardiomyopathy

Gene

RPS6KA3

CACNA2D1 CACNA2D3 RPS6KA3

ATP2A2 NDUFB5

0.02

NDUFS1

ATP5B

0.29
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Table 12: Data of Individual Genes in the Downregulated KEGG Pathways in
Cachectic Skeletal Muscle.
Gene
Gene Full Name
Fold
Symbol
Change
Muscle-Down / Hypertrophic cardiomyopathy (HCM)
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow
-2.36
twitch 2
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta
-3.37
subunit 1
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta
-3.65
subunit 3
ITGB6
integrin, beta 6
-5.09
PRKAB2
protein kinase, AMP-activated, beta 2 non-catalytic
-2.64
subunit
SGCD
sarcoglycan, delta (35kDa dystrophin-associated
-2.53
glycoprotein)
TTN
Titin
-2.09
TPM2
tropomyosin 2 (beta)
-2.44
Muscle-Down / Dilated cardiomyopathy
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow
-2.36
twitch 2
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta
-3.37
subunit 1
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta
-3.65
subunit 3
ITGB6
integrin, beta 6
-5.09
SGCD
sarcoglycan, delta (35kDa dystrophin-associated
-2.53
glycoprotein)
TTN
Titin
-2.09
TPM2
tropomyosin 2 (beta)
-2.44
Muscle-Down / Insulin signaling pathway
PHKA1
phosphorylase kinase, alpha 1 pseudogene 1;
-2.21
phosphorylase kinase, alpha 1 (muscle)
PHKB
phosphorylase kinase, beta
-2.46
PHKG1
phosphorylase kinase, gamma 1 (muscle)
-2.14
PRKAB2
protein kinase, AMP-activated, beta 2 non-catalytic
-2.64
subunit
PPP1R3A
protein phosphatase 1, regulatory (inhibitor) subunit
-2.52
3A
PPP1R3B
protein phosphatase 1, regulatory (inhibitor) subunit
-2.97
3B
PPP1R3C
protein phosphatase 1, regulatory (inhibitor) subunit
-2.53
3C
SOS2
son of sevenless homolog 2 (Drosophila)
-2.39
Muscle-Down / Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow
-2.36
twitch 2
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta
-3.37
subunit 1
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta
-3.65
subunit 3
CTNNA3
catenin (cadherin-associated protein), alpha 3
-4.38
ITGB6
integrin, beta 6
-5.09
SGCD
sarcoglycan, delta (35kDa dystrophin-associated
-2.53

PValue
0.0096
0.0018
0.0052
0.0002
0.0001
0.0137
0.0135
0.0019
0.0096
0.0018
0.0052
0.0002
0.0137
0.0135
0.0019
0.0185
0.0016
0.0142
0.0001
0.0099
0.0040
0.0081
0.0005
0.0096
0.0018
0.0052
0.0007
0.0002
0.0137
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glycoprotein)
Muscle-Down / Cardiac muscle contraction
ATP1B4
ATPase, (Na+)/K+ transporting, beta 4 polypeptide
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow
twitch 2
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta
subunit 1
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta
subunit 3
TPM2
tropomyosin 2 (beta)
Muscle-Down / Valine, leucine and isoleucine degradation
AUH
AU RNA binding protein/enoyl-Coenzyme A
hydratase
ACADM
acyl-Coenzyme A dehydrogenase, C-4 to C-12
straight chain
ACADSB
acyl-Coenzyme A dehydrogenase, short/branched
chain
DLD
dihydrolipoamide dehydrogenase
Muscle-Down / Parkinson's disease
ATP5B
ATP synthase, H+ transporting, mitochondrial F1
complex, beta polypeptide
Ndufb5
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 5, 16kDa
NDUFS1
NADH dehydrogenase (ubiquinone) Fe-S protein 1,
75kDa (NADH-coenzyme Q reductase)
Pink1
PTEN induced putative kinase 1
park2
Parkinson disease (autosomal recessive, juvenile) 2,
parkin
ube2g1
ubiquitin-conjugating enzyme E2G 1 (UBC7
homolog, yeast)
Muscle-Down / Calcium signaling pathway
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow
twitch 2
CAMK2G
calcium/calmodulin-dependent protein kinase II
gamma
PLCB1
phospholipase C, beta 1 (phosphoinositide-specific)
PHKA1
phosphorylase kinase, alpha 1 pseudogene 1;
phosphorylase kinase, alpha 1 (muscle)
PHKB
phosphorylase kinase, beta
PHKG1
phosphorylase kinase, gamma 1 (muscle)
PPP3CB
protein phosphatase 3 (formerly 2B), catalytic
subunit, beta isoform
Muscle-Down / Long-term potentiation
CAMK2G
calcium/calmodulin-dependent protein kinase II
gamma
PLCB1
phospholipase C, beta 1 (phosphoinositide-specific)
PPP3CB
protein phosphatase 3 (formerly 2B), catalytic
subunit, beta isoform
RPS6KA3
ribosomal protein S6 kinase, 90kDa, polypeptide 3
Muscle-Down / MAPK signaling pathway
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta
subunit 1
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta
subunit 3
EGF
epidermal growth factor (beta-urogastrone)

-2.87
-2.36

0.0126
0.0096

-3.37

0.0018

-3.65

0.0052

-2.44

0.0019

-2.16

0.0007

-3.64

0.0004

-2.20

0.0055

-2.09

0.0026

-2.10

0.0012

-2.04

0.0009

-2.34

0.0005

-2.16
-3.26

0.0153
0.0012

-2.01

0.0063

-2.36

0.0096

-2.09

0.0068

-2.06
-2.21

0.0057
0.0185

-2.46
-2.14
-2.06

0.0016
0.0142
0.0139

-2.09

0.0068

-2.06
-2.06

0.0057
0.0139

-2.02

0.0001

-3.37

0.0018

-3.65

0.0052

-2.41

0.0008
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MEF2C
PPP3CB

myocyte enhancer factor 2C
protein phosphatase 3 (formerly 2B), catalytic
subunit, beta isoform
PTPRR
protein tyrosine phosphatase, receptor type, R
RPS6KA3
ribosomal protein S6 kinase, 90kDa, polypeptide 3
SOS2
son of sevenless homolog 2 (Drosophila)
Muscle-Down / Alzheimer's disease
ATP5B
ATP synthase, H+ transporting, mitochondrial F1
complex, beta polypeptide
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow
twitch 2
Ndufb5
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 5, 16kDa
NDUFS1
NADH dehydrogenase (ubiquinone) Fe-S protein 1,
75kDa (NADH-coenzyme Q reductase)
PLCB1
phospholipase C, beta 1 (phosphoinositide-specific)
PPP3CB
protein phosphatase 3 (formerly 2B), catalytic
subunit, beta isoform

-2.12
-2.06

0.0163
0.0139

-7.61
-2.02
-2.39

0.0177
0.0001
0.0005

-2.10

0.0012

-2.36

0.0096

-2.04

0.0009

-2.34

0.0005

-2.06
-2.06

0.0057
0.0139

4.3.3.2 Discussion
Cardiac Muscle Contraction and Cardiac Myopathy Pathway
Expression of two L-type voltage-gated calcium channel (VGCC) subunits genes are
downregulated in the "cardiac muscle contraction and cardiac myopathy" pathway;
CACNA2D1 and CACNA2D3. VGCCs are multi-subunit membrane proteins that
regulate calcium influx into excitable cells (i.e. cardiac, smooth, and skeletal muscle
cells) [146]. Specific subunits are expressed differentially in different tissue types.
CACNA2D1 and CACNA2D3 are α2δ genes that form two linked subunits; α2 and δ
(which are both the product of the same gene) that interacts the most with the α1
subunit. Co-expression of the α2δ enhances the level of expression of the α1
subunit and causes an increase in current amplitude, faster activation and
inactivation kinetics and a hyperpolarizing shift in the voltage dependence of
inactivation.
Other downregulated genes in the same pathway are the ATP2A2 and TPM2.These
two genes previously reported as a short-term response gene in muscle in response
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to atrophy induction [147]. ATP2A2 encodes one of the SERCA Ca2+-ATPases,
which are intracellular pumps located in the sarcoplasmic reticulum of muscle cells
which function is coupled with the calcium transient from the cytosol to the
sarcoplasmic reticulum lumen, and is involved in calcium sequestration associated
with muscular excitation and contraction. TPM2 is a skeletal muscle contractile gene
that is reported to cause muscle weakness when mutated [148, 149]. PRKAB2, on
the other hand, is the regulatory non-catalytic beta subunit gene for the AMPactivated protein kinase (AMPK). PRKAB2 is a positive regulator of the AMPK that is
highly expressed in skeletal muscle [150]. AMPK is an important energy-sensing
enzyme that monitors cellular energy status in response to cellular metabolic
stresses. PRKAB2 is also reported to be

downregulated in a mouse model of

severe cachexia [151]. These two genes (TPM2 and PRKAB2) might contribute to
the muscular fatigability and decreased mobility that are evident signs of cachexia.
The SGCD gene is one of four known components of the sarcoglycan complex,
which is a family of transmembrane proteins and a subcomplex of the dystrophinglycoprotein complex (DGC). DGC is responsible for connecting the muscle fibre
cytoskeleton to the extracellular matrix, preventing muscular damage. Mutations in
this gene have been associated with autosomal recessive limb-girdle muscular
dystrophy which is characterized by progressive muscle wasting [152].
Titin (TTN) is the third most abundant sarcomeric protein in muscle; an adult human,
80 kg weight, have approximately 0.5 kg of titin [153]. Mutation in TTN gene is
known to cause tibial muscular dystrophy which is characterized by weakness and
atrophy that is usually confined to the tibialis anterior muscle [154]. One of the main
functions of titin is to support the contractile elements and maintain muscular
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elasticity [154]. Titin also plays a key role in multiple signaling pathways, being a
binding site for multiple ligands for a large number of other muscle proteins [154].
The integrin beta 6 (ITGB6) gene is highly expressed in skeletal muscle [155]. It is
downregulated in mouse models of cachexia [156]. Integrins are a group of
transmemebrane receptors that have two different chains, the alpha and beta
subunits that form obligate heterodimers. In mammals, there are eighteen α and
eight β subunits [157]. This downregulation of ITGB6 is of unique interest in the
context of cachexia because our data shows upregulation in almost every single
subunit in all integrins (though not statistically significant in any) except for the
ITGB6.
CTNNA3 is one of three alpha-catenin genes [158]. Alpha-T-catenin belongs to the
family of cell–cell adhesion molecules and is believed to act as a link between
cadherins and actin-containing filaments of the cytoskeleton resulting in strong cell–
cell adhesion [158]. It is expressed in cardiomyocytes, skeletal muscle, testis and
brain [158]. In silico analysis revealed that the alpha-T-catenin promoter contains
several binding sites for cardiac and muscle-specific transcription factors [158]. The
two known promoters for CTNNA3 are either unexpressed (GATA4) or significantly
downregulated (MEF2C) in our cachectic muscle samples (data from original file)
[158].
Glycogen Metabolism Pathway
Another downregulated pathway is the insulin signaling pathway which we rather
call "Glycogen metabolism Pathway" due to the function of the genes involved.
Three phosphorylase kinase genes (PHKA1, PHKB, and PHKG1) and three protein
phosphatase 1 (PP1) genes (PPP1R3A, PPP1R3B, and PPP1R3C) are
downregulated. Phosphorylase kinases are a serine/threonine-specific protein
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kinase which activates glycogen phosphorylase to release glucose-1-phosphate
from glycogen [159]. Protein phosphatases 1, on the other hand, are a class of
protein serine/threonine phosphatases that inactivate the active (phosphorylated)
form of phosphorylase and also activate the inactive form of glycogen synthase
[160]. These two groups of proteins play a crucial role in the regulation of glycogen
metabolism. In muscle cells, to power activity instantly when energy is in demand,
glycogenolysis is needed to hydrolyze the stores of glycogen to glucose by the
sequential removal of glucose monomers. This provided a prompt energy supply for
immediate activity in muscle cells [159]. Phosphorylase kinase stimulates glycogen
hydrolysis into free glucose by phosphorylating glycogen phosphorylase and
stabilizing

its

active

conformation[159].

This

is

the

rate-limiting

step

in

glycogenolysis [159]. Phosphorylase "a" in its active R state has PP1 bound tightly
preventing any phosphatase activity of PP1 and maintains the active phosphorylated
configuration resulting in a cascade of events that generate the required energy.
These changes in gene expression are likely to be involved in the known reduction
in glycogen turnover in patients with cancer cachexia, which in turn leads to muscle
weakness and rapid fatigue [161]. PRKAB2is a 5'-AMP-activated protein kinase
subunit beta-2 that encodes for the regulatory subunit of the AMP-activated protein
kinase (AMPK). AMPK is an important energy-sensing enzyme that monitors cellular
energy status. This subunit may be a positive regulator of AMPK activity that is
highly expressed in skeletal muscle [162]. PRKAB2 knockout mice had reduced
maximal and endurance exercise capacity during treadmill running which was also
associated with also reduced levels of muscle and liver glycogen [162].
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Calcium Signaling Pathway and Long Term Potentiation
CAMK2G encodes for calcium/calmodulin-dependent protein kinase type II gamma,
which is involved in sarcoplsamic reticulum Ca2+ transport in skeletal muscle [163].
In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum Ca2+
transport and in fast-twitch muscle participates in the control of Ca2+ release from the
sarcoplasmic reticulum through phosphorylation of the ryanodine receptor-coupling
factor triadin. In neurons, may participate in the promotion of dendritic spine and
synapse formation and maintenance of synaptic plasticity which enables long-term
potentiation (LTP).
PLCB1 encodes for phospholipase C, beta 1 which catalyzes the formation of
inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5bisphosphatephosphatidylinositol 4,5-bisphosphate. This is an important part of the
calcium signaling second messenger system that is crucial for muscle cell growth
and differentiation [164].
Parkinson’s Disease and Alzheimer’s Disease
Three genes are downregulated in Parkinson's and Alzheimer's diseases; NDUFS1,
NDUFB5, and ATP5B. Both NDUFS1 and NDUFB5 encode subunits of proteins in
the Complex I. Complex I or NADH: ubiquinone oxidoreductase, is the first enzyme
of the mitochondrial electron transport chain that initiate cellular respiration or
oxidative

phosphorylation

in

the

mitochondria

in

the

inner

mitochondrial

membrane.ATP5B is a subunit of the ATP synthase. It catalyzes ATP synthesis
through using the proton motive force created by the electron transport chain across
the inner membrane as a source of energy in the process of oxidative
phosphorylation.
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It is clear that common genes in the Parkinson's and Alzheimer's diseases might
sound at the face value to be irrelevant in the context of cancer cachexia. However,
these are genes at the core requirements for cellular respiration, and hence energy
generation in muscle cells and can clearly contribute to the poor mobility and
fatigability in cachectic patients.
4.4

Analysis of Highly Significantly Altered Genes in Cachectic Muscles

From our experience, data generated via high throughput gene expression
technology is more likely to be reproduced via other confirmatory gene expression
methods such as quantitative RT-PCR only when it has the highest statistical
significance levels. Thus, we decided to data-mine our expression data and isolate
selected genes with more than two-fold change, highest P-value, and lowest
possible FDR. In muscle, 30 genes showed highly significant change in expression
(5 upregulated and 25 downregulated: P<0.0005 - P<0.00001, FDR 0.2).
4.4.1

Highly Significantly Upregulated Genes
4.4.1.1 Results

Table 13 shows the 5 highly significantly upregulated genes in cachectic muscle.
(P<0.0005 - P<0.00001, FDR 0.2). They include 2 involved with calcium signaling
and 2 with cell matrix interactions, and one transcriptional regulator. Table 13
categorizes individual gene function into respective functional domain. It also shows
the full gene name, fold change, and the P-value.
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Table 13: Highly Significantly Upregulated Genes in Cachectic Skeletal Muscle.
Gene
Symbol
Signaling

Gene Full Name

Fold
change

PLCXD1

P-Value

phosphatidylinositol-specific phospholipase C, X domain
containing 1
PITPNM2 phosphatidylinositol transfer protein, membraneassociated 2
Cell Matrix interaction

4.60

<0.00001

3.82

0.00005

ESAM

endothelial cell adhesion molecule

3.39

0.0004

PXN

Paxillin

2.16

<0.00001

2.36

< 0.0003

Transcription
MLLT1

myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 1

4.4.1.2 Discussion
Calcium Signaling Genes
Two genes which are suggested to be involved in signaling are significantly
upregulated in cachectic muscles; PLCXD1 and PITPNM2. PLCXD1 codes for
phosphatidylinositol-specific

phospholipase

C,

X

domain

containing

1.

Phospholipase C (PLC) is a group of enzymes with differences in domain structure,
that cleave the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl
glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG remains bound to the
membrane, and IP3 is released as a soluble structure into the cytosol to bind to IP3
receptors, particularly calcium channels in the smooth endoplasmic reticulum. This
causes the cytosolic concentration of calcium to increase, causing a cascade of
intracellular changes and activity [165, 166]. In turn, calcium and DAG together work
to activate protein kinase C, which goes on to phosphorylate other molecules,
leading to altered cellular activity [165]. Phospholipases are ubiquitously expressed
and have diverse biological functions [166]. In tumor cells, PLCXD1 suppress
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growth when transfected in melanoma cell line [167]. There are no further functional
studies characterizing this gene, however, like other phospholipases, it undoubtedly
plays an important role in cellular signaling specifically through calcium release,
which is important in modulating many muscle-related functions.
The second upregulated gene is PITPNM2 which codes for phosphatidylinositol
transfer protein (PITP) membrane-associated 2 protein. PITP proteins are
ubiquitous cytosolic domain involved in transport of phospholipids from their site of
synthesis in the endoplasmic reticulum and Golgi to other cell membranes.
PITPNM2 is not functionally characterized yet. However, PITPα, a member of the
PITP family that was also upregulated in our study, was identified as an essential
component in ensuring substrate supply to phospholipase C by dictating the rate of
inositol trisphosphate production by promoting the synthesis of PIP2 [168].
Thus, these two genes could be functioning through IP3/DAG pathway. Thus,
PITPNM2 might be promoting PIP2 synthesis and making it readily available for PLC
(in our case is PLCXD1) which in turn cleaves the PIP2 into PIP3 and DAG. Both of
which work as key second messengers, which via multiple cascades of events,
causes Ca2+ transient into the cytosol. Calcium, in turn, participates in the cascade
by activating proteins.
Cell Matrix Interaction
Two cell matric interaction genes were markedly upregulated in cachectic muscles;
ESAM and PXN. ESAM encodes is an endothelial cell-selective adhesion molecule.
Though ESAM has never been studied, per se, in skeletal muscle, it has been
studied in the context of coronary vascular disease (CVD) and kidney disease [169].
Skeletal muscle vasculature is of considerable importance. Around 20% of cardiac
output is directed toward skeletal muscle vasculature during rest and more than
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80% of cardiac output can be directed to contracting muscles. Increased expression
of ESAM may indicate early endothelial dysfunction that precedes kidney function
decline among individuals with established CVD [169]. Also, induced endothelial
dysfunction in skeletal muscle arterioles compromise glucose utilization and
facilitates the development of hypertension in diabetes [170]. Muscular vasculature
is of a great importance to muscle development, maintenance, and function. The
dysfunctional vascular endothelium associated with higher ESAM in CVD and
kidney disease may indicate the importance of ESAM in healthy muscular
vasculature. Thus, higher ESAM in the muscle of cachectic patients may have a
deleterious effect in vasculature compromising blood flow and/or glucose utilization.
Paxillin (encoded by PXN) is a signal transduction, adaptor, cytoskeletal,
extracellular matrix (focal adhesion) protein involved in actin-membrane attachment
[171]. The C-terminal region of paxillin contains four LIM domains that target paxillin
to focal adhesions. It is presumed through a direct association with the cytoplasmic
tail of beta-integrin [171]. The N-terminal region of paxillin is rich in protein–protein
interaction sites [171].
One might wonder why two cell matrix interaction proteins are upregulated in
muscles of patients with early cachexia. However, muscle hypertrophy (not
hyperplasia) in both cardiac and skeletal muscle is an adaptation to regular,
increasing workloads that exceed the preexisting capacity of the muscle fibers. Thus
hypertrophy allows cardiac muscle to pump blood more effectively, while skeletal
muscle becomes more efficient at transmitting forces through its tendonous
attachments to bones [172]. Paxillin has been associated with the regulation of
cytoskeletal organization, focal adhesion formation, cell migration and cell motility
[173]. Paxillin is also localized to the myotendinous and neuromuscular junctions of

61

skeletal muscle [174]. While expression of non-phosphorylatable paxillin mutants in
canine tracheal smooth muscle inhibits tension development [173].
Wasted patients are usually weaker. That said, normal/regular activities can be
envisioned as progressive overload causing intermittent levels of stress to skeletal
muscle. Thus, as an adaptation to wasting, paxillin may be attempting but failing to
promote hypertrophy in this situation. Muscular hypertrophy means its ability to
adapt by increasing the size and amount of contractile proteins (cell matrix
interaction proteins), which comprise the myofibrils within each muscle fiber, leading
to an increase in the size of the individual muscle fibers and their consequent force
production [172]. That is similar to previously reported evidence of the increased in
paxillin expression along other proteins upon the increased mechanical load per unit
of cross-sectional area during short period of an increasing load [175].
Transcriptional Regulation
Transcriptional regulation is a complicated series of mechanisms used by cells to
increase or decrease the expression of specific gene products. These sophisticated
programs of gene expression serve several purposes of which developmental and
adaptive responses are just a few. Transcriptional regulation is a versatile and
adaptable mechanism allowing the cell to express proteins when needed. For these
reasons, upregulation of genes involved in transcriptional regulation is expected in
the context of wasting muscle. Whether cachectic muscles die via apoptosis or
necrosis, attempt to regenerate or differentiate, or just change in its morphogenic
features, regulation of transcription is definitely needed.
MLLT1 gene, or myeloid/lymphoid or mixed-lineage leukemia translocated to 1,
codes for a transcriptional regulator that is highly significantly upregulated in
cachectic muscle. MLLT1 has never been studied in the context of cachexia nor
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muscular transcriptional regulation. However, evidence suggests an important
developmental role of this gene. MLLT1 has nuclear localization signal, and
expressed widely in variant tissues suggesting its role as a coactivator activating
individual lineage developmental programs [176]. MLLT1 has been shown to be
required for early embryonic development in the mouse, as knock-out embryos are
non-viable [176]. Also, an enhanced MLLT1 expression plays a role in testicular
germ cell tumors [177]. Thus, MLLT1 gene could be an activator for gene
expression of multiple genes that can either explain the pathology of wasting and/or
illustrate an early compensatory role to resist wasting. Identifying which of these
roles MLLT1 plays would require further investigation.
4.4.2

Highly Significantly Downregulated Genes
4.4.2.1 Results

Table 14 shows the 5 highly significantly downregulated genes in cachectic muscle.
(P<0.0005 - P<0.00001, FDR 0.2). Analysis of the 25 downregulated genes involved
include 7 that are involved with metabolism (5 of which are mitochondrial); 4 with
signaling; 4 with ubiquitination; and 3 with intracellular trafficking. There was marked
downregulation of multiple genes involved in glycogen metabolism which correlates
with the lack of glycogen, muscle weakness, and fatigue; characteristic of cachexia.
Table 14, also categorizes individual gene function into respective functional
domain. It also shows the full gene name, fold change, and the P-value.
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Table 14: Highly Significantly Downregulated Genes in Cachectic Skeletal Muscle.
Gene
Gene Full Name
Symbol
Mitochondrial Metabolism
SUCLA2
ALDH5A1
ACADM
NARS2

Fold
P-Value
Change

succinate-CoA ligase, ADP-forming, beta subunit
aldehyde dehydrogenase 5 family, member A1
acyl-CoA dehydrogenase, C-4 to C-12 straight chain
asparaginyl-tRNAsynthetase 2, mitochondrial
(putative)
nicotinamide nucleotide transhydrogenase

-2.33
-4.16
-3.64
-2.05

<0.0003
<0.00001
<0.0004
0.0003

-2.62

0.00003

protein kinase, AMP-activated, beta 2 non-catalytic
subunit
amylo-alpha-1, 6-glucosidase, 4-alphaglucanotransferase

-2.64

0.0001

-3.51

0.0002

phospholipase C-like 1
neurexophilin and PC-esterase domain family,
member 3
ZFYVE9
zinc finger, FYVE domain containing 9
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3
ZNF41
zinc finger protein 41
Muscle Contraction

-3.64
-2.90

<0.00008
<0.00005

-2.07
-2.02
-2.12

0.0002
<0.00008
0.0003

PPP1R12B protein phosphatase 1, regulatory subunit 12B
Cell Matrix Interaction

-2.10

0.00005

ITGB6
integrin, beta 6
Ubiquitination

-5.09

0.0002

WWP1

-3.37

0.00001

ZYG11B
zyg-11 family member B, cell cycle regulator
FBXL17
F-box and leucine-rich repeat protein 17
DCAF6
DDB1 and CUL4 associated factor 6
Intacellular Trafficking

-3.01
-2.38
-2.59

0.00007
0.00005
0.0004

RAB9B
RAB10

-3.10
-2.18

<0.00009
0.00006

CLASP2
cytoplasmic linker associated protein 2
Apolipoproteins

-2.30

0.0004

VLDLR
very low density lipoprotein receptor
APOOL
apolipoprotein O-like
Uncharachterized

-2.9
-2.06

<0.00005
<0.0003

C1orf192

-3.87

<0.0004

NNT
Metabolism
PRKAB2
AGL
Signaling
PLCL1
NXPE3

WW domain containing E3 ubiquitin protein ligase 1

RAB9B, member RAS oncogene family
RAB10, member RAS oncogene family

chromosome 1 open reading frame 192
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4.4.2.2 Discussion
Mitochondrial Metabolism
SUCLA2 (succinyl-CoA ligase [ADP-forming] mitochondrial) encodes for ADPforming succinyl-CoA synthetase, a mitochondrial matrix enzyme which catalyzes
the reversible synthesis of succinyl-CoA from succinate and CoA [178]. It plays a
key role as one of the catalysts involved in the citric acid cycle, a central pathway in
cellular metabolism [165]. Decreased SUCLA2 activity due to mutation was found in
muscle mitochondria of patients with encephalomyopathy and mtDNA depletion
[179].Myopathy is a disease of dysfunctional muscle fibers resulting in muscular
weakness.
ALDH5A1 codes for succinate-semialdehyde dehydrogenase, mitochondrial, an
enzyme that belongs to the aldehyde dehydrogenase family of proteins [180].
ALDH5A1 deficiency results in muscle hypotonia and developmental delay [181,
182]. Hypotonia is a state of low muscle tone (the amount of tension or resistance to
stretch in a muscle), often involving reduced muscle strength. Mice with a
homozygous knockout of ALDH5A1 exhibit symptoms including reduced body
weight [183].
ACADM encodes for an acyl-coenzyme a dehydrogenase that is important for
hydrolyzing medium-chain fatty acids to produce energy, especially during periods
of fasting [184]. Fatty acid oxidation spares glucose during fasting and is also
required for amino acid metabolism, which is essential for the maintenance of
adequate glucose production [185]. With a deficiency of this enzyme, medium-chain
fatty acids cannot be hydrolysed then these fatty acids are not converted into
energy, leading to weakness, lethargy, and low blood sugar [186]. Training
increases fatty acid oxidation and skeletal muscle oxidative capacity by increasing
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expression of ACADM which results in increased use fatty acids to enhance skeletal
muscle oxidative capacity [187].
NARS2 codes for asparaginyl-tRNA synthetase 2 [188]. This class-II synthetase is
specific

for

alanine,

asparagine,

aspartic

acid,

glycine,

histidine,

lysine,

phenylalanine, proline, serine, and threonine [189]. NARS2 mutations cause severe
myopathy characterized by proximal muscle weakness, severe amyotrophy
(progressive wasting of muscle tissues), excessive fatigability, dysarthria, paresis of
facial muscles, and ptosis [190]. Skeletal muscle biopsies show atrophic fibers,
ragged-red fibers, and enlarged mitochondria [190]. Other NARS2 mutations cause
Leigh Syndrome, which results in hypotonia (low muscle tone and strength),
dystonia (involuntary, sustained muscle contraction), and ataxia (lack of control over
movement). Mutations in mitochondrial seryl-tRNAsynthetase, another member of
the class II amino-acyl tRNA family, cause severe cachexia [191].
NNT codes for nicotinamide nucleotide transhydrogenase, an integral protein of the
inner mitochondrial membrane. Under physiological conditions, this enzyme uses
energy from the mitochondrial proton gradient to produce high concentrations of
NADPH. The resulting NADPH is used for biosynthesis and in free radical
detoxification [192].
Metabolism
As mentioned above PRKAB2 is the regulatory non-catalytic beta subunit gene for
the AMP-activated protein kinase (AMPK). PRKAB2 is a positive regulator of the
AMPK that is highly expressed in skeletal muscle [150]. AMPK is an important
energy-sensing enzyme that monitors cellular energy status. PRKAB2 is also
reported to be downregulated in a mouse model of severe cachexia [151]. PRKAB2
knockout mice had reduced maximal and endurance exercise capacity during
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treadmill running which was also associated with also reduced levels of muscle and
liver glycogen [162]. Thus, PRKAB2 might contribute to the muscular fatigability and
the decreased mobility that are evident signs of cachexia.
AGL codes for the glycogen debranching enzyme which facilitates the hydrolysis of
glycogen in through glucosyltransferase and glucosidase activity [193]. Mutation in
AGL causes one of the glycogen storage diseases (type III) and results in peripheral
muscular impairment which can vary from minimal to severe [194] as well as muscle
weakness [195].
Signaling
PLCL1 codes for phospholipase C-Like 1, one of several phosphoinositide
phospholipase C enzymes that play an important role in signal transduction [196].
These

enzymes

participate

in

phosphatidylinositol

4,5-bisphosphate

(PIP2)

metabolism in a calcium-dependent manner. All members in this family are capable
of catalyzing the hydrolysis of PIP2 into two important second messenger molecules
(DAG and IP3), which go on to alter multiple cellular responses such as proliferation,
differentiation, apoptosis, cytoskeleton remodeling, vesicular trafficking, ion channel
conductance, endocrine function and neurotransmission.
However, it is not the only member in the PLC family that is downregulated. PLCB1
is also downregulated in multiple muscle downregulated KEGG pathways (Table
12). This is important since calcium signaling is important for muscle contraction and
thus, it affects muscle contraction and eventually causes weakness. NXPE3 codes
for neurexophilin and PC-esterase domain family, member 3 which is another
uncharacterized gene [197].
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ZFYVE9 encodes a zinc finger FYVE domain-containing protein 9 or SARA (SMAD
anchor for receptor activation) [198]. SARA contains a double zinc finger (FYVE
domain). SARA is an anchoring protein involved in transforming growth factor beta
(TGF-β) signaling. It binds to the R-SMADs SMAD2 and SMAD3 [199].It facilitates
the phosphorylation of the R-SMAD, which subsequently dissociates form SARA
and the receptor and binds a co-SMAD where they enter the nucleus as
transcription factors. All SMADs are downstream to myostatin (and TGF-β and all of
its related proteins), which is believed to be activated in wasting muscle. However,
our data shows significantly downregulatedmyostatin in cachectic muscles (as will
be explained in details later). Thus, a downregulated ZFYVE9 may be further
evidence of an adaptive response to myostatin signaling in cachexia.
RPS6KA3 codes for the ribosomal protein S6 kinase which is a member of the RSK
(ribosomal

S6

kinase)

family

of

serine/threonine

kinases.

This

kinase

phosphorylates various substrates, including members of the mitogen-activated
kinase (MAPK) signaling pathway (which one of the downregulated KEGG pathways
in cachectic muscles as above) [200]. The activity of this enzyme has been
implicated in controlling cell growth and differentiation. In muscle cells, it mediates
cellular differentiation through regulation of NFAT3 [201]. Mutations in this gene are
associated with Coffin-Lowry syndrome [202], which is characterized by growth and
psychomotor retardation, hypotonia, and progressive skeletal changes [203]. Also,
RPS6KA3 knockout mice have altered extracellular signal-regulated kinase
signaling and glycogen metabolism in skeletal muscle, 10% reduction in weight, and
are 14% shorter than wild-type littermates [204]. A study of patients with CoffinLowry syndrome showed episodes of sudden, non-epileptic collapse with atonia,
described as a form of cataplexy (Cataplexy comprises an abrupt, complete, or
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partial loss of voluntary muscle tone and is usually seen in response to strong
emotion) [205].
ZNF41 encodes for zinc finger protein 41, a member of zinc finger family of
transcription factors [206]. So far, little is known about ZNF41. However, having one
of the highest expressions of ZNF41 in skeletal muscle [207] is an indicator of its
transcriptional importance.
Muscle Contraction
PPP1R3A codes for the regulatory subunit and myosin binding subunits of myosin
light chain phosphatase (MLCP), which is abundantly expressed in skeletal and
cardiac muscle [208]. This gene plays an important regulatory role in muscle
contraction.
Ubiquitination
Ubiquitination (also known as ubiquitylation) is an enzymatic, post-translational
modification (PTM) process in which ubiquitin protein is attached to a substrate
protein, targeting the protein for degradation. This results in the addition of one
(monoubiquitination) or multiple (polyubiquitination) ubiquitin molecules to the
substrate protein [209]. The ubiquitination system functions in a wide variety of
cellular processes.
WWP1 codes for a NEDD4-like E3 ubiquitin-protein ligase, which belongs to a family
of E3 ubiquitin-ligases that regulate key trafficking decisions, including targeting of
proteins to proteosomes or lysosomes. Interestingly, studies aimed at understanding
chicken muscular dystrophy showed mutations in WWP1 in dystrophic chicken
[210]. Another study on chickens treated with dexamethasone (which causes
wasting) found that WWP1 expression was dependent on the duration of
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dexamethasone treatment; short-term resulted in decreased WWP1 expression,
while long-term increased WWP1 expression [211]. Detection of highly significant
downregulation of WWP1 in cachectic muscles in our patients suggests an adaptive
response to the early cachexia.
ZYG11B codes for zyg-11 family member B, a cell cycle regulator protein. It
probably acts as target recruitment subunit in the E3 ubiquitin ligase complex
ZYG11B-CUL2-Elongin BC [212]. One study showed that erythropoietin (EPO)
functional knock-out mice have lower ZYG11B expression in skeletal muscle
compared to controls [213]. The EPO receptor is highly expressed in muscle and
may suggest important role of EPO in stimulating skeletal muscle regeneration
[213].
FBXL17 codes for the F-box and leucine-rich repeat protein 17, a member of the Fbox protein family. Complexes, formed by the presence of F-box proteins act as
protein-ubiquitin ligases [214]. There is no further information regarding this gene.
Intacellular Trafficking
RAB9B codes for a member of sub-family of the RAS small guanosine triphosphate
(GTP)-binding proteins that regulate membrane trafficking. The encoded protein
may be involved in endosome-to-Golgi transport [215]. Diseases associated with
RAB9B include pelizaeus-merzbacher disease which has early onset hypotonia.
With progressive disease, even more severe muscular involvement is evident.
RAB10 codes for another member in the RAS oncogene family [216]. RAB10 has
the highest expression in heart and skeletal muscle [217]. It is involved in the insulin
signaling cascade that causes intracellular vesicles containing glucose transporter-4
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(GLUT4) to translocate to and fuse with the plasma membrane and enhance
glucose uptake [218, 219].
CLASP2 codes for cytoplasmic linker associated protein 2, a microtubule plus-end
tracking protein that promotes the stabilization of dynamic microtubules. It is also
required for the polarization of the cytoplasmic microtubule arrays in migrating cells
towards the leading edge of the cell. Like RAB10, CLASP2 has a role in insulin
signaling and glucose uptake in myocytes and adipocytes [220]. CLASP2
colocalizes with the glucose transporter GLUT4 at the plasma membrane within
areas of insulin-mediated cortical actin remodeling [220]. CLASP2 knockdown
inhibits insulin-stimulated GLUT4 translocation and glucose transport [220].
This downregulation of this pathway undoubtedly contributes to the insulin
resistance and muscle fatigue in cachectic patients.
On the other hand, a hallmark of the neuromuscular junction (NMJ) is the high
density of acetylcholine receptors (AChRs) in the postsynaptic muscle membrane
[221, 222]. CLASP2 mediates microtubule capturing at the synaptic membrane for
the maintenance of a normal neuromuscular phenotype [222, 223]. The absence of
CLASP2 impairs the maintenance of the neuromuscular junction with a decreased
subsynaptic membrane in muscles, and a decrease of synaptic AChRs [224]. The
significant downregulation of CLASP2 in cachectic muscles will alter the vitality of
the NMJ and it turn cause impairment of muscle excitability [224]. Even more
interestingly, the regulation of CLASP2 strictly controlled by agrin (AGRN) [223],
which is itself downregulated in the KEGG pathways as discussed above.
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Apolipoproteins
VLDLR is a very-low-density-lipoprotein receptor; a transmembrane lipoprotein
receptor of the low-density-lipoprotein (LDL) receptor family. VLDLR is widely and
highly expressed in heart, muscle, and adipose tissues, which are active in fatty acid
metabolism [225], so the receptor targets lipoproteins to these tissues [226].
Although the mechanism of VLDLR function in muscle is not fully understood, the
defective clearance of triglyceride-rich lipoproteins leads to impaired energy
metabolism, reduced exercise capacity, cachexia, and malnutrition syndrome in
patients with advanced chronic kidney disease [227]. Also, reduced levels of
lipoprotein lipase and VLDLR contribute to cachexia and reduced exercise capacity
[227]. Mutations of this gene causes type I lissencephaly; a condition of which one
of the symptoms is hypotonia [228].
APOOL encodes an apolipoprotein O-like protein. The apoliprotein 0-like domain is
found in the protein component of circulating lipoprotein complexes. Apolipoprotein
O is a cardiolipin-binding component of the Mitofilin/MINOS protein complex
determining cristae morphology in mitochondria (the folds in the inner membrane of
a mitochondrion) [229]. Downregulation of APOOL impairs mitochondrial respiration
and causes major alterations in cristae morphology; which are only altered under
pathological conditions [229]. The important paralog; APOO [229]. APOO transgenic
mouse fed a high-fat diet exhibited depressed ventricular function with reduced
fractional shortening and ejection fraction, and the myocardial sections revealed
mitochondrial degenerative changes [230]. Hence, APOO represents a link between
impaired mitochondrial function and cardiomyopathy onset causing impaired
contractility [230]. Furthermore, APOO enhances mitochondrial uncoupling and
respiration, both of which were reduced by targeted knockdown of APOO [230]. If
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that is the case in cardiac muscle, then APOOL downregulation in our cachectic
muscle could be an early sign of impairment in skeletal muscle contractility as a
result of damaged mitochondria.
4.5

Anticipated Results from Previous Studies

Preclinical studies have a few produced findings in multiple settings that attempt to
explain the pathogenesis of cancer cachexia. Without exception, these findings so
far have failed to explain cachexia in the clinical setting. This section aims to look at
some of the prominent findings from clinical and preclinical models of cancer
cachexia in order to see its reproducibility in our sequencing data.
4.5.1

Preclinical Findings
4.5.1.1 Atrophy-Specific Ubiquitin Ligases

It is long believed that cachexia is a result of a negative nitrogen balance caused by
decreased protein synthesis combined with increased protein degradation. The
ubiquitin proteasome pathway is the main protein degradation pathway involved.
Two genes were repeatedly found to be downregulated in preclinical models of
cachexia; FBXO32 (atrogin-1/MAFbx) and TRIM63 (MURF1).
FBXO32 codes for F-box only protein 32 [231], while TRIM63 codes for E3 ubiquitinprotein ligase also known as MURF1. These are two atrophy-specific ubiquitin
ligases that are two of the several key regulators of the ubiquitin proteasome
degradation pathway. Both of the genes mediate sarcomeric breakdown and inhibit
protein synthesis [232]. FBXO32 expression was significantly upregulated in
atrophying muscles in cachectic rats and mice secondary to fasting, diabetes, renal
failure or experimental cancer [231]. This upregulation was also confirmed in vitro in
a murine skeletal muscle cell line [233]. Both MuRF1 and MAFbx were substantially
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upregulated in rat skeletal muscle after immobilization, denervation, hind limb
suspension or treatment with interleukin-1 or dexamethasone; conditions that are all
associated with a significant loss of muscle mass [234].
In our data of cachectic muscle, nether of the two genes were found to be
upregulated. Indeed, in contrast, FBXO32 was even found to be significantly
downregulated. Similarly, the two major microarray experiments documenting gene
expression changes in human muscle biopsies of cachectic patients also found no
change in the expression level of either of these two genes, which were long
believed to be key players in the pathogenesis of cachexia [235, 236]. The
downregulation of FBXO32 was not a surprise since the downregulation of the
ubiquitin pathway was also evident with 4 other highly significantly downregulated
genes (as discussed earlier). Downregulation of this protein degradation pathway
may be a compensatory mechanism to defend against wasting in the cachectic
subjects.
Myostatin (MSTN) and its associated receptor activin (ACVR2B) have recently
stolen the limelight as a possible cause of cachexia. MSTN or growth and
differentiation factor 8 (GDF8) is a TGF-β family member. Mutations in the MSTN
gene causes muscular hypertrophy in animals [237] as well as humans [238]. On
the other hand, overexpression of MSTN caused pronounced muscular atrophy
[239].
MSTN which is mainly synthesized in skeletal muscle cells works by activating
ACVR2B receptor that in turn, recruits an Alk family kinase resulting in activation of
a SMAD2 and SMAD3 transcription factor complex and leading to activation of
muscle loss signals that are as yet not fully understood [240]. For that, many
attempts have been tried to block this signals in atrophying muscle. For example,
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blocking the ACVR2B receptor in mice can reverse cachexia and muscle wasting
[241].
Neither the present study nor the previous clinical expression studies have shown
any upregulation in MSTN, its receptor, or any downstream elements. In contrast,
our data shows significant downregulation in both, MSTN and ACVR2B, which again
may reflect the bodies' complicated response to try to prevent wasting. Based on the
previous animal studies, several clinical trials are currently investigating the outcome
of blocking MSTN with monoclonal antibodies or inhibiting elements of its
downstream signaling. We believe that because the receptor and downstream
elements are downregulated that these trials are desined to failure. However, it
might give some reversal to the syndrome in unique settings. It should be noted that
some cancers appear themselves to produce MSTN [242]. If this is found to be a
general phenomenon then downregulation of muscle MSTN and its receptor may be
considered adaptive responses to protect the muscle from tumor-derived MSTN.
A very interesting finding from our data is the significant overexpression of GDF15.
GDF15 is a growth and development factor 15 (NAG-1; MIC-1). It belongs to the
transforming growth factor beta superfamily [243] that has a role in regulating
inflammatory and apoptotic pathways in injured tissues and during disease
processes [244]. In advanced cancer, high serum levels of GDF15 can lead to
cachexia via central regulation of appetite [245]. In mice, cachexia induced by
GDF15 overexpression can be reversed by anti-GDF15 monoclonal antibodies
[245]. Our data shows a very interesting significantly upregulated GDF15 in
cachectic muscle (12.9 fold change; P-value 0.028). This level of change is reported
for the first time within the muscle, indicating its probable role in cachexia
pathogenesis that warrants further investigation.
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4.5.2

Previous Clinical Findings
4.5.2.1 Inflammatory Cytokines and Tumor Specific Factors

The proteolysis-inducing factor (PIF) was isolated from urine using monoclonal
antibody in murine cachexia model [246] as well as human subjects with pancreatic
cancer [247]. PIF is believed to possess an ability to degrade skeletal muscle.
Although PIF has been linked with weight loss in patients, other groups have failed
in reproducing the above finding; hence PIF was not redetected [248]. Despite our
knowledge that PIF was originally captured in subjects' urine, we were still
interested in checking its expression within the cachectic muscles. PIF (DCD;
dermicidin) was not detected in our sequencing data. It should be noted that if the
tumor itself is the source of PIF, we would not have expected to detect it in the
muscle tissue; so we cannot discount its existence at this time.
Many inflammatory cytokines have long been implicated in muscle wasting. Those
include tumor necrosis factor-alpha (TNF), interleukin-6 (IL6), and interferon-gamma
(IFNG). Preclinical studies showed significant contribution of each of these cytokines
in the development of cachexia [96, 110, 111]. Unlike TNF and IFNG which were
not found to correlate to weight loss in human [112], circulating levels of IL-6 have
been shown to correlate with weight loss in cancer patients [249]. In the present
study, the expression levels of these three cytokines in cachectic muscle were not
statistically significant (Table 15). However, for IL6 and IFNG expression was
higher, but not significant. It is possible that expression of these cytokines is
increased in some but not all cachectic patients.
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Table 15: Inflammatory Cytokines and Tumor Specific Factors.
Gene Full Name

Gene

Tumor necrosis factors-alpha
Interleukin-6
Interferon-gamma
Dermcidin/proteolysis-inducing factor

TNF
IL6
IFNG
DCD/PIF

4.5.3

Fold Change

P-Value

1.12
0.8997
6.96
0.2241
5.47
0.1819
Not expressed

Results from Previous Genome Wide Expression Analysis

Stephens et al. (2010) were the first group to look at genome wide expression
profiling in muscle biopsies obtained from weight losing cancer patients compared to
weight stable non-cancer controls [235]. Using muscle biopsies from the rectus
abdominis, eight genes were found to be differentially expressed by the microarray
that were also confirmed by RT-PCR. Changes in expression of these eight genes
were then rechecked in two different groups of muscles (diaphragm and vastus
lateralis) from a different center. Only two genes were reproducible from the 8
genes; TIE1 and CAMK2B. Both genes are "endurance exercise"-activated genes.
Overexpression of such two genes may signal muscles attempt to maintain its
viability through activation of pathways usually active during moderate endurance
activity [235]. We looked at the expression level of all the genes that was found to
be significant in the previous microarray study 1 (Table 16). Only TIE1 was found to
be significantly upregulated in the present study, in-line with what was previously
reported. How HTIE1 functions is still unknown, however it is an exercise activated
gene, usually upregulated in response to prolonged training [250].
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Table 16: Results of Significantly Altered Genes in Previous Microarray Study 1.
Gene Full Name

Gene

Fold Change

P-Value

Adenomatosis polyposis coli down-regulated 1
Calcium/calmodulin-dependent protein kinase
II beta
Eukaryotic translation initiation factor 3, subunit
I
Hepatocyte growth factor-regulated tyrosine
kinase substrate
NudC nuclear distribution protein
Polymerase (RNA) mitochondrial (DNA
directed)
Tyrosine kinase with immunoglobulin-like and
EGF-like domains 1
Tuberous sclerosis 2
Serum/glucocorticoid regulated kinase 1

APCDD1

3.50

0.1063

CAMK2B

1.00

0.9963

EIF3I

-1.11

0.5461

HGS

2.67

0.0936

NUDC

-1.16

0.5105

POLRMT

1.25

0.7541

TIE1

4.50

0.0218

TSC2
SGK1

1.81
4.52

0.031
0.3278

In 2012, the same group of investigators of the above study reattempted another
microarray-based, genome-wide expression analysis of quadriceps muscle biopsies
in single biopsies from healthy controls and in paired biopsies (pre-resection
baseline and 8 month post-resection follow-up) from cachectic cancer patients [236].
They detected 10 genes where expression was significantly changed (Table 17).
Table 17: Results of Significantly Altered Genes in Previous Microarray Study 2.
Gene Full Name

Gene

Cartilage oligomeric matrix protein
Adiponectin, C1Q and collagen domain
containing
Matrix metallopeptidase 3
Phosphoenolpyruvatecarboxykinase 1
(soluble)
Angiopoietin-like 7
Heat shock protein 90kDa alpha (cytosolic),
class B member 1
Solute carrier family 25 (mitochondrial iron
transporter), member 37
Prospero homeobox 1
Regulator of calcineurin 1
Histidine triad nucleotide binding protein 3

COMP
ADIPOQ
MMP3

Fold Change

P-Value

Not expressed
6.98

0.3605

Not expressed

PCK1

15.29

0.2891

ANGPTL7

1.75

0.3664

HSP90AB1

-1.29

0.2028

SLC25A37

-1.24

0.229

PROX1
RCAN1
HINT3

-1.4
2.41
-2.45

0.4232
0.3536
0.0061
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Of the genes studied, the only significantly changed gene that is common with the
present study is the HINT3. HINT3 is a histidine triad nucleotide binding protein 3
[251]. It is an uncharacterized gene. However, it has been recently found to be
expressed in skeletal muscle in the chimpanzee [252].
4.6

Verified Results Using Real-Time Reverse Transcription PCR

Despite of the high reliance of the quantitative capability of the RNA sequencing
results, it is important to verify part of the expression results using a different
method. A cherry-picked selection of genes that are of a high significance and high
fold-change were picked. Confirming the difference of high fold-change expression
data can allow us to check and verify them later-on at protein level. Four
upregulated

genes;

COL4A2,

NRXN2,

NOTCH1,

and

downregulated genes; NDUFS1, and PTPRR were chosen.

AGRN,

and

two
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4.6.1

Results

AGRN


3

P 0.0039
Relative Expression

Relative Expression

15.0

COL4A2

10.0

5.0

0.0

2

1

0

Control Cachexia

Control Cachexia

NOTCH1

NRXN2
1.5



P < 0.0001
Relative Expression

Relative Expression

6.9



P <0.0001

4.6

2.3

0.0
Control Cachexia



P 0.0008

1.0

0.5

0.0
Control Cachexia

Figure 3: Upregulation of Expression of Selected Genes Confirmed by Real-Time
RT-PCR in Cachectic Skeletal Muscle.
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NDUFS1


2.1

P 0.0008
Relative Expression

Relative Expression

1.8

PTPRR

1.2

0.6

0.0

P 0.0983

1.4

0.7

0.0
Control Cachexia

Control Cachexia

Figure 4: Downregulation of Expression of Selected Genes Confirmed by Real-Time
RT-PCR in Cachectic Skeletal Muscle.

All chosen genes that were previously shown to be upregulated/downregulated were
reproducible via real-time RT-PCR (Figure 3 and 4).
4.6.2

Discussion

Expressions of four upregulated genes that are statistically significant were
confirmed via real-time RT-PCR.
AGRN (Agrin) and COL4A2 (collagen type 4 alpha 2) (section 4.3.2.2) are elements
in the extracellular matrix-receptor interaction. AGRN fragments are under
investigation as a possible biomarker for sarcopenia [136] and was also found to be
upregulated in cachectic muscles. Also, COL4A2 is a component of the myocyte
basal lamina [137].
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However, the other two genes; NOTCH1 receptor (section 4.3.2.2), an activators of
the notch pathway [131, 132], and NRXN2 (a cell adhesion molecules) are two
poorly characterized genes in skeletal muscle and their confirmed upregulation
warrant further research.
The confirmed downregulated genes were the NDUFS1 and the PTPRR. The
NDUFS1 is upregulated in the Parkinson's and Alzheimer's diseases (section
4.3.3.2). NDUFS1 encodes subunit of proteins in the Complex I. Complex I or
NADH: ubiquinone oxidoreductase, is the first enzyme of the mitochondrial electron
transport chain that initiate cellular respiration or oxidative phosphorylation in the
mitochondria in the inner mitochondrial membrane.ATP5B is a subunit of the ATP
synthase. It catalyzes ATP synthesis through using the proton motive force created
by the electron transport chain across the inner membrane as a source of energy in
the process of oxidative phosphorylation.
PTPRR is a protein tyrosine phosphatase, receptor type, R. PTPRR gene is a
MAPK signaling pathwaygenethat is uncharacterized in the skeletal muscle and is
correlated for the first time to cachexia.
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Chapter 5: Results and Discussions – Adipose Tissue
5.1

Demographic and Biochemical Characteristics of Subjects
5.1.1

Results

Demographic and biochemical details of patients for fat cachexia samples (FS) and
fat weight-stable controls (FC) are shown in bellow tables. The tables show data for
6 samples in each group. Samples were analyzed based on weight, BMI, some
nutritional parameters, inflammatory markers and other related demographics.
Table 18 shows subjects oncological diagnoses for visceral adipose tissue biopsies.
All patients were with histologically confirmed malignancies. Age and gender
distribution were not significantly different between cachexia fat cases (FS) and
weight-stable controls (FC) (Table 19). All biochemical nutritional parameters (i.e.
hemoglobin, total protein, albumin, urea, and creatinine) and inflammatory markers
(i.e. WBC and CRP) were not significantly different between both groups (Table 19).
Baseline weights and BMIs in the cachexia group did not differ significantly from the
control. The time range between current (at time of biopsy) and baseline weights
(preceding date of biopsy) was 3-6 months. Mean weight loss from baseline in the
cachexia group was 4.6 kg which is 6.5% of baseline body weight (i.e. 3-6 months
before the date of sample collection). Amount and percentage of weight loss was
significantly different from controls that had relatively stable weights; P-value of
0.0001 and < 0.0001, respectively.
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Table 18: Subjects' Diagnoses for Adipose Tissue Biopsies.
Cachexia Fat Cases (FS)

Weight-stable Fat Controls (FC)

FS1: Malignant Neoplasm of Rectum
FS2: Malignant Neoplasm of Stomach
FS3: Malignant Neoplasm of Rectum

FC3: Malignant Neoplasm of Colon
FC5: Malignant Neoplasm of Colon
FC6: Malignant Neoplasm of Connective
and Soft Tissue
FC7: Malignant Neoplasm of Rectum
FC9: Malignant Neoplasm of Rectum
FC10: Malignant Neoplasm of Colon

FS4:Malignant Neoplasm of Duodenum
FS5: Malignant Neoplasm of Colon
FS6: Malignant Neoplasm of Pancreas

Table 19: Demographic Data for Adipose Cachectic Cases and Weight-Stable
Adipose Controls.
Gender
(M/F)
FS: 4/2; FC: 4/2
Characteristics
Age
Hemoglobin
Creatinine
Urea
Total protein
Albumin
WBC
CRP
Baseline BMI
Current BMI
Baseline
weights
Current weights
Amount of WT
loss
% of WT Loss

FS:
N=6
FC:
N=6
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.
Cach.
Cont.

Mean

SEM

Median

Range

P-Value

58.67
55.50
115.5
118.2
64.40
66.83
5.940
4.100
52.20
61.50
27.80
35.33
9.633
7.100
11.00
18.40
24.79
28.41
23.12
28.37
70.10
78.07
65.48
77.93
4.617
0.133
6.489
0.178

6.677
4.387
4.0978.
356
8.035
6.300
1.520
0.5013
3.555
5.620
3.382
2.929
1.295
1.186
5.874
5.810
2.290
0.8553
2.027
0.9097
5.168
2.843
4.748
2.883
0.7241
0.2171
0.8185
0.2991

56.00
58.00
117.0
121.0
59.00
64.50
5.300
3.800
50.00
64.00
26.00
37.00
9.350
5.900
7.000
19.00
25.27
28.66
23.61
28.58
73.50
75.50
68.45
75.30
4.500
0.0000
5.826
0.0000

44-83
41-66
103-125
90-143
41-84
49-94
2.9-11.1
3.0-6.5
46-66
42-79
20-40
23-44
6.0-13.3
4.4-12.1
1-34
1-34
15.57-30.86;
9..96-31.23
14.81-28.96;
24.91-31.23
45.00-81.00;
71.40-89.00
42.80-76.00;
72.00-89.00
2.200-7.000
(-0.6000)-1.000
4.558-9.589
(-0.8403)- 1.370

0.7002
0.7803
0.8142
0.2451
0.2163
0.1248
0.1797
0.3966
0.1692
* 0.0397
0.2066
*0.0489
*** 0.0001
***< 0.0001
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Table 20 compares weight and BMI changes between current and baseline within
each group (paired t-test). The cachectic fat cases (FS) had a significant difference
between current and baseline data while weight-stable fat controls (FC) had no
significant change.
Table 20: Paired t-Tests for Weight and BMI Change for Adipose Biopsies.
Characteristics

FS/FC: N=6/6

Mean

SEM

Median

Range

P-Value

Weight FS
(cachectic)
BMI FS
(cachectic)
Weight FC
(weight-stable)
BMI FC
(weight-stable)

Baseline
Current
Baseline
Current
Baseline
Current
Baseline
Current

70.10
65.48
24.79
23.12
78.07
77.93
28.41
28.37

5.168
4.748
2.290
2.027
2.843
2.883
0.8553
0.9097

73.50
68.45
25.27
23.61
75.50
75.30
28.66
28.58

45.00-81.00
42.80-76.00
15.57-30.86
14.81-28.96
71.40-89.00
72.00-89.00
25.26-31.23
24.91-31.23

**0.00.2

5.1.2

**0.0035
0.5659
0.6247

Discussion

Similar to the discussion in section 4.1.2, in the above demographic analysis,
patients included in the study were chosen meticulously to be at the early stages of
cachexia (i.e. 5 - < 10% weight loss). Our subjects had a mean percentage of weight
loss of 6.5% (range 4.6-9.6 %). Since systemic inflammation measured via serum
CRP may or may not be present in patients with cachexia [7], our subjects were
included regardless of their CRP values (range 1-34, Table 19). However, the CRP
values between cachectic cases (FS) and weight-stable controls (FC) were ensured
to be not statistically significant; P= 0.325 in muscle.
Nutritional and nutrition-related biochemical markers were all ensured to be
comparable in both groups to objectively exclude the possibility of malnutrition as
the primary cause of weight loss.
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5.2

Heat Map of RNA Sequencing Data
5.2.1

Results

Figure 5shows the heat map of differentially regulated genes between cachectic fat
cases (FS) and weight-stable fat controls (FC). The figure shows separation
between both groups but not as clear cut as that seen in skeletal muscle. The heat
map shows a total of 365 significantly upregulated genes and 93 downregulated
genes (P-value < 0.05; and FDR < 0.5).

Figure 5: Heat Map Representation of the Differentially Expressed Genes in Adipose
Tissue.
Gene expression is shown for the cachectic fat cases (FS; purple bars; lower panel)
and weight-stable fat controls (FC; green bar; upper panel). Colors represent scaled
and centered expression values: red represents higher expression, blue represents
lower expression.
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5.2.2

Discussion

This simple hierarchical cluster analysis revealed a clear visual distinction of gene
expression signature between cachexia fat cases (FS) from those with weight-stable
fat controls (FC).
5.3

Analysis of Differentially Expressed KEGG pathways
5.3.1

Upregulated KEGG Pathways in Cachectic Adipose Tissue
5.3.1.1 Results

Five KEGG pathways are differentially upregulated in cachectic fats cases vs.
weight-stable control fats; Prion diseases, steroid biosynthesis, cytokine-cytokine
receptor

interaction,

systemic

lupus

erythematosus

(SLE),

and

N-Glycan

biosynthesis. These pathways have 5, 3, 11, 6, and 4 significantly upregulated
genes respectively (Table 21). Table 21 shows the individual genes in each pathway
and the overall statistical significance for each of these pathways. The level of
statistical significance for the prion disease pathway is an order of magnitude
greater than that for the other pathways. Thus, it was the only discussed pathway as
below. However, Table 22 shows a summary of the full gene name, fold change,
and P-value for individual genes in each pathway.
Table 21: Differentially Upregulated KEGG Pathways in Cachectic Adipose Tissue.
KEGG Pathway

Gene

Gene

Gene

Gene

Gene

Prion diseases
Steroid biosynthesis
Cytokine-cytokine
receptor interaction
Systemic lupus
erythematosus
N-Glycan
biosynthesis

BAX
EPB
CCR1
IL23A
FCGR1A

C1QC
SQLE
CCR5
MET
C1QC

C6
SOAT1
CXCL10
TGFB1
C6

LOC407835

NCAM2

ALG1

Gene

Pvalue
0.0065
0.051
IL20RA 0.056

FDR

0.062

0.87

0.077

0.87

CXCL11
IL1R1
TNFRSF11A TNFRSF8
HIST1H3I
HLASNRPB
DMA
DPM2 MAN1B1 RPN1

0.56
0.96
0.91
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Table 22: Data of Individual Genes in the Upregulated KEGG Pathways in Cachectic
Adipose Tissue.
Gene
Gene Full Name
Symbol
Fat-Up / Prion diseases
BAX
BCL2-associated X protein
C1QC
complement component 1, q subcomponent, C
chain
C6
complement component 6
LOC407835
mitogen-activated protein kinase kinase 2
pseudogene
NCAM2
neural cell adhesion molecule 2
Fat-Up / Steroid biosynthesis
EBP
emopamil binding protein (sterol isomerase)
SQLE
squaleneepoxidase
SOAT1
sterol O-acyltransferase 1
Fat-Up / Cytokine-cytokine receptor interaction
CCR1
chemokine (C-C motif) receptor 1
CCR5
chemokine (C-C motif) receptor 5
CXCL10
chemokine (C-X-C motif) ligand 10
CXCL11
chemokine (C-X-C motif) ligand 11
IL1R1
interleukin 1 receptor, type I
IL20RA
interleukin 20 receptor, alpha
IL23A
interleukin 23, alpha subunit p19
MET
met proto-oncogene (hepatocyte growth factor
receptor)
TGFB1
transforming growth factor, beta 1
TNFRSF11A tumor necrosis factor receptor superfamily, member
11a, NFKB activator
TNFRSF8
tumor necrosis factor receptor superfamily, member
8
Fat-Up / Systemic lupus erythematosus (SLE)
FCGR1A
Fc fragment of IgG, high affinity Ic, receptor (CD64);
Fc fragment of IgG, high affinity Ia, receptor (CD64)
C1QC
complement component 1, q subcomponent, C
chain
C6
complement component 6
HIST1H3I
histone cluster 1, H3j; histone cluster 1, H3i; histone
cluster 1, H3h; histone cluster 1, H3g; histone
cluster 1, H3f; histone cluster 1, H3e; histone cluster
1, H3d; histone cluster 1, H3c; histone cluster 1,
H3b; histone cluster 1, H3a; histone cluster 1, H2ad;
histone cluster 2, H3a; histone cluster 2, H3c;
histone cluster 2, H3d
HLA-DMA
major histocompatibility complex, class II, DM alpha
SNRPB
small nuclear ribonucleoprotein polypeptides B and
B1
Fat-Up / N-Glycan biosynthesis
ALG1
asparagine-linked glycosylation 1, beta-1,4mannosyltransferase homolog (S. cerevisiae)
DPM2
dolichyl-phosphate mannosyltransferase
polypeptide 2, regulatory subunit
MAN1B1
mannosidase, alpha, class 1B, member 1
RPN1
ribophorin I

Fold
Change

PValue

2.30
3.24

0.0272
0.0239

2.26
3.65

0.0473
0.0246

2.27

0.0406

2.34
2.45
2.22

0.0266
0.0161
0.0222

2.48
2.10
4.31
5.84
2.04
5.71
2.98
2.08

0.0234
0.0293
0.0364
0.0076
0.0339
0.0094
0.0389
0.0307

2.40
3.35

0.0235
0.0087

2.96

0.0302

4.26

0.0118

3.24

0.0239

2.26
4.14

0.0473
0.0345

2.03
2.01

0.0036
0.0205

2.24

0.0107

2.52

0.0212

2.14
2.02

0.0460
0.0176
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5.3.1.2 Discussion
Prion Diseases
BAX is a pro-apoptotic member of the Bcl-2 gene family. Apoptosis regulator BAX
promotes apoptosis by binding to and antagonizing the Bcl-2 protein [253]. Activated
BAX results in the release of cytochrome c and other pro-apoptotic factors from the
mitochondria, often referred to as mitochondrial outer membrane permeabilization,
leading to activation of caspases [254].
C6 gene codes for complement component 6 protein that is involved in the
complement system. It is part of the membrane attack complex which can insert into
the cell membrane and cause cell lysis to clear pathogens from an organism via a
number of small proteins. The system is stimulated by one of several triggers
causing release of proteases that cleave specific proteins to release cytokines and
initiate an amplifying cascade of further cleavages. Thus results in massive
amplification of the response and activation of the cell-killing membrane attack
complex. Activation of BAX and C6 in adipose cells of cachectic patients could
reflect their same functional properties prior to wasting of adipose tissue. NCAM2
encodes for one of three neural cell adhesion molecule (NCAM), also called CD56,
is expressed on the surface of neurons, glia, skeletal muscle and natural killer cells.
5.3.2

Downregulated KEGG Pathways in Cachectic Adipose Tissue
5.3.2.1 Results

One KEGG pathway is differentially downregulatedin cachectic fat cases vs. weightstable fat controls; the neuroactive ligand-receptor interaction. This pathway has 6
significantly downregulated genes and overall has a very high level of statistical
significance (Table 23). Table 23 shows the individual genes in the pathway. Table
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24 shows a summary of the full gene name, fold change, and P-value for individual
genes in the neuroactive ligand-receptor interaction pathway.
Table 23: Differentially Downregulated KEGG Pathway in Cachectic Adipose Tissue.
KEGG Pathway
Neuroactive receptor
ligand interaction

Gene
GABRG1

Gene
GRIA4

Gene
LEP

Gene
Gene
Gene P-value FDR
LHCGR NMUR1 NPY1R 0.002 0.068

Table 24: Data of Individual Genes in the Downregulated KEGG Pathway in
Cachectic Adipose Tissue.
Gene
Gene Full Name
Symbol
Fat-Down / Neuroactive ligand-receptor interaction
GABRG1
GRIA4
LEP
LHCGR
NMUR1
NPY1R

gamma-aminobutyric acid (GABA) A receptor, gamma 1
glutamate receptor, ionotrophic, AMPA 4
Leptin
luteinizing hormone/choriogonadotropin receptor
neuromedin U receptor 1
neuropeptide Y receptor Y1

Fold
Change
-3.26
-3.10
-3.50
-3.90
-2.69
-3.47

PValue
0.0249
0.0172
0.0032
0.0028
0.0133
0.0242

5.3.2.2 Discussion
Neuroactive Ligand-Receptor Interaction Pathway
LEP encodes for leptin, a "satiety hormone" that signals energy sufficiency and
thereby inhibits hunger. Leptin discovery was a breakthrough in 1994. It is secreted
from adipocytes in proportion to fat stores and acts on receptors in the
hypothalamus to regulate appetite [255]. Leptin suppresses feeding and decreases
adiposity in part by release of αMSH and cocaine and amphetamine related
transcript that directly suppress appetite, in part by inhibiting hypothalamic NPY
synthesis and release, since NPY stimulates appetite, and partly by inhibiting
release of agouti-related peptide that acts by blocking the action of αMSH at its
receptor [256]. The regulation of appetite is a complex process involving multiple
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hormones [257]. Hypothalamus is the main appetite regulator in the body that
senses external multiple hormonal stimuli.
Leptin decreases food intake by affecting the balance between orexigenic and
anorexigenic hypothalamic pathways [258]. Low leptin increases appetite and body
weight. Crosstalk between leptin and inflammatory signaling known to be activated
may be responsible for this paradox [258]. Many studies looked at the serum level of
leptin in cancer patients. Cachectic esophageal cancer patients had decreased
circulating leptin [259-262].
Interestingly, in vitro and in vivo, insulin plays a major transcriptional activation that
stimulates leptin circulation level [263]. However, patients with cachexia do usually
have high insulin resistance which does not elevate, at least in our study, the
adipocyte production of leptin. This downregulation of leptin production in adipocyte
does not seem to increase appetite in cancer patient. This reflects that the
deregulation of appetite and weight in cachectic patient is a complex process.
Leptin levels are low, as expected, signaling that there are NOT sufficient energy
stores in fat. However, this is not reflected in the expected increase in appetite!
Paradoxically, NPY expression in the ARC is decreased (you would expect it to be
increased in the absence of leptin signaling) and that of POMC (source of αMSH)
increased (you would expect it to be decreased in absence of leptin). There is
speculation that this is a response to GAD15 in the hypothalamus and GAD15
expression was significantly increased in cachectic muscle in the present study
[258].
Leptin level are negatively correlated with the degree of cachexia [259]. Although
regulation of fat stores is deemed to be the primary function of leptin, obese
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individuals have a decreased sensitivity to leptin occurs, resulting in an inability to
detect satiety despite high energy stores [264].
LHCGR codes for the luteinizing hormone/choriogonadotropin receptor protein.
LHCGR is abundantly expressed in preadipocytes and mature adipocytes [265]. It is
studied the most in the gonads. In the ovary, the LHCGR is required for follicular
maturation and ovulation, as well as luteal function upon hormonal stimulation [266].
Low levels of the receptor are repeatedly linked to infertility.
While the function of this receptor is uncharacterized in adipose tissue, we do
believe there is a strong correlation between the downregulation of that receptor and
the depletion of fat stores. Female athletes one of the commonest examples of
infertility caused by depletion of fat stores which both could be possibly due, at least
in part, to the downregulation of the receptor in gonads and adipose tissue.
NPY1R codes for the Neuropeptide Y receptor type 1 protein. NPY, the
neuropeptide Y, is a neurotransmitter involved in food intake and body weight
regulation [267] and prevention of lipolysis [268] via Y1 and Y5 receptors. Y1
receptors are coded by NPY1R which is increased in adipose tissue samples of
obese patients and in turn signals for inhibition of lipolysis [269].

Additionally,

NPY1R expression in visceral adipose tissue is positively correlated with body
weight, BMI, and insulin levels [267]. Downregulation of the gene in cachectic
adipose tissue neutralizes its "lipolysis inhibition" signal which may contribute to
adipose wasting.
NMUR1 codes forneuromedin-U (NMU) receptor 1. NMU overexpressing tumors in
mice resulted in lowering of body weight and cachexia [270]. NMUR1 in human is
highly expressed in intestinal adipose tissue [271].

92

Intracerebroventricular administration of NMU markedly suppresses food intake in
rats [272]. The downregulation of NMUR1 could be a compensatory mechanism to
oppose the possible outcome of receptor stimulation with is documented to lead to
cachexia in mice.
GABRG1 encodes for gamma-aminobutyric acid receptor subunit gamma-1 protein
which is a subunit of the GABAA receptor. GABAA receptors are located
synaptically as well as presynaptically and are activated by gamma-aminobutyric
acid (GABA) [273]. GABA is a neuroinhibitory transmitter in the brain [273]. Oral
GABA given activates peripheral GABA receptors and this improves glucose
tolerance, improves insulin sensitivity, and prevents obesity without altering calorie
intake in mice [274]. Thus, the downregulation in cachectic adipose tissue could play
a role in insulin resistance seen in cachectic cancer patients and could be a
compensatory measure trying to stimulate weight gain.
GRIA4 encodes for glutamate receptor 4. It is a member of a family of L-glutamategated ion channels that mediate fast synaptic excitatory neurotransmission.
Glutamate receptors are protein complexes known to be the main excitatory
neurotransmitter receptors in the mammalian brain [275]. The regulation of
glutamate receptors is influenced by leptin levels [276] which is also downregulated
in cachectic adipose tissues.
Surprisingly, five out of the six above genes are receptors. The sixth gene is leptin,
which also functions to downregulate one of receptors (i.e. GRIA4) is also
downregulated. Most of these receptors are well studied and characterized in the
brain, while this is the first time they are reported, as far of our knowledge, to be
collectively downregulated in human adipose tissue.
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5.4

Analysis of Highly Significantly Altered Genes in Cachectic Adipose

Tissues
In visceral fat, 16 genes showed highly significant change in expression (10
upregulated and 6 downregulated: P<0.001-0.0002, FDR 0.5).
5.4.1

Highly Significantly Upregulated Genes
5.4.1.1 Results

Table 25 shows the 10 highly significantly upregulated genes in cachectic fat
(P<0.001-0.0002; DFR 0.5). They include 2 involved with transcriptional regulation,
2 transporters, on in each of the development, angiogenesis inhibitor, metabolism,
and signaling, and 2 uncharacterized.
Table 24 categorizes individual gene into respective functional domain. It also
shows the full gene name, fold change, and P-value.
Table 25: Highly Significantly Upregulated Genes in Cachectic Adipose Tissue.
Gene
Gene Full Name
Symbol
Transcription regulation

Fold
Change

PValue

RPP40
RibonucleaseP protein subunit p40
IGF2BP2
insulin-like growth factor 2 mRNA binding protein 2
Transporters

3.49
2.49

0.001
<0.001

SLC19A1
Solute carrier family 19 (folate transporter), member 1
STEAP3
Metalloreductase STEAP3
Development

2.34
2.57

0.001
0.0002

IFRD2
interferon-related developmental regulator 2
Angiogenesis Inhibitor

2.25

0.001

BAI2
Brain-specific angiogenesis inhibitor 2
Metabolism

4.43

0.0008

PUSL1
Signaling

2.37

0.001

LYPD1
Ly6/PLAUR domain-containing protein 1
Un-characterized

5.54

0.001

CCDC94
C15orf57

2.51
2.49

0.0003
0.001

pseudouridylate synthase-like 1

Coiled-coil domain containing 94
chromosome 15 open reading frame 57
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5.4.1.2 Discussion
Transcription Regulation
RPP40 encodes for ribonuclease P protein subunit p40, which generates mature
tRNA molecules by cleaving the 5'-end of the leader sequence of precursor tRNA.
RNase P is a ribozyme; a unique form of RNase that functions as a catalyst in the
same way that a protein enzymes work [277] and is required for normal and efficient
transcription of various small noncoding RNAs, such as tRNA, 5S rRNA, SRP RNA
and U6 snRNA genes [278, 279]. However the RNase P in human mitochondria is a
protein with no RNA component. Moreover, the enzyme is composed of a tRNA
methyltransferase, a short-chain dehydrogenase/reductase-family member, and a
protein of hitherto unknown functional and evolutionary origin, possibly representing
the enzyme's metallonuclease moiety [280].
IGF2BP2 encodes insulin-like growth factor 2 mRNA-binding protein 2, a member of
the IGF-II mRNA-binding protein family [281]. It functions by binding to the 5' UTR of
the insulin-like growth factor 2 mRNA and regulates its translation by modulating the
rate and location at which it encounters the translational apparatus and shields it
from endonuclease attacks or microRNA-mediated degradation [281]. An important
paralog of this gene is IGF2BP3 [281]. There is a strong association between
IGF2BP2 insulin resistance and type 2 diabetes mellitus, however, the exact
mechanisms has not been determined [282-285].
On the other hand, adipose tissue plays a role in secreting a variety of factors which
are involved in the modulation of adipose mass [286]. Adipose tissue development
and metabolism are regulated by growth hormone (GH) and the insulin-like growth
factor (IGF) system [286]. GH plays an anti-insulin effect; however, the mechanism
by which GH antagonizes insulin stimulation of lipogenesis is unknown [286].
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IGF2BP2 downregulates the expression of IGF2; a growth factor that plays a pivotal
role in controlling adipogenesis [287]. Therefore, IGF2BP2 may contribute to type 2
diabetes through alterations in adipose tissue [287]. Also, a more than two-fold
increase in IGF2BP2 expression level was observed in the adipose tissue of diabetic
patients compared to controls [288]. Similarly, an altered expression of IGF2BP2 in
adipocytes of subjects with type 2 diabetes compared with healthy people was also
detected [289]. Thus, an increase in the IGF2BP2 in the adipose tissue of cachectic
subject in our study is no surprise since it alters adipogenesis and promotes insulin
resistance.
Transporters
SLC19A1 encodes for solute carrier family 19 (folate transporter), member 1 protein.
It facilitates intracellular uptake of reduced folate to maintain intracellular
concentrations of folate. Despite of the plethora of studies on SLC19A1, the majority
of these investigated it in terms of polymorphic effects on drug dosing (i.e. the
antimetabolite; methotrexate). Thus, studies investigating the role of this transporter
in adipose tissues are lacking. However, SLC19A1 has three protein kinase C (PKC)
phosphorylation sites [290]. Effect of PKC is cell type specific. In adipose tissue,
PKC transduces the effects of adrenergic agonists (specifically agonists of the β3
receptor). β3-adrenergic agonists stimulate brown adipose tissue thermogenesis
[291]. In white adipose tissues; however, β3-adrenergic agonists increase energy
expenditure and lipolysis, which in turn promote lipid mobilization [291]. These
effects causes adipose tissue wasting and decreased fat stores [291] which are all
key manifestations in the cachectic patients. β3-Adrenergic agonists also enhance
glucose disposal to provide energy for the maintenance of metabolic activity and
muscle function under limited energy availability [291]. Other adrenoreceptors have
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other effects on lipid and glucose metabolism; α1-adrenoceptors and β2adrenoceptors are linked to glycogenolysis and gluconeogenesis in adipose tissue;
while β1-adrenoceptors and β3-adrenoceptorsare linked to lipolysis in adipose
tissue [292].
STEAP3 codes for six-transmembrane epithelial antigen of prostate STEAP family
member 3, a metalloreductase that is capable of converting iron from an insoluble
ferric (Fe3+) to a soluble ferrous (Fe2+) form. This family comprises STEAP1-4; all of
which share metalloreductases activity [293]. They participate in a wide range of
biologic processes, such as molecular trafficking in the endocytic and exocytic
pathways and control of cell proliferation and apoptosis [293]. STEAP3 is also
known as tumor-suppressor activated pathway-6 (TSAP6) or dudulin-2. Mutations in
STEAP3 result in an autosomal recessive trait characterized by an inefficient supply
of iron to erythrocytes, leading to anemia and iron overload [294].
STEAP3 is upregulated in white adipose tissue of rats fed high fat diet and
significantly downregulated in rats treated with capsaicin (a potential anti-obesity
drug) [295]. This indicate that STEAP3 increases when fat supply is abundant and
not during times of energy deficit. It is possible that STEAP3 increases as a
compensatory mechanism to signal resistance to fat loss and/or to stimulate energy
storage that mimic the state of abundance under the forces or triggers of wasting.
On the other hand, one anti-obesity strategy is to block adipocyte differentiation,
preventing fat storage and the secretion of adipokines [296]. STEAP3 is upregulated
in differentiating adipocytes [296]. This suggests that the adipose tissue in cachexia
is undergoing an early-onset protective mechanism by inducing adipocyte
differentiation in an attempt to prevent further lipolysis and wasting.
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Development
IFRD2 codes for interferon-related developmental regulator 2. Very little is known,
so far, about I the FRD2 gene. However another member of this gene family, IFRD1
is expressed in skeletal and cardiac muscle. It is also expressed in differentiating
myoblasts in vitro [297]. IFRD1 knockout mice have delayed muscular regeneration
after muscle crush damage [298]. In contrast, upregulation of IFRD1 in injured
muscle potentiates muscle regeneration [299].
IFRD1 was also recently studied in white adipose tissue in obese mice, where its
expression is increased [300]. It is also upregulated under stressful stimuli such as
hypoxia [300], where it prevents the inhibition of adipogenesis [300]. This effect is
abrogated by knockdown of IFRD1 by shRNA which inhibits adipogenesis. These
findings suggest that IFRD1 may play a role in adipogenesis under conditions of
hypoxia and obesity.
The uniqueness of importance of IFRD1 in muscle regeneration and adipogenesis,
suggests a similar mechanism of action for IFRD2, which may be more specific for
adipose tissue. Furthermore, since IFRD1 potentiates the regenerative process,
IFRD2 might be activated in cachectic adipose tissue as a defense mechanism to
reduce the loss of adipocytes due to wasting.
Metabolism
PUSL1

encodes

for

pseudouridylate

synthase-like

1,

an

uncharacterized

metabolism protein with pseudouridine synthase activity. Pseudouridylate synthase
is an enzyme that catalyzes the conversion of uracil and D-ribose 5-phosphate to
pseudouridine 5'-phosphate and H2O. This enzyme belongs to the family of lyases
that participate in pyrimidine metabolism; an indicator for the rate of DNA turnover
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[301]. Despite not knowing exactly how the PUSL1 enzyme functions in adipose
tissue, what we know so far about pyrimidine metabolism is extremely exciting. All
pyrimidine nucleotides are synthesized de novo, mainly in the liver. Pseudouridine is
an intermediate in the pyrimidine synthesis pathway. Pseudouridylate synthase
activity allows E. coli to grow in the presence of pseudouridine, with growth
paralleling measured enzymic activity [302]. More excitingly, pseudouridylate
synthase is a catabolite repressible enzyme [303]. Catabolite repression, usually
observed in bacteria and other microorganisms, is the inhibition of synthesis of
enzymes involved in catabolism of carbon sources other than the preferred one
[304].
The above data can be correlated to cachectic patients whose adipose tissues is
trying to repress catabolism and as a compensatory mechanism, rather trying to
build up the key building blocks of adipogenesis (i.e. ribonucleic acid material or
pyrimidines). With pyrimidines being mostly synthesized in the liver; it is not
surprising that unlike the atrophying livers of patients losing weight due to starvation,
the livers of patients with cachexia become significantly enlarged, probably due to
overload.
Signaling
LYPD1 encodes for Ly6/PLAUR domain-containing protein 1. However, the
understanding of this protein in the context of cachexia is hard since very little, if
any, is known about it.

LYPD1 partial silencing results in a highly significant

increase in overall anchorage-independent growth in HeLaHF cells. LYPD1
overexpression reduced cell survival and anchorage-independent growth and
induced higher levels of apoptosis in soft agar [305].
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LYPD1 is associated with bannayan-riley-ruvalcaba syndrome, a rare overgrowth
syndrome [306]. One of the predominant features of the syndrome is the occurrence
of multiple subcutaneous lipomas [306, 307].
Angiogenesis Inhibitor
BAI2 encodes for brain-specific angiogenesis inhibitor 2, a member of the adhesionG-protein coupled receptors (adhesion-GPCRs) family of receptors [308]. BAI2 and
BAI3 are similar to BAI1, have similar tissue specificities and structure and may also
play a role in angiogenesis [309]. BAI2 is dominantly expressed in the brain [310].
However, its functions are still unclear but it is suggested that BAI2 is a functional
GPCR regulated by proteolytic processing and activates the NFAT pathway [310]. It
is known that the nuclear factor of activated T cell (NFAT) group of transcription
factors contributes to glucose and insulin homeostasis [311]. Expression of NFATc2
and NFATc4 is induced upon adipogenesis and in obese mice, while ablation of
both NFATc2 and NFATc4 increases insulin sensitivity [311].
If BAI2 upregulation is confirmed to activate the NFAT pathway, this suggests that
such activation signals induced adipogenesis as an adaptive response to the
wasting triggers in cachexia. Also, upregulation of this pathway could explain, at
least in part, by the increased insulin resistance in these patients.
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5.4.2

Highly Significantly Downregulated Genes in Cachectic Adipose

Tissues
5.4.2.1 Results
Table 26: Highly Significantly Downregulated Genes in Cachectic Adipose Tissue.
Gene Symbol
Metabolism

Gene Full Name

Fold Change

P-Value

CES1

Liver carboxylesterase 1

-5.65

0.0006

NQO1
NAD(P)H dehydrogenase [quinone] 1
Transcription Factor

-3.82

<0.0006

AFF3
AF4/FMR2 family member 3
Angiogenesis Inhibitor

-2.30

0.00003

TNMD
Tenomodulin
Uncharacterized

-15.46

<0.0007

LOC100996634
TRIM16L

-15.24
-2.98

0.0001
<0.0002

Transmembrane protein FLJ37396
Tripartite motif containing 16-like

5.4.2.2 Discussion
Metabolism
CES1 codes for the liver carboxylesterase 1 enzyme. CES1 is present in most
tissues with higher levels in the liver [312], and is highly regulated in adult adipose
tissue [313], with higher levels in obese subjects and lower levels during weight loss
[314]. This enzyme hydrolyzes long-chain fatty acid esters and thioesters. CES1 is
an inducible serine esterase that hydrolyses many drugs (to activate or inactivate
them) and a nutrients, as well as cholesterol esters, etc. CES1 could be an
important player in metabolism of triglycerides and cholesterol in adipocytes [315].
Thus, CES1 is suggested to play a major role in the trafficking of lipids and lipid
metabolism in hepatocytes and its upregulation mediates adipocyte lipolysis through
the hydrolysis of cholesteryl esters and triglycerides [313]. Studies correlated
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increased expression to be a measure of adiposity and insulin resistance (well here
we have decreased adiposity but insulin resistance.
Expression level of CES1 in adipose tissue was positively associated with body
mass index, homeostasis model assessment-insulin resistance, and level of fasting
glucose, insulin, and triglycerides [315]. In murine adipocytes, CES3 was identified
as a gene that increased lipid storage [316]. All of which are measures and/or
triggers of adiposity.
In vitro and in vivo studies suggested that inhibition of CES1 could help treat type 2
diabetes [316]. In murine models of diabetes, a CES3 inhibitor protected animals
from weight gain, decreased liver lipid accumulation and increased insulin sensitivity
[316]. CES1 activity was upregulated in adipose tissue from patients with type 2
diabetes, compared with that in lean controls [316], and also upregulated in obese
children [313].
Hence, the highly significantly downregulated CES1 in the adipose tissue of our
cachectic patients reflects the actual weight losing state of our patients, and explain
the compensatory state of adipose tissue to resist lipolysis and the state of insulin
resistance.
NQO1 codes for an NAD(P)H dehydrogenase [quinone] 1 enzyme which is a
member of

family of enzymes that prevents the one electron reduction and

detoxification of quinones and their derivatives that results in the production of
radical species [317]. NQO1 has a high expression in human adipose tissue,
particularly in large adipocytes and is reduced by weight loss (similar to CES1) and
also correlates with adiposity [318].
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NQO1 regulates the ubiquitin-independent p53 degradation pathway through
stabilization of p53. NQO1 downregulation reduces p53 stability, leading to
resistance to some drugs including chemotherapeutics. One important and exciting
correlation is the increased hematotoxicity in benzene-exposed workers in China
with a certain NQP1 genotype isolated from bone marrow that showed failure to
express NQO1 [319]. NQO1 null mice exhibited increased toxicity when
administered menadione [320]. However, these mice exhibit significantly lower
levels of abdominal adipose tissue, lower blood levels of glucose, no change in
insulin, and higher levels of triglycerides, b-hydroxy butyrate, pyruvate, lactate, and
glucagon and insulin resistant as compared with wild-type mice [317]. Also, the liver
glycogen reserve was found to be decreased [317]. All of which data suggest that
the loss of NQO1 causes alteration in the intracellular redox activities leading to
reduction in pyridine nucleotide synthesis and reduced glucose and fatty acid
metabolism resulting in a significant reduction in the amount of abdominal adipose
tissue [317]. In addition, the loss of NQO1 leads to the alteration in lipid deposition
due to the decrease in gluconeogenesis and fatty acid metabolism [321].
NQO1 mutations are also found to be associated with tardive dyskinesia (TD) an
incurable form of dyskinesia; a disorder resulting in involuntary, repetitive, and
tardive (slow or belated onset) body movements [322].
Transcription Factor
AFF3 is an AF4/FMR2 family member 3 that encodes a tissue-restricted nuclear
transcriptional activator [323] that functions in lymphoid development and
oncogenesis [324, 325]. AFF3 is associated with kidney disease in diabetics with
type 1 [326] but not type 2 diabetics [327].
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Angiogenesis Inhibitor
TNMD

codes

for

tenomodulin;

a

novel

chondromodulin-I

related

gene.

Chondromodulin-I is a cartilage-specific glycoprotein that functions to stimulate
chondrocyte growth and to inhibit tube formation of endothelial cells [328]. The
TNMD transcript is found in hypovascular tissues such as tendons and ligaments
and that is believed to be an angiogenesis inhibitor [329]. TNMD is also expressed
in both the adipocyte and stromal vascular fraction of adipose tissue [330].
TNMD expression is decreased in the adipose tissue of subjects who have lost
weight and its expression level is strongly correlated with body mass index [330].
Expression remained was also consistently remained downregulated after weight
loss of subjects on a low-calorie diet and after weight maintenance [331]. TNMD is
associated the risk of developing diabetes [332], although this association is not yet
well-understood. However, genetic variation of the TNMD gene is associated with
serum levels of systemic immune mediators which have a well-established
connection to obesity, metabolic syndrome, and type 2 diabetes [333].
The potential mechanisms that links TNMD with the pathogenesis of obesity,
diabetes, and metabolic syndromes are yet to be confirmed [330]. However, in the
context of our weight losing cachectic patients, TNMD downregulation is perhaps
expected. However, the 15-fold downregulation is massive given the small degree
(5-10%) weight loss. Thus, we believe this dramatic downregulation is important
given the effect of weight loss, insulin resistance, and the metabolic syndrome of
cachexia.
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5.5

Anticipated Results from Previous Studies
5.5.1

Preclinical Findings

Adipose depletion in cachexia is a function of lipolysis [334]. Adipose tissue atrophy
starts with the excessive hydrolysis of triglycerides to free fatty acids and glycerol
that is then mobilized and released in the circulation. The key enzymes catalyzing
this reaction are the hormone sensitive lipase (LIPE) and adipose triglyceride lipase
(PNPLA2) [335]. Preclinical studies showed that inhibition of lipolysis through
genetic ablation of LIPE or PNPLA2 ameliorates certain features of murine model of
cancer cachexia [336]. Expressions of neither LIPE nor PNPLA2 were significantly
altered in the present study. However, a different lipid mobilizing factor; zinc-α
glycoprotein 1(AZGP1), has been previously shown to be involved in cachexia as a
clinical finding [337]. Expression of AZGP1 was also increased in the present study
but with only borderline significance (Fold change 2.79, P-value 0.0576).
Parathyroid hormone-related protein (PTHLH) is a causative factor of hypercalcemia
in malignancy. A recent suggested hypothesis to cancer cachexia is that there is
adipose tissue "browning" that results in an increased in energy expenditure leading
and greater thermogenesis [338]. In murine model cancer cachexia, PTHLH induced
the expression of genes involved in thermogenesis in adipose tissues while blocking
PTHLH blocked adipose tissue browning [339]. The present study revealed no
change in expression of either PTHLH or its associated receptor, PTH1R suggesting
that tissue browning theory that mediates thermogenesis and consequently an
increase in energy expenditure is not the one of the contributing factors in human
subjects.
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5.5.2

Clinical Findings

In recent years, adipose tissue is been recognized to have major endocrine
functions [340]. Several pro-inflammatory cytokines and hormones are believed to
be produced in cancer cachexia patients, at least in part by the adipose tissue.
Cytokines (TNF, IL6, and IFNG) and hormones (such as leptin) have been
investigated in the context of cancer cachexia. Leptin is the "satiety hormone" made
by adipose cells that helps in the regulation of energy balance by suppressing
appetite [255]. In obese individuals, however, the body has a decreased sensitivity
to leptin resulting in an inability to detect satiety despite of the high energy stores
[264]. Clinical studies found that leptin levels are significantly lower in cachectic
patients [259, 261, 341] while higher levels of IL6 were associated with future
development of cachexia [341].
The present study shows a significant reduction in leptin expression as expected
(Fold change -3.50, P-value 0.0032). This suggests that leptin does not play an
important role in cancer cachexia development but rather an indicator for depleting
adipose stores in these patients. On the other hand, expression of IL6 was elevated
but not statistically significant. However, it is possible that IL6 expression is
increased in some but not all cachectic cancer patients.
5.6

Verified Results Using Real-Time Reverse Transcription PCR

Despite of the high reliance of the quantitative capability of the RNA sequencing
results, it is important to verify part of the expression results using a different
method. A cherry-picked selection of genes that are of a high significance and high
fold-change were picked. Confirming the difference of high fold-change expression
data can allow us to check and verify them later-on at protein level. One upregulated
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gene; CXCL11, and three downregulated genes; TNMD, LEP, and LHCGR were
confirmed.
5.6.1

Results



C
Figure 6: Upregulation of Expression of Selected Genes Confirmed by Real-Time
RT-PCR in Cachectic Adipose Tissue.
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Figure 7: Downregulation of Expression of Selected Genes Confirmed by Real-Time
RT-PCR in Cachectic Adipose Tissue.
All chosen genes that were previously shown to be upregulated/downregulated were
reproducible via real-time RT-PCR (Figure 6 and 7).
5.6.2

Discussion

Expressions of one upregulated gene; CXCL11 that is statistically significant was
confirmed via real-time RT-PCR.
CXCL11 codes for chemokine (C-X-C motif) ligand 11 protein (Table 22). It is a
small cytokine that belongs to the CXC chemokine family that is also called
interferon-inducible T-cell alpha chemoattractant (I-TAC) and Interferon-gammainducible protein 9 (IP-9)[342]. Normally, expression of CXCL11 in mice adipose
tissue was found to be consistently very low [343]. Adipose tissue macrophages
(ATM), which are tissue resident macrophages, are present in adipose tissue. It was
found that these ATMs are transiently recruited to adipose tissue at times of acute
weight loss [344, 345]. ATM was found to have a high level expression of CXCL11
[346]. So far, the right justification of elevated levels of CXCL11 in adipose tissue is
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not reached. However, we know that their expression level is normally
downregulated.
The confirmed downregulated genes were TNMD, LEP, and LHCGR. The TNMD
(section 5.4.2.2) is an angiogeneic inhibitor gene that codes for tenomodulin; a novel
chondromodulin-I related gene. TNMD is expressed in both the adipocyte and
stromal vascular fraction of adipose tissue [330]. TNMD expression is decreased in
the adipose tissue of subjects who have lost weight and its expression level is
strongly correlated with body mass index [330]. Expression remained was also
consistently remained downregulated after weight loss of subjects on a low-calorie
diet and after weight maintenance [331]. TNMD is associated the risk of developing
diabetes [332], although this association is not yet well-understood. However,
genetic variation of the TNMD gene is associated with serum levels of systemic
immune mediators which have a well-established connection to obesity, metabolic
syndrome, and type 2 diabetes [333].
The potential mechanisms that links TNMD with the pathogenesis of obesity,
diabetes, and metabolic syndromes are yet to be confirmed [330]. However, in the
context of our weight losing cachectic patients, TNMD downregulation is perhaps
expected. However, the 15-fold downregulation is massive given the small degree
(5-10%) weight loss. Thus, we believe this dramatic downregulation is important
given the effect of weight loss, insulin resistance, and the metabolic syndrome of
cachexia.
LEP (as discussed in section 5.3.2.2) encodes for leptin, a "satiety hormone" that
signals energy sufficiency and thereby inhibits hunger. Leptin discovery was a
breakthrough in 1994. It is secreted from adipocytes in proportion to fat stores and
acts on receptors in the hypothalamus to regulate appetite [255]. Leptin suppresses
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feeding and decreases adiposity in part by release of αMSH and cocaine and
amphetamine related transcript that directly suppress appetite, in part by inhibiting
hypothalamic NPY synthesis and release, since NPY stimulates appetite, and partly
by inhibiting release of agouti-related peptide that acts by blocking the action of
αMSH at its receptor [256]. The regulation of appetite is a complex process involving
multiple hormones [257]. Hypothalamus is the main appetite regulator in the body
that senses external multiple hormonal stimuli.
Leptin decreases food intake by affecting the balance between orexigenic and
anorexigenic hypothalamic pathways [258]. Low leptin increases appetite and body
weight. Crosstalk between leptin and inflammatory signaling known to be activated
may be responsible for this paradox [258]. Many studies looked at the serum level of
leptin in cancer patients. Cachectic esophageal cancer patients had decreased
circulating leptin [259-262].
Interestingly, in vitro and in vivo, insulin plays a major transcriptional activation that
stimulates leptin circulation level [263]. However, patients with cachexia do usually
have high insulin resistance which does not elevate, at least in our study, the
adipocyte production of leptin. This downregulation of leptin production in adipocyte
does not seem to increase appetite in cancer patient. This reflects that the
deregulation of appetite and weight in cachectic patient is a complex process.
Leptin levels are low, as expected, signaling that there are NOT sufficient energy
stores in fat. However, this is not reflected in the expected increase in appetite!
Paradoxically, NPY expression in the ARC is decreased (you would expect it to be
increased in the absence of leptin signaling) and that of POMC (source of αMSH)
increased (you would expect it to be decreased in absence of leptin). There is
speculation that this is a response to GAD15 in the hypothalamus and GAD15
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expression was significantly increased in cachectic muscle in the present study
[258].
Leptin level are negatively correlated with the degree of cachexia [259]. Although
regulation of fat stores is deemed to be the primary function of leptin, obese
individuals have a decreased sensitivity to leptin occurs, resulting in an inability to
detect satiety despite high energy stores [264].
LHCGR

(as

discussed

in

section

5.3.2.2)

codes

for

the

luteinizing

hormone/choriogonadotropin receptor protein. LHCGR is abundantly expressed in
preadipocytes and mature adipocytes [265]. It is studied the most in the gonads. In
the ovary, the LHCGR is required for follicular maturation and ovulation, as well as
luteal function upon hormonal stimulation [266]. Low levels of the receptor are
repeatedly linked to infertility.
While the function of this receptor is uncharacterized in adipose tissue, we do
believe there is a strong correlation between the downregulation of that receptor and
the depletion of fat stores. Female athletes one of the commonest examples of
infertility caused by depletion of fat stores which both could be possibly due, at least
in part, to the downregulation of the receptor in gonads and adipose tissue.
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Chapter 6: Overlapping Genes in Skeletal Muscle and Adipose Tissue
This chapter aims at looking at the significantly altered gene expressions that are
commonly altered in both; muscle and adipose tissues.
6.1

Upregulated Genes
6.1.1

Results
Table 27: Upregulated Overlapping Genes.

Gene
Symbol

Gene Full Name

ASS1
CLCN2

Argininosuccinate Synthase 1
Chloride Channel, VoltageSensitive 2
Post-GPI Attachment To Proteins
3
Ribosomal Protein S10

PGAP3
RPS10
SLC36A1

TGM2

6.1.2

Solute Carrier Family 36
(Proton/Amino Acid Symporter),
Member 1
Transglutaminase 2

Muscle
Fold
P-Value
change
3.70
0.0064
9.48
0.0163

Fat
Fold
change
2.14
2.29

PValue
0.0323
0.0239

2.80

0.0032

2.12

0.0066

4.58

0.0045

2.18

0.0256

4.00

0.0039

2.07

0.0323

2.20

0.0114

2.42

0.0244

Discussion

ASS1 is an argininosuccinate synthase enzyme that catalyzes the penultimate step
of the arginine biosynthetic pathway. Arginine is classified as a semi-essential or
conditionally essential amino acid, depending on the developmental stage and
health status of the individual [347]. Arginine biosynthesis is only needed in
unhealthy individuals because there are not getting enough nutritional supply. It
serves many important roles such as cell division, wound healing, ammonia
metabolism, immune function, and the release of hormones [347, 348]. The direct
correlation of argininosuccinate synthase function in skeletal and adipose tissues in
cachectic individuals is unknown. It can be stipulated that in both tissues (when
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combined, they constitute the majority of human body mass), cachexia is a huge
insult requiring healing and repair (probably), and definitely replacement.
On the other hand, mutations in the ASS1 gene cause type I citrullinemia because
of alteration of an important step of the urea cycle [349]. Individuals with type I
citrullinemia develop symptoms when alteration in the enzyme causes ammonia
build up in the body. Hyperammonemia is significantly higher in terminally ill cancer
patients [350]. Symptoms of hyperammonemia in type I citrullinemia includes lack of
energy (lethargy), poor feeding, vomiting, and others. All of which are seen in
cachexia. Skeletal muscle plays a role in ammonia detoxification. Ammonia is also
known to stimulate the hypothalamic satiety centers which suppress appetite and
lead to cachexia [351]. Generally, L-arginine reduces adiposity, increase muscle
mass, and improve the metabolic profile in animals and humans [352]. All of which
are important adaptive requirement in cachectic patients.
CLCN2 codes for chloride channel protein 2 that is one of 13 members in the
chloride channel superfamily of poorly understood ion channels that are implicated
in many cellular processes. Chloride channels in skeletal muscle play a role in
setting and restoring the resting membrane potential, thus preventing muscle
stiffness or myotonia [353]. Mutations in the human skeletal muscle chloride channel
are associated with dominant and recessive congenital myotonia [353]. While such a
role is clearly correlated to muscle regulation, the reason of the upregulation in
adipose tissue is yet to be understood.
PGAP3

codes

for

post-GPI

attachment

to

proteins

3

that

encodes

a

glycophosphatidylinositol (GPI)-specific phospholipase A2 that is expressed in the
Golgi apparatus. The enzyme is involved in fatty acid GPI remodeling that is critical
for proper association between GPI-anchored proteins and lipid rafts [354]. In
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muscle, mutation in PGAP3 causes muscular hypotonia [354]. PGAP3 is
responsible for the modification of the fatty acid residues on the GPI anchor in a
maturation process that occurs in the endoplasmic reticulum and Golgi [354].
RPS10 is another important gene in the cachectic organs that is likely to be involved
in the adaptive responses to the forces of wasting. RPS10 codes for the 40S
ribosomal protein S10 that is one of the two subunits making the ribosomes; the
organelles that catalyze protein synthesis [355]. Also, RPS10 expressed sequence
tags were isolated from the skeletal muscle of neonatal healthy and splay leg piglets
[356]. It belongs to the S10E family of ribosomal proteins. RPS10 expression was
reduced in brown adipose tissue of hibernating arctic ground squirrels compared to
mice [357]. Hibernation is an energy-saving strategy adopted by a wide range of
mammals to survive highly seasonal or unpredictable environments.
SLC36A1 codes for a solute carrier family 36 (a proton-coupled amino acid
transporter (PAT1) protein, that mediates symport of protons and small neutral
amino acids. This carrier has a role in absorption of amino acids from luminal protein
digestion of the brush border membrane driving transport of amino acids into the
cytosol (presumably in the gut during absorption) [358]. These amino acids, in turn,
activate mTORC1, and subsequently stimulate protein synthesis and consequently
skeletal muscle growth [359]. SLC36A1 expression was increased following
resistance exercise in young and older men [359]. Also, following a single bout of
high-intensity resistance exercise, SLC36A1 expression increased amongst many
other skeletal muscle amino acid transporters in both healthy men and women,
independent of age [360]. SLC36A1 is yet to be characterized in adipose tissue.
TGM2 codes for tissue transglutaminase, a calcium dependent enzyme of the
protein-glutamine γ-glutamyltransferases family [361]. It cross-links proteins
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between a lysine residue and a glutamine residue, creating an inter- or
intramolecular bond that is highly resistant to proteolysis [362]. What proteins get
cross-linked and the consequence of that cross-linking in the context of cachexia is
yet to be investigated. TGM2 −/− and F13a1−/− double null mice showed no loss of
bone mass and maintained normal bone mineral density to 12 months age. Bone
marrow adipocity showed large increases in both fat percent (+70.7%) and
adipocyte numbers (+65%) suggesting that TG2 and FXIIIA might regulate an
osteoblast-adipocyte switch via fibronectin matrix stabilization [363, 364].
TGM2 is downregulated in bone marrow in response to age as it was found to
enhance cell growth and survival through anti-apoptosis signaling which is usually
downregulated during aging [365]. TGM2 was one of several genes that have higher
expression in human brown adipose tissues compared to white adipose tissues
[366].
6.2

Downregulated Genes
6.2.1

Results
Table 28: Downregulated Overlapping Genes.

Gene
Symbol

Gene Full Name

AC007246.3

Antisense. Uncharacterized
LOC728730
Glycosylphosphatidylinositol
Specific Phospholipase D1
Glutathione S-Transferase Theta 1

GPLD1
GSTT1
LOC283731
PPP1R9A
SYNM

Uncharacterized LOC283731
Protein Phosphatase 1, Regulatory
Subunit 9A
Synemin, Intermediate Filament
Protein

Muscle

Fat

Fold
change
-2.98

PValue
0.0166

Fold
change
-2.23

PValue
0.019

-6.27

0.0172

-2.22

0.012

-2.73

0.0108

-3.40

0.046

-13.65
-2.62

0.0006
0.0052

-4.04
-2.04

0.045
0.022

-2.26

0.0126

-2.26

0.035
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6.2.2
GPLD1

Discussion

codes

for

phosphatidylinositol-glycan-specific

phospholipase

D1

enzyme[367]. Many proteins at the extracellular plasma membranes are attached
via a glycosylphosphatidylinositol (GPI) anchor. GPLD1 is a GPI degrading enzyme
that hydrolyzes the inositol phosphate linkage in proteins anchored by GPI thereby
allowing release of the attached protein [368]. In vitro, GPLD1 overexpression is
associated with increased expression of de novo lipogenesis genes [369]. Also,
insulin resistance in human subjects was found to be associated with increased
serum levels of GPLD1 which is also involved in lipid metabolism (triglyceride
metabolism) [370]. It could be, therefore, a gene that is downregulated in cachectic
muscle and adipose tissue as a compensation for the presence of insulin resistance.
Despite this evidence, the role of the gene in muscle has not yet been investigated.
GSTT1 codes for glutathione S-transferase theta-1, that is a member of a
superfamily of enzymes that catalyze the conjugation of reduced glutathione.
Glutathione exists in both reduced (GSH) and oxidized (GSSG) states. In healthy
states, the majority of glutathione are in the reduced form (GSH). The ratio of
oxidized-to-reduced (GSSG-to-GSH) is considered indicative of oxidative stress
[371]. GSTT1 functions on the reduced glutathione. GSTT1 is expressed in both,
muscle [372] and adipose tissue [373].
Fat deposition was investigated in fat vs. lean chicken. GSTT1 was found to be one
of the differentially upregulated genes in adipose tissue of fat chicken [374].
GSTT1 was found to co-vary with NNAT expression in murine fed high fat diet white
adipose tissue [373]. NNAT is an acute diet-responsive gene in white adipose tissue
and hypothalamus; it may play an important role in metabolism, adipogenesis, and
resolution of oxidative stress and inflammation in response to dietary excess [373].
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Thus, this decreased expression of GSTT1 in the skeletal muscle and adipose
tissues of cachectic subject could reflect reduced cellular ability to manage free
radicals and consequently altering cellular functions.
PPP1R9A codes for protein phosphatase 1, regulatory subunit 9A. The PPP1R9A
protein is involved in actin cytoskeleton dynamics and in synaptic formation and
function [375, 376]. PPP1R9A is also imprinted mainly in skeletal muscle [376]. It is
found to be highly concentrated in the synapses of developed neurons [377]. It is
suggested that downregulation of PPP1R9A and other genes is an evidence that
deficiencies in cytoskeletal dynamics play a role in Huntington's disease
pathogenesis [378]. PPP1R9A was one of many expressed genes that were stably
retained in H9-hESCs cell line throughout differentiation [379].
SYNM (synemin or desmuslin) codes for an intermediate filament (IF) protein [380].
IFs function by integrating mechanical stress and maintain structural integrity in
eukaryotic cells. Diseases involving Ifs have defects in the organization of the
contractile apparatus of skeletal and cardiac muscle [381]. SYNM was mainly
studied in the sarcomere of skeletal myocytes [380]. It localizes at the Z-disk and
has been shown to act as a mechanical linker, transmitting force laterally throughout
the tissue, especially between the contractile myofibrils and extracellular matrix
[380]. Synemin is expressed mainly in heart and skeletal muscle [380].
Synemin knockout mice have a mild skeletal muscle phenotype, characterized by
decreased fiber size and increased sarcolemmal deformability and susceptibility to
injury [381]. On the other hand, abnormal accumulations of synemin and desmin in
muscle fibres was seen in multiple myopathies [382]. Other study on synemin
knockout mice showed a higher hypertrophic capacity with increased maximal force
and fatigue resistance following mechanical overload, compared with control mice
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[383]. Molecularly, this increased remodeling capacity was accompanied by the
decreased expression of myostatin and atrogin expression, and increased follistatin
expression [383].
Knockdown of synemin expression with siRNAs within mammalian cells resulted in
significantly compromised cell adhesion and cell motility, suggesting a possible role
of synemin as a focal adhesion molecule that is essential for cell adhesion and
migration [384].
Synemin upregulation or downregulation has marked effects on skeletal muscle. In
cachectic patients, the downregulation of expression of this gene may have put the
muscle under higher susceptibility for injury while decreasing the fiber size and
contributing to the wasting phenotype. However, so far, no data is available about
the role of synemin in adipose tissue.
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Chapter 7: Overall Discussion
Cancer cachexia is a multifactorial syndrome that is responsible for at least one-third
of cancer-related death worldwide and contributes to the death of many others.
More than 80% of cancer patients are cachectic towards the end of life. Despite
intensive research, the mechanisms of cancer cachexia are still poorly understood
and its multi-faceted etiopathogenesis has never been thoroughly reflected on in a
single set of experiments. In vitro and in vivo experimentation, so far, has not led to
any leap in our understanding of cachexia, since no model is able to recapitulate the
whole spectrum of the cancer cachexia syndrome. In addition, the few conducted
clinical studies using microarray had neither given us good insight, nor were
reproducible.
It is our believe that identification of early changes in gene expression in cachexia
target tissues (muscle and adipose tissue) will lead to an improved understanding of
the mechanisms that trigger this important problem in cancer patients. Next
generation sequencing is the state-of-the-art technique to generate high throughput,
high quality results. This technique has proven to be much more powerful and
discriminatory than microarray and is now considered to be the state-of-the-art.
The decisions to include all of the cachectic and non-cachectic cancer patients was
made solely based on body weight changes in the past 3-6 months and by
meticulous exclusion of samples that might have reflected any etiogenesis that
could contribute/aggravate cachexia (i.e. malnutrition, muscular/endocrine/other
metabolic diseases, etc.). The cachectic and the weight-stable group showed no
significant differences in any of the measured biochemical parameters. The
Glasgow prognostic score, which is suggested to be a measure for diagnosing and a
guide for treatment of cachexia, failed to distinguish a signature difference in the
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cachectic group. It contrast it revealed more advance scores in non-cachectic
controls. However, our small sample size cannot fully refute the possibility of that
measure to predict cachexia if applied on a larger scale of samples. Yet, we believe
it may not be the method of choice for looking at early stages of cachexia.
7.1

Changes in Gene Expression in Skeletal Muscle

Genes whose expression changed in cachectic muscles reflect of a large spectrum
of genes encoding skeletal muscle structural proteins, proteins in the muscle
contractile machinery, energy metabolism, and others.
Several skeletal muscle proteins in the basement membrane were upregulated,
namely agrin, perlecan, collagen, laminin, and neurexin (Figure 8). Agrin is required
for the organization of the cytoskeleton and amelioration of function in diseased
muscle [385]; perlecan is important in maintaining muscular integrity [386]; collagen
and laminin are upregulated during endurance training [387]. On the other hand,
many genes encoding transmembrane and intracellular muscular structural proteins
were downreguated, such asintegrins, sarcospan, elements of sarcoglycan complex,
myotilin, desmin, titin, and α-catinin. Collectively, the functions of the upregulated
genes in the basement membrane of myocyte reflect a defensive adaptive protective
response to maintain muscular homeostasis which is possibly triggered by the down
regulation of essential interacellular proteins.
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Neurexin

Collagen

Sarcospan

Agrin

Perlecan

Integrins

Titin

α-Catenin

Figure 8: Skeletal Muscle Extracellular Matrix and Structural Muscle Proteins.
Items circled in red are upregulated; items circled in blue are downregulated.
Amended from [388].
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In addition, integrins, titin [389], and tropomysin [390], which were also
downregulated, are essential component in the contractile machinery (Figure 9).
Normally, an action potential causes skeletal muscle to depolarize opening the
voltage-gated L-type calcium channels (two subunits of which are downreguated).
This increases intracellular calcium causing it to bind to calmodulin, which in turn
activates myosin light chain kinase (MLCK) (both of which are downregulated).
MLCK then phosphorylates the regulatory light chains of the myosin heads leading
to a cascade of events that causes muscle contraction (Figure 10). Both, the
signaling cascade and the structural response machinery are altered in the muscle
of our cachectic patients. Another interesting change in expression was seen in
genes involved in the cytoskeleton and myofibers. This indicates that morphological
changes can be also evident in cachectic muscles before/during the cachectic
changes. Expressions of genes implicated in cellular trafficking were also affected.
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Tropomysin

Figure 9: Muscular Contractile Machinery.
Items circled in blue are downregulated. Amended from [391].
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L-Type
calcium
channel

Figure 10: Molecular Signaling in Muscular contraction.
Items circled in blue are downregulated. Amended from [392].
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Glycogen is an immediate reserve source of energy for skeletal muscle. Many
disorders of glycogen metabolism (as mentioned above) result in muscular
phenotypes. Many genes encoding proteins or protein subunits that are necessary
components in the machinery needed for glycogen metabolism were downregulated
in the cachectic muscles (Figure 11). The involved genes are necessary for either
the initiation or progression of glycogenesis (e.g. PGM1; encoding phosphomutase,
protein hosphatase; PPP1R3A, PPP1R3B, and PPP1R3C; necessary for activation
of glycogen synthase, and AGL; encoding glycogen branching enzyme), or
glycogenolysis (Phosphorylase kinase; PHKA1, PHKB, PHKG1; necessary for
activation of glycogen phosphorylase) (Figure 11). Athletes experiencing a
phenomenon called "hitting the wall", which is caused by depletion of glycogen
stores [393], often experience sudden fatigue and loss of energy [394];two
symptoms repeatedly reported by cachectic patients. Such alteration in the glycogen
turnover in cachectic patients limits energy availability and redirects muscle cells to
energy from other sources, such as fat and protein catabolism.
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UDP-glucose phosphorylase

glycogensynthase
Phosphorylase
kinase; PHKA1,
PHKB, PHKG1

Glycogen branching enzyme

Figure 11: Glycogen Metabolism.
Items circled in blue are downregulated. Amended from [395].
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PPP1R3C
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Aerobic cellular respiration is responsible for the most efficient energy production in
cells[396]. Interestingly in our findings, the machinery responsible for that process
was found to be downregulation at many levels. Normally, aerobic respiration is
initiated by glycolysis leading to the production of pyruvate. Pyruvate is then
converted into acetyl-CoA via a 3-step sequence of enzymatic activities mediated by
"pyruvate dehydrogenase complex". Dihydrolipoyl dehydrogenase (E3) enzyme that
is responsible for the last step of the process was found to be downregulated.
Acetyl-CoA should then be used in the "citric acid cycle"

to generating

NADH(nicotinamide adenine dinucleotide) [159]. Three enzymes (dihydrolipoyl
succinyltransferase, succinyl-CoA synthetase, and succinate dehydrogenase) in this
multistep process were found to be downregulated. NADH can finally enters the
oxidative phosphorylation via the electron transport pathway [159], which is itself
has several downregulated genes in its 5 different complexes (Complex I: NDUFB5
and NDUFS1; complex II: SDHC; complex III: CYCS and UQCRC2; complex IV:
COX20; and complex V: ATP5B).
Our evidence of the disrupted aerobic cellular respiration and the clinical evidence of
an increased lactate production in muscle of cachectic patients [397], is suggestive
of the possible domination of the anaerobic respiration. This process occurs in
animal cells under hypoxic (or partially anaerobic) conditions in oxygen starved
muscles. In cachectic patients, hypoxic conditions might not be the direct cause for
such switch but rather the slowed aerobic respiration process with increasing
demands of muscles for energy production. In many tissues, this is a cellular last
resort for energy that most animal tissue cannot tolerate for an extended period of
time. It is an energy wasting process that requires lactate to be recycled back into
glucose by the liver. The production of lactate via glycolysis as a source of energy
and the followed recycling results in a net loss of 4 ATP molecules which could be
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the direct cause of cachexia due to an increasing demand of tissue catabolism to
meet the required demand of energy (Figure 12).

Net ATP loss is:
4 ATPs

This energy wasting
process contributes to
cachexia

Figure 12: Liver Lactate Recycling and Net ATP Production.

128

The pentose-phosphate pathway is a parallel pathway to glycolysis [398]. The
reaction sequences of central metabolism, glycolysis and the pentose phosphate
pathway provide essential precursors for nucleic acids, amino acids and lipids [398].
The upregulation of this pathway (Figure 13) is one finding in this study that reflects
adaptation or compensatory muscular changes. We also found upregulation of
genes involved in skeletal muscle proliferation, differentiation, and regeneration. We
believe that increased expression of these genes reflects a compensatory
mechanism that is attempting to maintain muscular homeostasis. These above
mechanisms require adequate and strong cell-cell contacts which were evident with
the upregulation of many cell adhesion molecules and extracellular matrix pathway
genes.
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Figure 13: Pentose Phosphate Pathway.
Items circled in red are upregulated. Amended from [399].
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Symptoms of cachexia were also reflected in changes in gene expression.
Weakness and easily fatigability may also be explained by changes in expression of
multiple genes implicated in maintenance of muscular tone, and contractile
machinery. In addition, many of the downregulated genes have a documented
evidence of genetically inherited muscular ailments which are known to affect
muscular tonicity and contractile ability. Also, expression of multiple genes that are
implicated in insulin resistance, a key feature of cachexia, were significantly altered.
The major degradation machinery (the ubiquitination pathway) was surprisingly
downregulated with reduction in expression of multiple genes and at various
different levels. The ubiquitin system has been repeatedly implicated in the
preclinical models as the major mechanisms leading to wasting in many in vitro and
in vivo experiments. All clinical studies have failed to reproduce any upregulation of
this degradation system in human skeletal muscle biopsies. However, amongst
other ground breaking changes in the signature of the cachexia, the present study is
the first to show that the pathway is actually significantly downregulated, perhaps in
compensation for the wasting triggers. This gave us a reassurance and evidence
that our samples represent true early cachectic changes that are subject to bodily
defensive compensatory mechanisms attempting to maintain homeostasis.
None of the inflammatory or tumor specific factors were significantly altered. For
example, no transcripts for the dermicidin gene, which contains the sequence that
codes for the backbone peptide of proteolysis-inducing factor, were detected.
Although of course their expression in the tumors themselves may well be altered.
Furthermore, the genes encoding inflammatory cytokines and their major receptors
were not found to be significantly altered. In contrast, inflammation is a direct cause
for cachexia in conditions such as sepsis, severe trauma, or burns. But cancer
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cachexia has a slower progression phenotype and may be mediated by
inflammatory cytokines, at least in part, in its advanced stages.
The myostatin pathway is at the top of the research agenda for cachexia
researchers. Many animal studies strongly correlated its upregulation to the
pathogenesis of wasting. However, expression of myostatin in our study was
significantly decreased as was its receptor, possibly reflecting end organ adaptation
to tumor produced myostatin.
One unique and interesting gene is TIE1. Expression of this gene was significantly
increased in a previous human microarray study and was also upregulated in the
present study. The TIE1 gene is not well characterized, however, its upregulation in
two separate genome-wide expression studies certainly warrants further attention.
7.2

Changes in Gene Expression in Adipose Tissue

Since cachexia is predominantly associated with skeletal muscle changes, changes
in adipose tissue have received much less attention with regard to the pathogenesis
of cachexia. Many of the genes implicated to be involved from the results of the
present study are either uncharacterized or have not been previously studied in
adipose tissue. However, several of these encode metabolic enzymes and
receptors.
Expression of leptin was downregulated as expected from many previous studies.
This is indicative of depleted fat stores and should result in increased feeding
(Figure 14). However, as has been discussed the hypothalamus does not respond
normally to decreased leptin in the cachectic state. Similar to leptin, tenomodulin
downregulation is also reflective of fat depletion [330] and further support the
involvement of fat wasting in the cachectic process.
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Expression of zinc-α-2-glycoprotein (lipid mobilizing factor) was significantly
upregulated as expected. On the other hand, the expression of other genes
previously implicated with cachexia, such as hormone sensitive lipase and adipose
tissue triglyceride lipase, were unchanged.

Figure 14: Leptin Production and its Function in the Central Nervous System.
Amended from [400].

Expression of genes that are involved in adipogenesis and implicated in insulin
resistance were also upregulated. On the other hand, expression of genes that
resist lipolytic forces were also upregulated, perhaps in an attempt to neutralize the
cachectic state. With the exception of leptin, there were no changes in expression of
any genes previously implicated implicated in cachexia, from either clinical or
preclinical studies, that were reproduced in our the present study on adipose tissue.
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7.3

Changes in Gene Expression in Both; Muscle and Adipose Tissue

With two large organs in the body, there must be a cross-talk mediating the
compensation or decompensation signals leading to wasting. Several altered genes
were found to be common between these two tissues. Many of these genes are yet
to be characterized while others need to be investigated at the context of the
pathogenesis of cachexia.
7.4

Conclusion

Progress in cancer cachexia research was, up till now, held back with poor progress
due to the lack of reliable and representative sample that serve as a "point of
reference" or a benchmark for future research. Cancer cachexia research continuum
have either worked in isolated in vitro and in vivo models which outcomes rarely
been a true reflection of what is seen in the clinic. In addition, studies conducted on
clinical samples didn't feed enough data reflecting the true complexity of the clinical
presentation.
Our enthusiasm took us back to the clinic to extract a meaningful representative
sample from cachectic cancer patients exhibiting early cachectic changes. We were
able for the first time to reflect on the big picture of the pathological changes in the
two major organs affected by cachexia (i.e. muscle and fat). This was achieved by
combination of factors that starts by looking at expression changes in early stages of
cachexia using simple diagnostic criteria, building on previous array studies where
we learnt from their limitations, and finally by utilizing the state-of-the-art technology
for generating the highest quality data. These studies confirmed that for a
multifactorial condition, genome wide transcriptome analysis is the method of choice
to explore the disease complexity. They explain some documented evidence in
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cachexia pathogenesis, highlight ambiguous data from animal models, and reveal
unexpected changes in gene expression that underlie the pathophysiology of the
cachectic state in cancer. These results bring reliable, representable, and consistent
data from the clinic and back to the bench with more focused insights to be
investigated and verified.
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Chapter 8: Limitations and Future Directions
8.1

Limitations

We were lucky that couple of genome-wide array studies have been published
during the time we were collecting our samples. We build part of our success by
starting at where they have ended. However, no study is limitation free. Due to
feasibility issues (time and accrual rate), the study couldn't further restrict its
inclusion criteria further (i.e. same age group, gender, diagnoses, etc). This may
have in part question the homogeneity of samples. However, we don't believe it is a
major influence in the major target organ (i.e. skeletal muscle) as was evident in the
muscle heat map. Functional assessment of subjects was not all done. For example,
none of the subjects were anorexic or malnourished at the time of obtaining
samples. On the other hand, other phenotypes (or symptoms) known to accompany
cachexia were not assessed (e.g. weakness and fatigability). Patients were
generally with good performance status. Thus, we believe that such symptoms are
only clearly evident with advanced cachexia. Our data documented the involvement
of many related genes which is a prerequisite to an evident functional impairment.
We were also not able to validate the data for all the differentially expressed genes.
It would have been wise if a larger separate group of samples is collected and to get
the data cross-validated, however, due to slow accrual rate, we restricted our
findings to what in hand.
8.2

Future Directions

Sample collection will continue using the same simple criteria to identify cachectic
patients in clinic using meticulous follow-up and recording of weight changes to
diagnose patients with cancer cachexia and separate them from non-cachectic

136

weight-stable controls. After this logical presentation of the complexity of cachexia
pathogenesis, the second best step is to be able to verify these changes on a
different and larger group of patients. Also, all reproducible changes should be
confirmed at protein level using western blotting and immunohistochemistry.
Changes in muscular morphology are also worth being investigated via electron
microscopy.
In future studies, we would measure circulating factors where changes were seen in
the present study, including inflammatory cytokines, GAD15, leptin, mysotatin,
proteolysis inducing factor, lipid mobilizing factor, etc.
Finally, it would be hard to completely characterize the role of all of these factors in
the development of cachexia unless we succeed in developing a reliable animal
model that truly reflects cachexia presentation in humans.

137

Bibliography
1.

KATZ AM, KATZ PB. Diseases of the heart in the works of Hippocrates. Br
Heart J. 1962;24:257-64. PubMed PMID: 14454369; PubMed Central
PMCID: PMCPMC1017881.

2.

Doehner W, Anker SD. Cardiac cachexia in early literature: a review of
research prior to Medline. Int J Cardiol. 2002;85(1):7-14. PubMed PMID:
12163205.

3.

Müller H. The Hunger Angel: A Novel: Metropolitan Books; 2012 2012-04-24.
304 p.

4.

von Haehling S, Anker SD. Cachexia as a major underestimated and unmet
medical need: facts and numbers. J Cachexia Sarcopenia Muscle.
2010;1(1):1-5. doi: 10.1007/s13539-010-0002-6. PubMed PMID: 21475699;
PubMed Central PMCID: PMCPMC3060651.

5.

Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al.
Cachexia: a new definition. Clin Nutr. 2008;27(6):793-9. doi:
10.1016/j.clnu.2008.06.013. PubMed PMID: 18718696.

6.

Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, et al.
Consensus definition of sarcopenia, cachexia and pre-cachexia: joint
document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in
chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr.
2010;29(2):154-9. doi: 10.1016/j.clnu.2009.12.004. PubMed PMID:
20060626.

7.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al.
Definition and classification of cancer cachexia: an international consensus.
Lancet Oncol. 2011;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7.
PubMed PMID: 21296615.

8.

Argilés JM, Anker SD, Evans WJ, Morley JE, Fearon KC, Strasser F, et al.
Consensus on cachexia definitions. J Am Med Dir Assoc. 2010;11(4):229-30.
doi: 10.1016/j.jamda.2010.02.004. PubMed PMID: 20439040.

9.

Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, et al. Cancer
cachexia: a systematic literature review of items and domains associated
with involuntary weight loss in cancer. Crit Rev Oncol Hematol.
2011;80(1):114-44. doi: 10.1016/j.critrevonc.2010.10.004. PubMed PMID:
21216616.

138

10.

Baracos VE. Pitfalls in defining and quantifying cachexia. J Cachexia
Sarcopenia Muscle. 2011;2(2):71-3. doi: 10.1007/s13539-011-0031-9.
PubMed PMID: 21766051; PubMed Central PMCID: PMCPMC3117999.

11.

Fox KM, Brooks JM, Gandra SR, Markus R, Chiou CF. Estimation of
Cachexia among Cancer Patients Based on Four Definitions. J Oncol.
2009;2009:693458. doi: 10.1155/2009/693458. PubMed PMID: 19587829;
PubMed Central PMCID: PMCPMC2705834.

12.

Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al.
Prognostic effect of weight loss prior to chemotherapy in cancer patients.
Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491-7.
PubMed PMID: 7424938.

13.

Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff
A. Symptom prevalence in patients with incurable cancer: a systematic
review.
J
Pain
Symptom
Manage.
2007;34(1):94-104.
doi:
10.1016/j.jpainsymman.2006.10.015. PubMed PMID: 17509812.

14.

Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor
M. Quality of life and survival prediction in terminal cancer patients: a
multicenter study. Cancer. 2004;101(5):1090-8. doi: 10.1002/cncr.20472.
PubMed PMID: 15329920.

15.

Inagaki J, Rodriguez V, Bodey GP. Proceedings: Causes of death in cancer
patients. Cancer. 1974;33(2):568-73. PubMed PMID: 4591273.

16.

Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):86271. doi: 10.1038/nrc927. PubMed PMID: 12415256.

17.

Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr
Opin
Clin
Nutr
Metab
Care.
2008;11(4):400-7.
doi:
10.1097/MCO.0b013e328300ecc1. PubMed PMID: 18541999.

18.

Sullivan DH, Liu L, Roberson PK, Bopp MM, Rees JC. Body weight change
and mortality in a cohort of elderly patients recently discharged from the
hospital. J Am Geriatr Soc. 2004;52(10):1696-701. doi: 10.1111/j.15325415.2004.52463.x. PubMed PMID: 15450047.

19.

Sullivan DH, Johnson LE, Bopp MM, Roberson PK. Prognostic significance
of monthly weight fluctuations among older nursing home residents. J
Gerontol A Biol Sci Med Sci. 2004;59(6):M633-9. PubMed PMID: 15215284.

139

20.

Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al. Cancer
cachexia: traditional therapies and novel molecular mechanism-based
approaches to treatment. Curr Treat Options Oncol. 2010;11(3-4):107-17.
doi: 10.1007/s11864-010-0127-z. PubMed PMID: 21128029; PubMed
Central PMCID: PMCPMC3016925.

21.

Heys SD, Walker LG, Smith I, Eremin O. Enteral nutritional supplementation
with key nutrients in patients with critical illness and cancer: a meta-analysis
of randomized controlled clinical trials. Ann Surg. 1999;229(4):467-77.
PubMed PMID: 10203078; PubMed Central PMCID: PMCPMC1191731.

22.

Parenteral nutrition in patients receiving cancer chemotherapy. American
College of Physicians. Ann Intern Med. 1989;110(9):734-6. PubMed PMID:
2494922.

23.

Torelli GF, Campos AC, Meguid MM. Use of TPN in terminally ill cancer
patients. Nutrition. 1999;15(9):665-7. PubMed PMID: 10467610.

24.

Grimble RF. Nutritional therapy for cancer cachexia. Gut. 2003;52(10):13912. PubMed PMID: 12970126; PubMed Central PMCID: PMCPMC1773821.

25.

Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, Garcíade-Lorenzo A, Zarazaga A, et al. N-3 fatty acids, cancer and cachexia: a
systematic review of the literature. Br J Nutr. 2007;97(5):823-31. doi:
10.1017/S000711450765795X. PubMed PMID: 17408522.

26.

Skipworth RJ, Fearon KC. The scientific rationale for optimizing nutritional
support in cancer. Eur J Gastroenterol Hepatol. 2007;19(5):371-7. doi:
10.1097/MEG.0b013e3280bdbf87. PubMed PMID: 17413286.

27.

Holland JC, Rowland J, Plumb M. Psychological aspects of anorexia in
cancer patients. Cancer Res. 1977;37(7 Pt 2):2425-8. PubMed PMID:
405097.

28.

Ardies CM. Exercise, cachexia, and cancer therapy: a molecular rationale.
Nutr Cancer. 2002;42(2):143-57. doi: 10.1207/S15327914NC422_1. PubMed
PMID: 12416253.

29.

Lowe SS, Watanabe SM, Courneya KS. Physical activity as a supportive
care intervention in palliative cancer patients: a systematic review. J Support
Oncol. 2009;7(1):27-34. PubMed PMID: 19278175.

140

30.

Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM.
Thalidomide in the treatment of cancer cachexia: a randomised placebo
controlled trial. Gut. 2005;54(4):540-5. doi: 10.1136/gut.2004.047563.
PubMed PMID: 15753541; PubMed Central PMCID: PMCPMC1774430.

31.

Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, et al.
Comparison of orally administered cannabis extract and delta-9tetrahydrocannabinol in treating patients with cancer-related anorexiacachexia syndrome: a multicenter, phase III, randomized, double-blind,
placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
J Clin Oncol. 2006;24(21):3394-400. doi: 10.1200/JCO.2005.05.1847.
PubMed PMID: 16849753.

32.

Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexiacachexia syndrome. Cochrane Database Syst Rev. 2005;(2):CD004310. doi:
10.1002/14651858.CD004310.pub2. PubMed PMID: 15846706.

33.

Bodenner D, Spencer T, Riggs AT, Redman C, Strunk B, Hughes T. A
retrospective study of the association between megestrol acetate
administration and mortality among nursing home residents with clinically
significant weight loss. Am J Geriatr Pharmacother. 2007;5(2):137-46. doi:
10.1016/j.amjopharm.2007.06.004. PubMed PMID: 17719516.

34.

Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral
methylprednisolone in terminal cancer patients: a prospective randomized
double-blind study. Cancer Treat Rep. 1985;69(7-8):751-4. PubMed PMID:
2410117.

35.

Della Cuna GR, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium
succinate on quality of life in preterminal cancer patients: a placebocontrolled, multicenter study. The Methylprednisolone Preterminal Cancer
Study Group. Eur J Cancer Clin Oncol. 1989;25(12):1817-21. PubMed PMID:
2698804.

36.

Willox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M.
Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin
Res Ed). 1984;288(6410):27. PubMed PMID: 6418303; PubMed Central
PMCID: PMCPMC1444189.

37.

Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of
preterminal gastrointestinal cancer. Cancer. 1974;33(6):1607-9. PubMed
PMID: 4135151.

141

38.

Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyenfeldt MF,
Saris WH. Effect of different tumor types on resting energy expenditure.
Cancer Res. 1991;51(22):6138-41. PubMed PMID: 1657379.

39.

Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol
Clin North Am. 2002;16(3):589-617. PubMed PMID: 12170570.

40.

Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al.
Dronabinol versus megestrol acetate versus combination therapy for cancerassociated anorexia: a North Central Cancer Treatment Group study. J Clin
Oncol. 2002;20(2):567-73. PubMed PMID: 11786587.

41.

Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, et al.
An eicosapentaenoic acid supplement versus megestrol acetate versus both
for patients with cancer-associated wasting: a North Central Cancer
Treatment Group and National Cancer Institute of Canada collaborative
effort. J Clin Oncol. 2004;22(12):2469-76. doi: 10.1200/JCO.2004.06.024.
PubMed PMID: 15197210.

42.

McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle
CS. A prospective randomized study of megestrol acetate and ibuprofen in
gastrointestinal cancer patients with weight loss. Br J Cancer. 1999;79(34):495-500. doi: 10.1038/sj.bjc.6690077. PubMed PMID: 10027319; PubMed
Central PMCID: PMCPMC2362415.

43.

Mantovani G. Randomised phase III clinical trial of 5 different arms of
treatment on 332 patients with cancer cachexia. Eur Rev Med Pharmacol
Sci. 2010;14(4):292-301. PubMed PMID: 20496538.

44.

Dixon J. Effect of nursing interventions on nutritional and performance status
in cancer patients. Nurs Res. 1984;33(6):330-5. PubMed PMID: 6387632.

45.

Heymsfield SB, McManus CB. Tissue components of weight loss in cancer
patients. A new method of study and preliminary observations. Cancer.
1985;55(1 Suppl):238-49. PubMed PMID: 3965090.

46.

Fearon KC. The Sir David Cuthbertson Medal Lecture 1991. The
mechanisms and treatment of weight loss in cancer. Proc Nutr Soc.
1992;51(2):251-65. PubMed PMID: 1438334.

47.

Melstrom LG, Melstrom KA, Ding XZ, Adrian TE. Mechanisms of skeletal
muscle degradation and its therapy in cancer cachexia. Histol Histopathol.
2007;22(7):805-14. PubMed PMID: 17455154.

142

48.

Michie HR. Metabolism of sepsis and multiple organ failure. World J Surg.
1996;20(4):460-4. PubMed PMID: 8662135.

49.

Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell mass in
cancer-bearing and anorexic patients. JPEN J Parenter Enteral Nutr.
1987;11(3):219-22. PubMed PMID: 3474427.

50.

Fearon KC, Tisdale MJ, Preston T, Plumb JA, Calman KC. Failure of
systemic ketosis to control cachexia and the growth rate of the Walker 256
carcinosarcoma in rats. Br J Cancer. 1985;52(1):87-92. PubMed PMID:
2861842; PubMed Central PMCID: PMCPMC1977175.

51.

Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the
acute-phase response, and resting energy expenditure in cachectic patients
with pancreatic cancer. Ann Surg. 1994;219(4):325-31. PubMed PMID:
7512810; PubMed Central PMCID: PMCPMC1243147.

52.

McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS.
Longitudinal study of body cell mass depletion and the inflammatory
response in cancer patients. Nutr Cancer. 1998;31(2):101-5. doi:
10.1080/01635589809514687. PubMed PMID: 9770720.

53.

McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The
relationship between circulating concentrations of C-reactive protein,
inflammatory cytokines and cytokine receptors in patients with non-small-cell
lung cancer. Br J Cancer. 2004;91(12):1993-5. doi: 10.1038/sj.bjc.6602248.
PubMed PMID: 15570310; PubMed Central PMCID: PMCPMC2410147.

54.

Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total
energy expenditure and physical activity in cachectic patients with pancreatic
cancer can be modulated by an energy and protein dense oral supplement
enriched with n-3 fatty acids. Br J Cancer. 2004;90(5):996-1002. doi:
10.1038/sj.bjc.6601620. PubMed PMID: 14997196; PubMed Central PMCID:
PMCPMC2409623.

55.

Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer
patients: possible cause of cancer-induced cachexia. J Cancer Res Clin
Oncol. 1986;111(1):82-5. PubMed PMID: 3949854.

56.

Nedergaard J, Ricquier D, Kozak LP. Uncoupling proteins: current status and
therapeutic
prospects.
EMBO
Rep.
2005;6(10):917-21.
doi:
10.1038/sj.embor.7400532. PubMed PMID: 16179945; PubMed Central
PMCID: PMCPMC1369193.

143

57.

Hoang T, Smith MD, Jelokhani-Niaraki M. Toward understanding the
mechanism of ion transport activity of neuronal uncoupling proteins UCP2,
UCP4,
and
UCP5.
Biochemistry.
2012;51(19):4004-14.
doi:
10.1021/bi3003378. PubMed PMID: 22524567.

58.

Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G. Increased gene
expression of brown fat uncoupling protein (UCP)1 and skeletal muscle
UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res.
2000;60(9):2405-10. PubMed PMID: 10811117.

59.

Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are
elevated in weight loss associated with gastrointestinal adenocarcinoma in
humans. Br J Cancer. 2002;86(3):372-5. doi: 10.1038/sj.bjc.6600074.
PubMed PMID: 11875702; PubMed Central PMCID: PMCPMC2375209.

60.

Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer
treatment. Oncogene. 2006;25(34):4633-46. doi: 10.1038/sj.onc.1209597.
PubMed PMID: 16892078.

61.

Sawayama H, Ishimoto T, Sugihara H, Miyanari N, Miyamoto Y, Baba Y, et
al. Clinical impact of the Warburg effect in gastrointestinal cancer (review).
Int J Oncol. 2014;45(4):1345-54. doi: 10.3892/ijo.2014.2563. PubMed PMID:
25070157.

62.

Holroyde CP, Skutches CL, Boden G, Reichard GA. Glucose metabolism in
cachectic patients with colorectal cancer. Cancer Res. 1984;44(12 Pt
1):5910-3. PubMed PMID: 6388829.

63.

Edén E, Edström S, Bennegård K, Scherstén T, Lundholm K. Glucose flux in
relation to energy expenditure in malnourished patients with and without
cancer during periods of fasting and feeding. Cancer Res. 1984;44(4):171824. PubMed PMID: 6367972.

64.

Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting
energy expenditure in relation to weight loss in unselected cancer patients.
Int J Cancer. 2001;93(3):380-3. PubMed PMID: 11433403.

65.

Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of
dietary counseling on food intake, body weight, response rate, survival, and
quality of life in cancer patients undergoing chemotherapy: a prospective,
randomized study. J Clin Oncol. 1993;11(10):2043-9. PubMed PMID:
8410128.

144

66.

Evans WK, Makuch R, Clamon GH, Feld R, Weiner RS, Moran E, et al.
Limited impact of total parenteral nutrition on nutritional status during
treatment for small cell lung cancer. Cancer Res. 1985;45(7):3347-53.
PubMed PMID: 2988769.

67.

Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM, et
al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or
cachexia. Cancer. 1990;65(12):2657-62. PubMed PMID: 2187585.

68.

Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN. Effect of
home total parenteral nutrition on body composition in patients with acquired
immunodeficiency syndrome. JPEN J Parenter Enteral Nutr. 1990;14(5):4548. PubMed PMID: 2122017.

69.

Streat SJ, Beddoe AH, Hill GL. Aggressive nutritional support does not
prevent protein loss despite fat gain in septic intensive care patients. J
Trauma. 1987;27(3):262-6. PubMed PMID: 3104621.

70.

Okusaka T, Okada S, Ishii H, Ikeda M, Kosakamoto H, Yoshimori M.
Prognosis of advanced pancreatic cancer patients with reference to calorie
intake. Nutr Cancer. 1998;32(1):55-8. doi: 10.1080/01635589809514717.
PubMed PMID: 9824858.

71.

Eley HL, Tisdale MJ. Skeletal muscle atrophy, a link between depression of
protein synthesis and increase in degradation. J Biol Chem.
2007;282(10):7087-97. doi: 10.1074/jbc.M610378200. PubMed PMID:
17213191.

72.

O'Keefe SJ, Ogden J, Ramjee G, Rund J. Contribution of elevated protein
turnover and anorexia to cachexia in patients with hepatocellular carcinoma.
Cancer Res. 1990;50(4):1226-30. PubMed PMID: 2153453.

73.

Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown
and the critical role of the ubiquitin-proteasome pathway in normal and
disease states. J Nutr. 1999;129(1S Suppl):227S-37S. PubMed PMID:
9915905.

74.

Furuno K, Goldberg AL. The activation of protein degradation in muscle by
Ca2+ or muscle injury does not involve a lysosomal mechanism. Biochem J.
1986;237(3):859-64. PubMed PMID: 3099758; PubMed Central PMCID:
PMCPMC1147067.

75.

Lowell BB, Ruderman NB, Goodman MN. Evidence that lysosomes are not
involved in the degradation of myofibrillar proteins in rat skeletal muscle.

145

Biochem J. 1986;234(1):237-40. PubMed PMID: 3707546; PubMed Central
PMCID: PMCPMC1146553.
76.

Gronostajski RM, Goldberg AL, Pardee AB. The role of increased proteolysis
in the atrophy and arrest of proliferation in serum-deprived fibroblasts. J Cell
Physiol. 1984;121(1):189-98. doi: 10.1002/jcp.1041210124. PubMed PMID:
6384241.

77.

Murachi T, Tanaka K, Hatanaka M, Murakami T. Intracellular Ca2+dependent protease (calpain) and its high-molecular-weight endogenous
inhibitor (calpastatin). Adv Enzyme Regul. 1980;19:407-24. PubMed PMID:
6278869.

78.

Waxman L. Calcium-activated proteases in mammalian tissues. Methods
Enzymol. 1981;80 Pt C:664-80. PubMed PMID: 6281623.

79.

Mellgren RL. Calcium-dependent proteases: an enzyme system active at
cellular membranes? FASEB J. 1987;1(2):110-5. PubMed PMID: 2886390.

80.

Schubert U, Antón LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid
degradation of a large fraction of newly synthesized proteins by
proteasomes. Nature. 2000;404(6779):770-4. doi: 10.1038/35008096.
PubMed PMID: 10783891.

81.

Tisdale MJ. The ubiquitin-proteasome pathway as a therapeutic target for
muscle wasting. J Support Oncol. 2005;3(3):209-17. PubMed PMID:
15915823.

82.

Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle
cachexia: it may be more than the proteasome. Biochem Biophys Res
Commun. 2002;290(1):1-10. doi: 10.1006/bbrc.2001.5849. PubMed PMID:
11779124.

83.

Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the
ubiquitin-proteasome pathway. N Engl J Med. 1996;335(25):1897-905. doi:
10.1056/NEJM199612193352507. PubMed PMID: 8948566.

84.

Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides
generated from protein by mammalian 26 and 20 S proteasomes.
Implications for understanding the degradative mechanism and antigen
presentation. J Biol Chem. 1999;274(6):3363-71. PubMed PMID: 9920878.

146

85.

Bålöw RM, Tomkinson B, Ragnarsson U, Zetterqvist O. Purification,
substrate specificity, and classification of tripeptidyl peptidase II. J Biol
Chem. 1986;261(5):2409-17. PubMed PMID: 3511062.

86.

Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway:
destruction for the sake of construction. Physiol Rev. 2002;82(2):373-428.
doi: 10.1152/physrev.00027.2001. PubMed PMID: 11917093.

87.

Goll DE, Thompson VF, Taylor RG, Christiansen JA. Role of the calpain
system in muscle growth. Biochimie. 1992;74(3):225-37. PubMed PMID:
1610936.

88.

Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitindependent proteolytic system in skeletal muscle during fasting. Am J Physiol.
1993;264(4 Pt 1):E668-76. PubMed PMID: 7682781.

89.

Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR, et al.
Metabolic acidosis stimulates muscle protein degradation by activating the
adenosine triphosphate-dependent pathway involving ubiquitin and
proteasomes. J Clin Invest. 1994;93(5):2127-33. doi: 10.1172/JCI117208.
PubMed PMID: 8182144; PubMed Central PMCID: PMCPMC294343.

90.

Chand A, Wyke SM, Tisdale MJ. Effect of cancer cachexia on the activity of
tripeptidyl-peptidase II in skeletal muscle. Cancer Lett. 2005;218(2):215-22.
doi: 10.1016/j.canlet.2004.07.047. PubMed PMID: 15670899.

91.

Khal J, Hine AV, Fearon KC, Dejong CH, Tisdale MJ. Increased expression
of proteasome subunits in skeletal muscle of cancer patients with weight
loss.
Int
J
Biochem
Cell
Biol.
2005;37(10):2196-206.
doi:
10.1016/j.biocel.2004.10.017. PubMed PMID: 16125116.

92.

Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the ATPubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a
hepatoma. Am J Physiol. 1995;268(5 Pt 1):E996-1006. PubMed PMID:
7539218.

93.

Jagoe RT, Redfern CP, Roberts RG, Gibson GJ, Goodship TH. Skeletal
muscle mRNA levels for cathepsin B, but not components of the ubiquitinproteasome pathway, are increased in patients with lung cancer referred for
thoracotomy. Clin Sci (Lond). 2002;102(3):353-61. PubMed PMID:
11869177.

147

94.

Scherstén T, Lundholm K. Lysosomal enzyme activity in muscle tissue from
patients with malignant tumor. Cancer. 1972;30(5):1246-51. PubMed PMID:
4263667.

95.

Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al.
Cancer cachexia is regulated by selective targeting of skeletal muscle gene
products. J Clin Invest. 2004;114(3):370-8. doi: 10.1172/JCI20174. PubMed
PMID: 15286803; PubMed Central PMCID: PMCPMC484974.

96.

Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, et al.
Tumors secreting human TNF/cachectin induce cachexia in mice. Cell.
1987;50(4):555-63. PubMed PMID: 3607879.

97.

Llovera M, García-Martínez C, López-Soriano J, Agell N, López-Soriano FJ,
Garcia I, et al. Protein turnover in skeletal muscle of tumour-bearing
transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett.
1998;130(1-2):19-27. PubMed PMID: 9751252.

98.

García-Martínez C, López-Soriano FJ, Argilés JM. Acute treatment with
tumour necrosis factor-alpha induces changes in protein metabolism in rat
skeletal muscle. Mol Cell Biochem. 1993;125(1):11-8. PubMed PMID:
8264567.

99.

Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by
oxidative stress in a murine model of cachexia is prevented by inhibitors of
nitric oxide synthesis and antioxidants. EMBO J. 1996;15(8):1753-65.
PubMed PMID: 8617220; PubMed Central PMCID: PMCPMC450091.

100.

Starnes HF, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W,
Oettgen HF, et al. Tumor necrosis factor and the acute metabolic response
to tissue injury in man. J Clin Invest. 1988;82(4):1321-5. doi:
10.1172/JCI113733. PubMed PMID: 3139712; PubMed Central PMCID:
PMCPMC442686.

101.

Ebisui C, Tsujinaka T, Morimoto T, Kan K, Iijima S, Yano M, et al. Interleukin6 induces proteolysis by activating intracellular proteases (cathepsins B and
L, proteasome) in C2C12 myotubes. Clin Sci (Lond). 1995;89(4):431-9.
PubMed PMID: 7493444.

102.

Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F, Nordan RP.
Suramin interferes with interleukin-6 receptor binding in vitro and inhibits
colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest.
1993;92(5):2152-9. doi: 10.1172/JCI116816. PubMed PMID: 8227330;
PubMed Central PMCID: PMCPMC288393.

148

103.

Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al.
Interleukin 6 receptor antibody inhibits muscle atrophy and modulates
proteolytic systems in interleukin 6 transgenic mice. J Clin Invest.
1996;97(1):244-9.

104.

Espat NJ, Auffenberg T, Rosenberg JJ, Rogy M, Martin D, Fang CH, et al.
Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to
induce an acute phase response. Am J Physiol. 1996;271(1 Pt 2):R185-90.
PubMed PMID: 8760219.

105.

Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, Carson JA.
Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr
Comp Physiol. 2008;294(2):R393-401. doi: 10.1152/ajpregu.00716.2007.
PubMed PMID: 18056981.

106.

Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in
rats. Proc Soc Exp Biol Med. 1994;205(2):182-5. PubMed PMID: 8108469.

107.

Llovera M, Carbó N, López-Soriano J, García-Martínez C, Busquets S,
Alvarez B, et al. Different cytokines modulate ubiquitin gene expression in rat
skeletal muscle. Cancer Lett. 1998;133(1):83-7. PubMed PMID: 9929164.

108.

Moldawer LL, Andersson C, Gelin J, Lundholm KG. Regulation of food intake
and hepatic protein synthesis by recombinant-derived cytokines. Am J
Physiol. 1988;254(3 Pt 1):G450-6. PubMed PMID: 2450475.

109.

Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, et al.
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body
proteins. Am J Physiol. 1989;256(3 Pt 2):R659-65. PubMed PMID: 2784290.

110.

Matthys P, Dijkmans R, Proost P, Van Damme J, Heremans H, Sobis H, et
al. Severe cachexia in mice inoculated with interferon-gamma-producing
tumor cells. Int J Cancer. 1991;49(1):77-82. PubMed PMID: 1908442.

111.

Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement
of interleukin 6 in experimental cancer cachexia. J Clin Invest.
1992;89(5):1681-4. doi: 10.1172/JCI115767. PubMed PMID: 1569207;
PubMed Central PMCID: PMCPMC443047.

112.

Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, et al. Serum
levels of tumour necrosis factor alpha and other cytokines do not correlate
with weight loss and anorexia in cancer patients. Support Care Cancer.
1997;5(2):130-5. PubMed PMID: 9069613.

149

113.

Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genet. 2009;10(1):57-63. doi: 10.1038/nrg2484.
PubMed PMID: 19015660; PubMed Central PMCID: PMCPMC2949280.

114.

Magic Z, Radulovic S, Brankovic-Magic M. cDNA microarrays: identification
of gene signatures and their application in clinical practice. J BUON. 2007;12
Suppl 1:S39-44. PubMed PMID: 17935276.

115.

Morin R, Bainbridge M, Fejes A, Hirst M, Krzywinski M, Pugh T, et al.
Profiling the HeLa S3 transcriptome using randomly primed cDNA and
massively parallel short-read sequencing. Biotechniques. 2008;45(1):81-94.
doi: 10.2144/000112900. PubMed PMID: 18611170.

116.

Chu Y, Corey DR. RNA sequencing: platform selection, experimental design,
and data interpretation. Nucleic Acid Ther. 2012;22(4):271-4. doi:
10.1089/nat.2012.0367. PubMed PMID: 22830413; PubMed Central PMCID:
PMCPMC3426205.

117.

UPLC-MS/MS Analysis of Bimatoprost and its Free Acid Metabolite from
Minipig
Skin
2015.
Available
from:
http://www.tandemlabs.com/documents/3274-ASMS-2011-Ford-web.pdf.

118.

Rehm H. Protein Biochemistry and Proteomics (The Experimenter Series):
Academic Press; 2006 2006-03-07. 256 p.

119.

Instruction Manual POLYTRON ® System PT 2100 2015. Available from:
http://www.ms0815.com/mall/shop_image/201111/%5B458%5D%EC%83%8
1%EC%84%B8%EC%84%A4%EB%AA%85%EC%84%9C.pdf.

120.

Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction: twenty-something
years on. Nat Protoc. 2006;1(2):581-5. doi: 10.1038/nprot.2006.83. PubMed
PMID: 17406285.

121.

Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem.
1987;162(1):156-9. doi: 10.1006/abio.1987.9999. PubMed PMID: 2440339.

122.

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al.
The MIQE guidelines: minimum information for publication of quantitative
real-time PCR experiments. Clin Chem. 2009;55(4):611-22. doi:
10.1373/clinchem.2008.112797. PubMed PMID: 19246619.

150

123.

Pabinger S, Dander A, Fischer M, Snajder R, Sperk M, Efremova M, et al. A
survey of tools for variant analysis of next-generation genome sequencing
data. Brief Bioinform. 2014;15(2):256-78. doi: 10.1093/bib/bbs086. PubMed
PMID: 23341494; PubMed Central PMCID: PMCPMC3956068.

124.

Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current
approaches
and
outstanding
challenges.
PLoS
Comput
Biol.
2012;8(2):e1002375. doi: 10.1371/journal.pcbi.1002375. PubMed PMID:
22383865; PubMed Central PMCID: PMCPMC3285573.

125.

Elbers CC, van Eijk KR, Franke L, Mulder F, van der Schouw YT, Wijmenga
C, et al. Using genome-wide pathway analysis to unravel the etiology of
complex
diseases.
Genet
Epidemiol.
2009;33(5):419-31.
doi:
10.1002/gepi.20395. PubMed PMID: 19235186.

126.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 2000;28(1):27-30. PubMed PMID: 10592173; PubMed
Central PMCID: PMCPMC102409.

127.

Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, et
al. From genomics to chemical genomics: new developments in KEGG.
Nucleic
Acids
Res.
2006;34(Database
issue):D354-7.
doi:
10.1093/nar/gkj102. PubMed PMID: 16381885; PubMed Central PMCID:
PMCPMC1347464.

128.

Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control
and signal integration in development. Science. 1999;284(5415):770-6.
PubMed PMID: 10221902.

129.

Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration
of regenerative potential to aged muscle. Science. 2003;302(5650):1575-7.
doi: 10.1126/science.1087573. PubMed PMID: 14645852.

130.

Kopan R, Nye JS, Weintraub H. The intracellular domain of mouse Notch: a
constitutively activated repressor of myogenesis directed at the basic helixloop-helix region of MyoD. Development. 1994;120(9):2385-96. PubMed
PMID: 7956819.

131.

Matsuno K, Diederich RJ, Go MJ, Blaumueller CM, Artavanis-Tsakonas S.
Deltex acts as a positive regulator of Notch signaling through interactions
with the Notch ankyrin repeats. Development. 1995;121(8):2633-44. PubMed
PMID: 7671825.

151

132.

Moloney DJ, Panin VM, Johnston SH, Chen J, Shao L, Wilson R, et al.
Fringe is a glycosyltransferase that modifies Notch. Nature.
2000;406(6794):369-75. doi: 10.1038/35019000. PubMed PMID: 10935626.

133.

Matsuno K, Ito M, Hori K, Miyashita F, Suzuki S, Kishi N, et al. Involvement
of a proline-rich motif and RING-H2 finger of Deltex in the regulation of Notch
signaling. Development. 2002;129(4):1049-59. PubMed PMID: 11861487.

134.

Yamamoto N, Yamamoto S, Inagaki F, Kawaichi M, Fukamizu A, Kishi N, et
al. Role of Deltex-1 as a transcriptional regulator downstream of the Notch
receptor.
J
Biol
Chem.
2001;276(48):45031-40.
doi:
10.1074/jbc.M105245200. PubMed PMID: 11564735.

135.

Conboy IM, Rando TA. The regulation of Notch signaling controls satellite
cell activation and cell fate determination in postnatal myogenesis. Dev Cell.
2002;3(3):397-409. PubMed PMID: 12361602.

136.

Drey M, Sieber CC, Bauer JM, Uter W, Dahinden P, Fariello RG, et al. Cterminal Agrin Fragment as a potential marker for sarcopenia caused by
degeneration of the neuromuscular junction. Exp Gerontol. 2013;48(1):76-80.
doi: 10.1016/j.exger.2012.05.021. PubMed PMID: 22683512.

137.

Moran JL, Li Y, Hill AA, Mounts WM, Miller CP. Gene expression changes
during mouse skeletal myoblast differentiation revealed by transcriptional
profiling.
Physiol
Genomics.
2002;10(2):103-11.
doi:
10.1152/physiolgenomics.00011.2002. PubMed PMID: 12181367.

138.

Smith LR, Meyer G, Lieber RL. Systems analysis of biological networks in
skeletal muscle function. Wiley Interdiscip Rev Syst Biol Med. 2013;5(1):5571. doi: 10.1002/wsbm.1197. PubMed PMID: 23188744; PubMed Central
PMCID: PMCPMC4076960.

139.

Fukada S, Uezumi A, Ikemoto M, Masuda S, Segawa M, Tanimura N, et al.
Molecular signature of quiescent satellite cells in adult skeletal muscle. Stem
Cells. 2007;25(10):2448-59. doi: 10.1634/stemcells.2007-0019. PubMed
PMID: 17600112.

140.

Cauchi S, Froguel P. TCF7L2 genetic defect and type 2 diabetes. Curr Diab
Rep. 2008;8(2):149-55. PubMed PMID: 18445358.

141.

Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J.
Improved glucose metabolism after subtotal pancreatectomy for pancreatic
cancer. Br J Surg. 1993;80(8):1047-50. PubMed PMID: 8402064.

152

142.

Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J. Is
profound peripheral insulin resistance in patients with pancreatic cancer
caused by a tumor-associated factor? Am J Surg. 1993;165(1):61-6;
discussion 6-7. PubMed PMID: 8380314.

143.

Chen J, Sadowski HB, Kohanski RA, Wang LH. Stat5 is a physiological
substrate of the insulin receptor. Proc Natl Acad Sci U S A. 1997;94(6):2295300. PubMed PMID: 9122188; PubMed Central PMCID: PMCPMC20081.

144.

Storz P, Döppler H, Wernig A, Pfizenmaier K, Müller G. TNF inhibits insulin
induced STAT5 activation in differentiated mouse muscle cells pmi28. FEBS
Lett. 1998;440(1-2):41-5. PubMed PMID: 9862421.

145.

Magnusson-Lind A, Davidsson M, Silajdžić E, Hansen C, McCourt AC,
Tabrizi SJ, et al. Skeletal muscle atrophy in R6/2 mice - altered circulating
skeletal muscle markers and gene expression profile changes. J Huntingtons
Dis. 2014;3(1):13-24. doi: 10.3233/JHD-130075. PubMed PMID: 25062762.

146.

Wang MC, Dolphin A, Kitmitto A. L-type voltage-gated calcium channels:
understanding function through structure. FEBS Lett. 2004;564(3):245-50.
doi: 10.1016/S0014-5793(04)00253-4. PubMed PMID: 15111104.

147.

Calura E, Cagnin S, Raffaello A, Laveder P, Lanfranchi G, Romualdi C.
Meta-analysis of expression signatures of muscle atrophy: gene interaction
networks in early and late stages. BMC Genomics. 2008;9:630. doi:
10.1186/1471-2164-9-630. PubMed PMID: 19108710; PubMed Central
PMCID: PMCPMC2642825.

148.

Gurnett CA, Alaee F, Desruisseau D, Boehm S, Dobbs MB. Skeletal muscle
contractile gene (TNNT3, MYH3, TPM2) mutations not found in vertical talus
or clubfoot. Clin Orthop Relat Res. 2009;467(5):1195-200. doi:
10.1007/s11999-008-0694-5. PubMed PMID: 19142688; PubMed Central
PMCID: PMCPMC2664426.

149.

The Sarcomere and Skeletal Muscle Disease (Advances in Experimental
Medicine and Biology). Laing NG, editor: Springer; 2008 2008-11-24. 228 p.

150.

Thornton C, Snowden MA, Carling D. Identification of a novel AMPK beta
subunit that is highly expressed in skeletal muscle. Biochem Soc Trans.
1997;25(4):S667. PubMed PMID: 9450095.

151.

Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, et
al. STAT3 activation in skeletal muscle links muscle wasting and the acute
phase response in cancer cachexia. PLoS One. 2011;6(7):e22538. doi:

153

10.1371/journal.pone.0022538. PubMed PMID: 21799891; PubMed Central
PMCID: PMCPMC3140523.
152.

Jung D, Duclos F, Apostol B, Straub V, Lee JC, Allamand V, et al.
Characterization of delta-sarcoglycan, a novel component of the oligomeric
sarcoglycan complex involved in limb-girdle muscular dystrophy. J Biol
Chem. 1996;271(50):32321-9. PubMed PMID: 8943294.

153.

Labeit S, Kolmerer B, Linke WA. The giant protein titin. Emerging roles in
physiology and pathophysiology. Circ Res. 1997;80(2):290-4. PubMed PMID:
9012751.

154.

Hackman P, Vihola A, Haravuori H, Marchand S, Sarparanta J, De Seze J, et
al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the
gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet.
2002;71(3):492-500. doi: 10.1086/342380. PubMed PMID: 12145747;
PubMed Central PMCID: PMCPMC379188.

155.

Ducceschi M, Clifton LG, Stimpson SA, Billin AN. Post-transcriptional
regulation of ITGB6 protein levels in damaged skeletal muscle. J Mol Histol.
2014;45(3):329-36. doi: 10.1007/s10735-014-9567-2. PubMed PMID:
24488487; PubMed Central PMCID: PMCPMC3983900.

156.

Cornwell EW, Mirbod A, Wu CL, Kandarian SC, Jackman RW. C26 cancerinduced muscle wasting is IKKβ-dependent and NF-kappaB-independent.
PLoS One. 2014;9(1):e87776. doi: 10.1371/journal.pone.0087776. PubMed
PMID: 24489962; PubMed Central PMCID: PMCPMC3906224.

157.

Humphries MJ. Integrin structure. Biochem Soc Trans. 2000;28(4):311-39.
PubMed PMID: 10961914.

158.

Vanpoucke G, Goossens S, De Craene B, Gilbert B, van Roy F, Berx G.
GATA-4 and MEF2C transcription factors control the tissue-specific
expression of the alphaT-catenin gene CTNNA3. Nucleic Acids Res.
2004;32(14):4155-65. doi: 10.1093/nar/gkh727. PubMed PMID: 15302915;
PubMed Central PMCID: PMCPMC514362.

159.

Berg JM, Tymoczko JL, Stryer L. Biochemistry, 6th Edition: W. H. Freeman;
2006 2006-05-19. 1026 p.

160.

Tournebize R, Andersen SS, Verde F, Dorée M, Karsenti E, Hyman AA.
Distinct roles of PP1 and PP2A-like phosphatases in control of microtubule
dynamics during mitosis. EMBO J. 1997;16(18):5537-49. doi:

154

10.1093/emboj/16.18.5537. PubMed PMID: 9312013; PubMed Central
PMCID: PMCPMC1170186.
161.

Liu J, Knezetic JA, Strömmer L, Permert J, Larsson J, Adrian TE. The
intracellular mechanism of insulin resistance in pancreatic cancer patients. J
Clin Endocrinol Metab. 2000;85(3):1232-8. doi: 10.1210/jcem.85.3.6400.
PubMed PMID: 10720068.

162.

Steinberg GR, O'Neill HM, Dzamko NL, Galic S, Naim T, Koopman R, et al.
Whole body deletion of AMP-activated protein kinase {beta}2 reduces
muscle AMPK activity and exercise capacity. J Biol Chem.
2010;285(48):37198-209. doi: 10.1074/jbc.M110.102434. PubMed PMID:
20855892; PubMed Central PMCID: PMCPMC2988326.

163.

Rose AJ, Kiens B, Richter EA. Ca2+-calmodulin-dependent protein kinase
expression and signalling in skeletal muscle during exercise. J Physiol.
2006;574(Pt 3):889-903. doi: 10.1113/jphysiol.2006.111757. PubMed PMID:
16690701; PubMed Central PMCID: PMCPMC1817750.

164.

Faenza I, Blalock W, Bavelloni A, Schoser B, Fiume R, Pacella S, et al. A
role for PLCβ1 in myotonic dystrophies type 1 and 2. FASEB J.
2012;26(7):3042-8. doi: 10.1096/fj.11-200337. PubMed PMID: 22459146.

165.

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular
Biology of the Cell: Garland Science; 2007 2007-11-16. 1392 p.

166.

Goldsworthy M, Absalom NL, Schröter D, Matthews HC, Bogani D, Moir L, et
al. Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance
and impaired glucose tolerance in mice. PLoS One. 2013;8(6):e61870. doi:
10.1371/journal.pone.0061870. PubMed PMID: 23826075; PubMed Central
PMCID: PMCPMC3691224.

167.

Mithani SK, Smith IM, Califano JA. Use of integrative epigenetic and
cytogenetic analyses to identify novel tumor-suppressor genes in malignant
melanoma.
Melanoma
Res.
2011;21(4):298-307.
doi:
10.1097/CMR.0b013e328344a003. PubMed PMID: 21606880; PubMed
Central PMCID: PMCPMC3131489.

168.

Cunningham E, Thomas GM, Ball A, Hiles I, Cockcroft S.
Phosphatidylinositol transfer protein dictates the rate of inositol trisphosphate
production by promoting the synthesis of PIP2. Curr Biol. 1995;5(7):775-83.
PubMed PMID: 7583124.

155

169.

Park M, Vittinghoff E, Ganz P, Peralta CA, Whooley M, Shlipak MG. Role of
soluble endothelial cell-selective adhesion molecule biomarker in albuminuria
and kidney function changes in patients with coronary artery disease: the
Heart and Soul Study. Arterioscler Thromb Vasc Biol. 2014;34(1):231-6. doi:
10.1161/ATVBAHA.113.301806. PubMed PMID: 24177327; PubMed Central
PMCID: PMCPMC4059045.

170.

Johnson FK, Johnson RA, Peyton KJ, Shebib AR, Durante W. Arginase
promotes skeletal muscle arteriolar endothelial dysfunction in diabetic rats.
Front Immunol. 2013;4:119. doi: 10.3389/fimmu.2013.00119. PubMed PMID:
23730303; PubMed Central PMCID: PMCPMC3657690.

171.

Turner CE, Glenney JR, Burridge K. Paxillin: a new vinculin-binding protein
present in focal adhesions. J Cell Biol. 1990;111(3):1059-68. PubMed PMID:
2118142; PubMed Central PMCID: PMCPMC2116264.

172.

Russell B, Motlagh D, Ashley WW. Form follows function: how muscle shape
is regulated by work. J Appl Physiol (1985). 2000;88(3):1127-32. PubMed
PMID: 10710412.

173.

Tang DD, Turner CE, Gunst SJ. Expression of non-phosphorylatable paxillin
mutants in canine tracheal smooth muscle inhibits tension development. J
Physiol. 2003;553(Pt 1):21-35. doi: 10.1113/jphysiol.2003.045047. PubMed
PMID: 12949231; PubMed Central PMCID: PMCPMC2343494.

174.

Turner CE, Kramarcy N, Sealock R, Burridge K. Localization of paxillin, a
focal adhesion protein, to smooth muscle dense plaques, and the
myotendinous and neuromuscular junctions of skeletal muscle. Exp Cell Res.
1991;192(2):651-5. PubMed PMID: 1899076.

175.

Flück M, Carson JA, Gordon SE, Ziemiecki A, Booth FW. Focal adhesion
proteins FAK and paxillin increase in hypertrophied skeletal muscle. Am J
Physiol. 1999;277(1 Pt 1):C152-62. PubMed PMID: 10409118.

176.

Doty RT, Vanasse GJ, Disteche CM, Willerford DM. The leukemiaassociated gene Mllt1/ENL: characterization of a murine homolog and
demonstration of an essential role in embryonic development. Blood Cells
Mol Dis. 2002;28(3):407-17. PubMed PMID: 12367585.

177.

Skotheim RI, Autio R, Lind GE, Kraggerud SM, Andrews PW, Monni O, et al.
Novel genomic aberrations in testicular germ cell tumors by array-CGH, and
associated gene expression changes. Cell Oncol. 2006;28(5-6):315-26.
PubMed PMID: 17167184.

156

178.

Johnson JD, Mehus JG, Tews K, Milavetz BI, Lambeth DO. Genetic
evidence for the expression of ATP- and GTP-specific succinyl-CoA
synthetases in multicellular eucaryotes. J Biol Chem. 1998;273(42):27580-6.
PubMed PMID: 9765291.

179.

Elpeleg O, Miller C, Hershkovitz E, Bitner-Glindzicz M, Bondi-Rubinstein G,
Rahman S, et al. Deficiency of the ADP-forming succinyl-CoA synthase
activity is associated with encephalomyopathy and mitochondrial DNA
depletion. Am J Hum Genet. 2005;76(6):1081-6. doi: 10.1086/430843.
PubMed PMID: 15877282; PubMed Central PMCID: PMCPMC1196446.

180.

Chambliss KL, Caudle DL, Hinson DD, Moomaw CR, Slaughter CA, Jakobs
C, et al. Molecular cloning of the mature NAD(+)-dependent succinic
semialdehyde dehydrogenase from rat and human. cDNA isolation,
evolutionary homology, and tissue expression. J Biol Chem.
1995;270(1):461-7. PubMed PMID: 7814412.

181.

Gropman A. Vigabatrin and newer interventions in succinic semialdehyde
dehydrogenase deficiency. Ann Neurol. 2003;54 Suppl 6:S66-72. doi:
10.1002/ana.10626. PubMed PMID: 12891656.

182.

Pearl PL, Gibson KM. Clinical aspects of the disorders of GABA metabolism
in children. Curr Opin Neurol. 2004;17(2):107-13. PubMed PMID: 15021235.

183.

JAX Mice Database - Growth Defects (homozygous) 2015. Available from:
http://jaxmice.jax.org/list/ra1162.html.

184.

Matsubara Y, Kraus JP, Yang-Feng TL, Francke U, Rosenberg LE, Tanaka
K. Molecular cloning of cDNAs encoding rat and human medium-chain acylCoA dehydrogenase and assignment of the gene to human chromosome 1.
Proc Natl Acad Sci U S A. 1986;83(17):6543-7. PubMed PMID: 3462713;
PubMed Central PMCID: PMCPMC386540.

185.

Goetzman ES, Alcorn JF, Bharathi SS, Uppala R, McHugh KJ, Kosmider B,
et al. Long-chain acyl-CoA dehydrogenase deficiency as a cause of
pulmonary surfactant dysfunction. J Biol Chem. 2014;289(15):10668-79. doi:
10.1074/jbc.M113.540260. PubMed PMID: 24591516; PubMed Central
PMCID: PMCPMC4036448.

186.

Sturm M, Herebian D, Mueller M, Laryea MD, Spiekerkoetter U. Functional
effects of different medium-chain acyl-CoA dehydrogenase genotypes and
identification of asymptomatic variants. PLoS One. 2012;7(9):e45110. doi:
10.1371/journal.pone.0045110. PubMed PMID: 23028790; PubMed Central
PMCID: PMCPMC3444485.

157

187.

Horowitz JF, Leone TC, Feng W, Kelly DP, Klein S. Effect of endurance
training on lipid metabolism in women: a potential role for PPARalpha in the
metabolic response to training. Am J Physiol Endocrinol Metab.
2000;279(2):E348-55. PubMed PMID: 10913035.

188.

Perona JJ, Rould MA, Steitz TA. Structural basis for transfer RNA
aminoacylation by Escherichia coli glutaminyl-tRNA synthetase.
Biochemistry. 1993;32(34):8758-71. PubMed PMID: 8364025.

189.

Rötig A. Human diseases with impaired mitochondrial protein synthesis.
Biochim
Biophys
Acta.
2011;1807(9):1198-205.
doi:
10.1016/j.bbabio.2011.06.010. PubMed PMID: 21708121.

190.

Vanlander AV, Menten B, Smet J, De Meirleir L, Sante T, De Paepe B, et al.
Two siblings with homozygous pathogenic splice-site variant in mitochondrial
asparaginyl-tRNA synthetase (NARS2). Hum Mutat. 2015;36(2):222-31. doi:
10.1002/humu.22728. PubMed PMID: 25385316.

191.

Belostotsky R, Ben-Shalom E, Rinat C, Becker-Cohen R, Feinstein S,
Zeligson S, et al. Mutations in the mitochondrial seryl-tRNA synthetase
cause hyperuricemia, pulmonary hypertension, renal failure in infancy and
alkalosis, HUPRA syndrome. Am J Hum Genet. 2011;88(2):193-200.

192.

Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P,
et al. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase
cause familial glucocorticoid deficiency. Nat Genet. 2012;44(7):740-2. doi:
10.1038/ng.2299. PubMed PMID: 22634753; PubMed Central PMCID:
PMCPMC3386896.

193.

Bao Y, Dawson TL, Chen YT. Human glycogen debranching enzyme gene
(AGL): complete structural organization and characterization of the 5'
flanking region. Genomics. 1996;38(2):155-65. PubMed PMID: 8954797.

194.

Parvari R, Moses S, Shen J, Hershkovitz E, Lerner A, Chen YT. A singlebase deletion in the 3'-coding region of glycogen-debranching enzyme is
prevalent in glycogen storage disease type IIIA in a population of North
African Jewish patients. Eur J Hum Genet. 1997;5(5):266-70. PubMed PMID:
9412782.

195.

Okubo M, Aoyama Y, Murase T. A novel donor splice site mutation in the
glycogen debranching enzyme gene is associated with glycogen storage
disease type III. Biochem Biophys Res Commun. 1996;225(2):695. PubMed
PMID: 8815868.

158

196.

Meldrum E, Parker PJ, Carozzi A. The PtdIns-PLC superfamily and signal
transduction. Biochim Biophys Acta. 1991;1092(1):49-71. PubMed PMID:
1849017.

197.

Bgee
Expression
data:
GEO;
2015.
Available
from:
http://bgee.unil.ch/bgee/bgee?page=expression&action=data&gene_id=ENS
G00000144815&organ_id=EV%3A0100377&stage_id=HsapDO%3A000015
4.

198.

Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE
domain protein that recruits Smad2 to the TGFbeta receptor. Cell.
1998;95(6):779-91. PubMed PMID: 9865696.

199.

Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta
signalling. Nature. 2004;431(7005):205-11. doi: 10.1038/nature02783.
PubMed PMID: 15356634.

200.

Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to
gene activation by RSK2, a growth factor-regulated CREB kinase. Science.
1996;273(5277):959-63. PubMed PMID: 8688081.

201.

Cho YY, Yao K, Bode AM, Bergen HR, Madden BJ, Oh SM, et al. RSK2
mediates muscle cell differentiation through regulation of NFAT3. J Biol
Chem. 2007;282(11):8380-92. doi: 10.1074/jbc.M611322200. PubMed
PMID: 17213202; PubMed Central PMCID: PMCPMC2824544.

202.

Jacquot S, Zeniou M, Touraine R, Hanauer A. X-linked Coffin-Lowry
syndrome (CLS, MIM 303600, RPS6KA3 gene, protein product known under
various names: pp90(rsk2), RSK2, ISPK, MAPKAP1). Eur J Hum Genet.
2002;10(1):2-5. doi: 10.1038/sj.ejhg.5200738. PubMed PMID: 11896450.

203.

Touraine RL, Zeniou M, Hanauer A. A syndromic form of X-linked mental
retardation: the Coffin-Lowry syndrome. Eur J Pediatr. 2002;161(4):179-87.
PubMed PMID: 12014383.

204.

Dufresne SD, Bjørbaek C, El-Haschimi K, Zhao Y, Aschenbach WG, Moller
DE, et al. Altered extracellular signal-regulated kinase signaling and
glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2
knockout mice. Mol Cell Biol. 2001;21(1):81-7. doi: 10.1128/MCB.21.1.8187.2001. PubMed PMID: 11113183; PubMed Central PMCID:
PMCPMC88782.

205.

Crow YJ, Zuberi SM, McWilliam R, Tolmie JL, Hollman A, Pohl K, et al.
"Cataplexy" and muscle ultrasound abnormalities in Coffin-Lowry syndrome.

159

J Med Genet. 1998;35(2):94-8. PubMed PMID: 9507386; PubMed Central
PMCID: PMCPMC1051210.
206.

Gommans WM, Haisma HJ, Rots MG. Engineering zinc finger protein
transcription factors: the therapeutic relevance of switching endogenous
gene expression on or off at command. J Mol Biol. 2005;354(3):507-19. doi:
10.1016/j.jmb.2005.06.082. PubMed PMID: 16253273.

207.

Shoichet SA, Hoffmann K, Menzel C, Trautmann U, Moser B, Hoeltzenbein
M, et al. Mutations in the ZNF41 gene are associated with cognitive deficits:
identification of a new candidate for X-linked mental retardation. Am J Hum
Genet. 2003;73(6):1341-54. doi: 10.1086/380309. PubMed PMID: 14628291;
PubMed Central PMCID: PMCPMC1180399.

208.

Fujioka M, Takahashi N, Odai H, Araki S, Ichikawa K, Feng J, et al. A new
isoform of human myosin phosphatase targeting/regulatory subunit (MYPT2):
cDNA cloning, tissue expression, and chromosomal mapping. Genomics.
1998;49(1):59-68. doi: 10.1006/geno.1998.5222. PubMed PMID: 9570949.

209.

Dikic I, Robertson M. Ubiquitin ligases and beyond. BMC Biol. 2012;10:22.
doi: 10.1186/1741-7007-10-22. PubMed PMID: 22420755; PubMed Central
PMCID: PMCPMC3305657.

210.

Matsumoto H, Maruse H, Inaba Y, Yoshizawa K, Sasazaki S, Fujiwara A, et
al. The ubiquitin ligase gene (WWP1) is responsible for the chicken muscular
dystrophy.
FEBS
Lett.
2008;582(15):2212-8.
doi:
10.1016/j.febslet.2008.05.013. PubMed PMID: 18501710.

211.

Song ZG, Zhang XH, Zhu LX, Jiao HC, Lin H. Dexamethasone alters the
expression of genes related to the growth of skeletal muscle in chickens
(Gallus gallus domesticus). J Mol Endocrinol. 2011;46(3):217-25. doi:
10.1530/JME-10-0162. PubMed PMID: 21325373.

212.

Vasudevan S, Starostina NG, Kipreos ET. The Caenorhabditis elegans cellcycle regulator ZYG-11 defines a conserved family of CUL-2 complex
components. EMBO Rep. 2007;8(3):279-86. doi: 10.1038/sj.embor.7400895.
PubMed PMID: 17304241; PubMed Central PMCID: PMCPMC1808032.

213.

Mille-Hamard L, Billat VL, Henry E, Bonnamy B, Joly F, Benech P, et al.
Skeletal muscle alterations and exercise performance decrease in
erythropoietin-deficient mice: a comparative study. BMC Med Genomics.
2012;5:29. doi: 10.1186/1755-8794-5-29. PubMed PMID: 22748015;
PubMed Central PMCID: PMCPMC3473259.

160

214.

Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW.
Systematic analysis and nomenclature of mammalian F-box proteins. Genes
Dev. 2004;18(21):2573-80. doi: 10.1101/gad.1255304. PubMed PMID:
15520277; PubMed Central PMCID: PMCPMC525538.

215.

Goitre L, Trapani E, Trabalzini L, Retta SF. The Ras superfamily of small
GTPases: the unlocked secrets. Methods Mol Biol. 2014;1120:1-18. doi:
10.1007/978-1-62703-791-4_1. PubMed PMID: 24470015.

216.

Chen YT, Holcomb C, Moore HP. Expression and localization of two low
molecular weight GTP-binding proteins, Rab8 and Rab10, by epitope tag.
Proc Natl Acad Sci U S A. 1993;90(14):6508-12. PubMed PMID: 7688123;
PubMed Central PMCID: PMCPMC46961.

217.

He H, Dai F, Yu L, She X, Zhao Y, Jiang J, et al. Identification and
characterization of nine novel human small GTPases showing variable
expressions in liver cancer tissues. Gene Expr. 2002;10(5-6):231-42.
PubMed PMID: 12450215.

218.

James DE, Brown R, Navarro J, Pilch PF. Insulin-regulatable tissues express
a
unique
insulin-sensitive
glucose
transport
protein.
Nature.
1988;333(6169):183-5. doi: 10.1038/333183a0. PubMed PMID: 3285221.

219.

Sano H, Roach WG, Peck GR, Fukuda M, Lienhard GE. Rab10 in insulinstimulated GLUT4 translocation. Biochem J. 2008;411(1):89-95. doi:
10.1042/BJ20071318. PubMed PMID: 18076383.

220.

Langlais P, Dillon JL, Mengos A, Baluch DP, Ardebili R, Miranda DN, et al.
Identification of a role for CLASP2 in insulin action. J Biol Chem.
2012;287(46):39245-53. doi: 10.1074/jbc.M112.394148. PubMed PMID:
22992739; PubMed Central PMCID: PMCPMC3493964.

221.

Basu S, Sladecek S, Martinez de la Peña y Valenzuela I, Akaaboune M,
Smal I, Martin K, et al. CLASP2-dependent microtubule capture at the
neuromuscular junction membrane requires LL5β and actin for focal delivery
of acetylcholine receptor vesicles. Mol Biol Cell. 2015;26(5):938-51. doi:
10.1091/mbc.E14-06-1158. PubMed PMID: 25589673; PubMed Central
PMCID: PMCPMC4342029.

222.

Basu S, Sladecek S, Pemble H, Wittmann T, Slotman JA, van Cappellen W,
et al. Acetylcholine receptor (AChR) clustering is regulated both by glycogen
synthase kinase 3β (GSK3β)-dependent phosphorylation and the level of
CLIP-associated protein 2 (CLASP2) mediating the capture of microtubule
plus-ends.
J
Biol
Chem.
2014;289(44):30857-67.
doi:

161

10.1074/jbc.M114.589457. PubMed PMID: 25231989; PubMed Central
PMCID: PMCPMC4215261.
223.

Schmidt N, Basu S, Sladecek S, Gatti S, van Haren J, Treves S, et al. Agrin
regulates CLASP2-mediated capture of microtubules at the neuromuscular
junction synaptic membrane. J Cell Biol. 2012;198(3):421-37. doi:
10.1083/jcb.201111130. PubMed PMID: 22851317; PubMed Central PMCID:
PMCPMC3413356.

224.

Bloch-Gallego E. Mechanisms controlling neuromuscular junction stability.
Cell Mol Life Sci. 2015;72(6):1029-43. doi: 10.1007/s00018-014-1768-z.
PubMed PMID: 25359233.

225.

Nimpf J, Schneider WJ. From cholesterol transport to signal transduction:
low density lipoprotein receptor, very low density lipoprotein receptor, and
apolipoprotein E receptor-2. Biochim Biophys Acta. 2000;1529(1-3):287-98.
PubMed PMID: 11111096.

226.

Beisiegel U, Heeren J. Lipoprotein lipase (EC 3.1.1.34) targeting of
lipoproteins to receptors. Proc Nutr Soc. 1997;56(2):731-7. PubMed PMID:
9264123.

227.

Nutritional Management of Renal Disease, Third Edition. Kopple JD, Massry
SG, Kalantar-Zadeh K, editors: Academic Press; 2012 2012-12-31. 816 p.

228.

Jones K. Smith's Recognizable Patterns Of Human Malformation Sixth
Edition (Smith's Recognizable Patterns of Human Malformation): Saunders;
2005 2005-08-17. 976 p.

229.

Weber TA, Koob S, Heide H, Wittig I, Head B, van der Bliek A, et al. APOOL
is a cardiolipin-binding constituent of the Mitofilin/MINOS protein complex
determining cristae morphology in mammalian mitochondria. PLoS One.
2013;8(5):e63683. doi: 10.1371/journal.pone.0063683. PubMed PMID:
23704930; PubMed Central PMCID: PMCPMC3660581.

230.

Turkieh A, Caubère C, Barutaut M, Desmoulin F, Harmancey R, Galinier M,
et al. Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart. J
Clin Invest. 2014;124(5):2277-86. doi: 10.1172/JCI74668. PubMed PMID:
24743151; PubMed Central PMCID: PMCPMC4001558.

231.

Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a
muscle-specific F-box protein highly expressed during muscle atrophy. Proc
Natl Acad Sci U S A. 2001;98(25):14440-5. doi: 10.1073/pnas.251541198.
PubMed PMID: 11717410; PubMed Central PMCID: PMCPMC64700.

162

232.

Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr
Metab Care. 2010;13(3):225-9. PubMed PMID: 20397318.

233.

Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-Pichon
S, Tintignac LA, et al. The initiation factor eIF3-f is a major target for
atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J.
2008;27(8):1266-76. doi: 10.1038/emboj.2008.52. PubMed PMID: 18354498;
PubMed Central PMCID: PMCPMC2367397.

234.

Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al.
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Science. 2001;294(5547):1704-8. doi: 10.1126/science.1065874. PubMed
PMID: 11679633.

235.

Stephens NA, Gallagher IJ, Rooyackers O, Skipworth RJ, Tan BH,
Marstrand T, et al. Using transcriptomics to identify and validate novel
biomarkers of human skeletal muscle cancer cachexia. Genome Med.
2010;2(1):1. doi: 10.1186/gm122. PubMed PMID: 20193046; PubMed
Central PMCID: PMCPMC2829926.

236.

Gallagher IJ, Stephens NA, MacDonald AJ, Skipworth RJ, Husi H, Greig CA,
et al. Suppression of skeletal muscle turnover in cancer cachexia: evidence
from the transcriptome in sequential human muscle biopsies. Clin Cancer
Res. 2012;18(10):2817-27. doi: 10.1158/1078-0432.CCR-11-2133. PubMed
PMID: 22452944.

237.

Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker
HG, et al. A mutation in the myostatin gene increases muscle mass and
enhances racing performance in heterozygote dogs. PLoS Genet.
2007;3(5):e79. doi: 10.1371/journal.pgen.0030079. PubMed PMID:
17530926; PubMed Central PMCID: PMCPMC1877876.

238.

Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, et al.
Myostatin mutation associated with gross muscle hypertrophy in a child. N
Engl J Med. 2004;350(26):2682-8. doi: 10.1056/NEJMoa040933. PubMed
PMID: 15215484.

239.

Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson
KN, et al. Induction of cachexia in mice by systemically administered
myostatin. Science. 2002;296(5572):1486-8. doi: 10.1126/science.1069525.
PubMed PMID: 12029139.

240.

Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, et al.
Smad2 and 3 transcription factors control muscle mass in adulthood. Am J

163

Physiol
Cell
Physiol.
2009;296(6):C1248-57.
10.1152/ajpcell.00104.2009. PubMed PMID: 19357234.

doi:

241.

Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer
cachexia and muscle wasting by ActRIIB antagonism leads to prolonged
survival. Cell. 2010;142(4):531-43. doi: 10.1016/j.cell.2010.07.011. PubMed
PMID: 20723755.

242.

Loumaye A, de Barsy M, Nachit M, Lause P, Frateur L, van Maanen A, et al.
Role of Activin A and Myostatin in human cancer cachexia. J Clin Endocrinol
Metab. 2015:jc20144318. doi: 10.1210/jc.2014-4318. PubMed PMID:
25751105.

243.

Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et
al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of
the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94(21):11514-9.
PubMed PMID: 9326641; PubMed Central PMCID: PMCPMC23523.

244.

Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG.
Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction
after kidney and lung injury. Shock. 2005;23(6):543-8. PubMed PMID:
15897808.

245.

Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, et al. Tumorinduced anorexia and weight loss are mediated by the TGF-beta superfamily
cytokine MIC-1. Nat Med. 2007;13(11):1333-40. doi: 10.1038/nm1677.
PubMed PMID: 17982462.

246.

Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor
(PIF) in cachexia induced by a human melanoma (G361). Br J Cancer.
1999;80(11):1734-7. doi: 10.1038/sj.bjc.6690590. PubMed PMID: 10468289;
PubMed Central PMCID: PMCPMC2374268.

247.

Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC.
Characteristics of patients with pancreatic cancer expressing a novel cancer
cachectic factor. Br J Surg. 2000;87(1):53-8. doi: 10.1046/j.13652168.2000.01317.x. PubMed PMID: 10606911.

248.

Wieland BM, Stewart GD, Skipworth RJ, Sangster K, Fearon KC, Ross JA, et
al. Is there a human homologue to the murine proteolysis-inducing factor?
Clin Cancer Res. 2007;13(17):4984-92. doi: 10.1158/1078-0432.CCR-070946. PubMed PMID: 17785548.

164

249.

Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship
between weight loss and interleukin 6 in non-small-cell lung cancer. Br J
Cancer. 1996;73(12):1560-2. PubMed PMID: 8664130; PubMed Central
PMCID: PMCPMC2074552.

250.

Gustafsson T, Rundqvist H, Norrbom J, Rullman E, Jansson E, Sundberg
CJ. The influence of physical training on the angiopoietin and VEGF-A
systems in human skeletal muscle. J Appl Physiol (1985). 2007;103(3):101220. doi: 10.1152/japplphysiol.01103.2006. PubMed PMID: 17569764.

251.

Chou TF, Cheng J, Tikh IB, Wagner CR. Evidence that human histidine triad
nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad
(HIT)
superfamily.
J
Mol
Biol.
2007;373(4):978-89.
doi:
10.1016/j.jmb.2007.08.023. PubMed PMID: 17870088.

252.

Maudhoo MD, Madison JD, Norgren RB. De novo assembly of the
chimpanzee transcriptome from NextGen mRNA sequences. Gigascience.
2015;4:18. doi: 10.1186/s13742-015-0061-x. PubMed PMID: 25897398;
PubMed Central PMCID: PMCPMC4403674.

253.

Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a
conserved homolog, Bax, that accelerates programmed cell death. Cell.
1993;74(4):609-19. PubMed PMID: 8358790.

254.

Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3
in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005;280(11):10491-500.
doi: 10.1074/jbc.M412819200. PubMed PMID: 15637055.

255.

Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human
physiology and pathophysiology--emerging clinical applications. Nat Clin
Pract Endocrinol Metab. 2006;2(6):318-27. doi: 10.1038/ncpendmet0196.
PubMed PMID: 16932309.

256.

Raposinho PD, Pedrazzini T, White RB, Palmiter RD, Aubert ML. Chronic
neuropeptide Y infusion into the lateral ventricle induces sustained feeding
and obesity in mice lacking either Npy1r or Npy5r expression. Endocrinology.
2004;145(1):304-10. doi: 10.1210/en.2003-0914. PubMed PMID: 14525913.

257.

Suzuki K, Jayasena CN, Bloom SR. The gut hormones in appetite regulation.
J Obes. 2011;2011:528401. doi: 10.1155/2011/528401. PubMed PMID:
21949903; PubMed Central PMCID: PMCPMC3178198.

165

258.

Engineer DR, Garcia JM. Leptin in anorexia and cachexia syndrome. Int J
Pept. 2012;2012:287457. doi: 10.1155/2012/287457. PubMed PMID:
22518191; PubMed Central PMCID: PMCPMC3303568.

259.

Diakowska D, Krzystek-Korpacka M, Markocka-Maczka K, Diakowski W,
Matusiewicz M, Grabowski K. Circulating leptin and inflammatory response in
esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome
(CAS) and non-malignant CAS of the alimentary tract. Cytokine.
2010;51(2):132-7. doi: 10.1016/j.cyto.2010.05.006. PubMed PMID:
20541434.

260.

Mondello P, Lacquaniti A, Mondello S, Bolignano D, Pitini V, Aloisi C, et al.
Emerging markers of cachexia predict survival in cancer patients. BMC
Cancer. 2014;14:828. doi: 10.1186/1471-2407-14-828. PubMed PMID:
25400234; PubMed Central PMCID: PMCPMC4239407.

261.

Weryńska B, Kosacka M, Gołecki M, Jankowska R. [Leptin serum levels in
cachectic and non-cachectic lung cancer patients]. Pneumonol Alergol Pol.
2009;77(6):500-6. PubMed PMID: 20013699.

262.

Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, Garcia JM.
Adipokines in patients with cancer anorexia and cachexia. J Investig Med.
2010;58(3):554-9. doi: 10.231/JIM.0b013e3181cf91ca. PubMed PMID:
20215915.

263.

Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R, et
al. Acute and chronic effects of insulin on leptin production in humans:
Studies in vivo and in vitro. Diabetes. 1996;45(5):699-701. PubMed PMID:
8621027.

264.

Pan H, Guo J, Su Z. Advances in understanding the interrelations between
leptin resistance and obesity. Physiol Behav. 2014;130:157-69. doi:
10.1016/j.physbeh.2014.04.003. PubMed PMID: 24726399.

265.

Dos Santos E, Dieudonné MN, Leneveu MC, Pecquery R, Serazin V,
Giudicelli Y. In vitro effects of chorionic gonadotropin hormone on human
adipose development. J Endocrinol. 2007;194(2):313-25. doi: 10.1677/JOE06-0101. PubMed PMID: 17641281.

266.

Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a
2002
perspective.
Endocr
Rev.
2002;23(2):141-74.
doi:
10.1210/edrv.23.2.0462. PubMed PMID: 11943741.

166

267.

Sitticharoon C, Chatree S, Churintaraphan M. Expressions of neuropeptide Y
and Y1 receptor in subcutaneous and visceral fat tissues in normal weight
and obese humans and their correlations with clinical parameters and
peripheral metabolic factors. Regul Pept. 2013;185:65-72. doi:
10.1016/j.regpep.2013.06.015. PubMed PMID: 23838112.

268.

Valet P, Berlan M, Beauville M, Crampes F, Montastruc JL, Lafontan M.
Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells
through a pertussis toxin-sensitive G protein. J Clin Invest. 1990;85(1):291-5.
doi: 10.1172/JCI114425. PubMed PMID: 2104880; PubMed Central PMCID:
PMCPMC296417.

269.

Gómez-Ambrosi J, Catalán V, Diez-Caballero A, Martinez-Cruz LA, Gil MJ,
García-Foncillas J, et al. Gene expression profile of omental adipose tissue
in human obesity. FASEB J. 2004;18(1):215-7. doi: 10.1096/fj.03-0591fje.
PubMed PMID: 14630696.

270.

Wu Y, McRoberts K, Berr SS, Frierson HF, Conaway M, Theodorescu D.
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a
novel promoter of tumor formation, lung metastasis and cancer cachexia.
Oncogene. 2007;26(5):765-73. doi: 10.1038/sj.onc.1209835. PubMed PMID:
16878152.

271.

Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, et
al. Identification and characterization of two neuromedin U receptors
differentially expressed in peripheral tissues and the central nervous system.
J Biol Chem. 2000;275(42):32452-9. doi: 10.1074/jbc.M004613200. PubMed
PMID: 10899166.

272.

Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, et al.
Identification of receptors for neuromedin U and its role in feeding. Nature.
2000;406(6791):70-4. doi: 10.1038/35017610. PubMed PMID: 10894543.

273.

Mendu SK, Bhandage A, Jin Z, Birnir B. Different subtypes of GABA-A
receptors are expressed in human, mouse and rat T lymphocytes. PLoS
One. 2012;7(8):e42959. doi: 10.1371/journal.pone.0042959. PubMed PMID:
22927941; PubMed Central PMCID: PMCPMC3424250.

274.

Tian J, Dang HN, Yong J, Chui WS, Dizon MP, Yaw CK, et al. Oral treatment
with γ-aminobutyric acid improves glucose tolerance and insulin sensitivity by
inhibiting inflammation in high fat diet-fed mice. PLoS One.
2011;6(9):e25338. doi: 10.1371/journal.pone.0025338. PubMed PMID:
21966503; PubMed Central PMCID: PMCPMC3178643.

167

275.

Valcárcel B, Ebbels TM, Kangas AJ, Soininen P, Elliot P, Ala-Korpela M, et
al. Genome metabolome integrated network analysis to uncover connections
between genetic variants and complex traits: an application to obesity. J R
Soc Interface. 2014;11(94):20130908. doi: 10.1098/rsif.2013.0908. PubMed
PMID: 24573330; PubMed Central PMCID: PMCPMC3973353.

276.

Moult PR, Cross A, Santos SD, Carvalho AL, Lindsay Y, Connolly CN, et al.
Leptin regulates AMPA receptor trafficking via PTEN inhibition. J Neurosci.
2010;30(11):4088-101. doi: 10.1523/JNEUROSCI.3614-09.2010. PubMed
PMID: 20237279; PubMed Central PMCID: PMCPMC2843829.

277.

Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S. The RNA
moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell.
1983;35(3 Pt 2):849-57. PubMed PMID: 6197186.

278.

Jarrous N, Reiner R. Human RNase P: a tRNA-processing enzyme and
transcription factor. Nucleic Acids Res. 2007;35(11):3519-24. doi:
10.1093/nar/gkm071. PubMed PMID: 17483522; PubMed Central PMCID:
PMCPMC1920233.

279.

Reiner R, Ben-Asouli Y, Krilovetzky I, Jarrous N. A role for the catalytic
ribonucleoprotein RNase P in RNA polymerase III transcription. Genes Dev.
2006;20(12):1621-35. doi: 10.1101/gad.386706. PubMed PMID: 16778078;
PubMed Central PMCID: PMCPMC1482482.

280.

Holzmann J, Frank P, Löffler E, Bennett KL, Gerner C, Rossmanith W.
RNase P without RNA: identification and functional reconstitution of the
human mitochondrial tRNA processing enzyme. Cell. 2008;135(3):462-74.
doi: 10.1016/j.cell.2008.09.013. PubMed PMID: 18984158.

281.

Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM,
Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins
represses translation in late development. Mol Cell Biol. 1999;19(2):1262-70.
PubMed PMID: 9891060; PubMed Central PMCID: PMCPMC116055.

282.

Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al.
Genome-wide association analysis identifies loci for type 2 diabetes and
triglyceride
levels.
Science.
2007;316(5829):1331-6.
doi:
10.1126/science.1142358. PubMed PMID: 17463246.

283.

Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A
genome-wide association study of type 2 diabetes in Finns detects multiple
susceptibility
variants.
Science.
2007;316(5829):1341-5.
doi:
10.1126/science.1142382. PubMed PMID: 17463248; PubMed Central
PMCID: PMCPMC3214617.

168

284.

Consortium WTCC. Genome-wide association study of 14,000 cases of
seven common diseases and 3,000 shared controls. Nature.
2007;447(7145):661-78. doi: 10.1038/nature05911. PubMed PMID:
17554300; PubMed Central PMCID: PMCPMC2719288.

285.

Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al.
Replication of genome-wide association signals in UK samples reveals risk
loci for type 2 diabetes. Science. 2007;316(5829):1336-41. doi:
10.1126/science.1142364. PubMed PMID: 17463249; PubMed Central
PMCID: PMCPMC3772310.

286.

Louveau I, Gondret F. Regulation of development and metabolism of adipose
tissue by growth hormone and the insulin-like growth factor system. Domest
Anim Endocrinol. 2004;27(3):241-55. doi: 10.1016/j.domaniend.2004.06.004.
PubMed PMID: 15451072.

287.

Wu HH, Liu NJ, Yang Z, Tao XM, Du YP, Wang XC, et al. IGF2BP2 and
obesity interaction analysis for type 2 diabetes mellitus in Chinese Han
population. Eur J Med Res. 2014;19:40. doi: 10.1186/2047-783X-19-40.
PubMed PMID: 25062844; PubMed Central PMCID: PMCPMC4121008.

288.

Chistiakov DA, Nikitin AG, Smetanina SA, Bel'chikova LN, Suplotova LA,
Shestakova MV, et al. The rs11705701 G>A polymorphism of IGF2BP2 is
associated with IGF2BP2 mRNA and protein levels in the visceral adipose
tissue - a link to type 2 diabetes susceptibility. Rev Diabet Stud. 2012;9(23):112-22. doi: 10.1900/RDS.2012.9.112. PubMed PMID: 23403707;
PubMed Central PMCID: PMCPMC3700024.

289.

Parikh H, Lyssenko V, Groop LC. Prioritizing genes for follow-up from
genome wide association studies using information on gene expression in
tissues relevant for type 2 diabetes mellitus. BMC Med Genomics.
2009;2:72. doi: 10.1186/1755-8794-2-72. PubMed PMID: 20043853;
PubMed Central PMCID: PMCPMC2815699.

290.

Nguyen TT, Dyer DL, Dunning DD, Rubin SA, Grant KE, Said HM. Human
intestinal folate transport: cloning, expression, and distribution of
complementary RNA. Gastroenterology. 1997;112(3):783-91. PubMed PMID:
9041240.

291.

Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M. Combined
effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid
stores of diet-induced overweight male Wistar rats. Life Sci.
2005;77(16):2051-8. doi: 10.1016/j.lfs.2005.04.008. PubMed PMID:
15935402.

169

292.

Masuo K, Lambert GW. Relationships of adrenoceptor polymorphisms with
obesity. J Obes. 2011;2011:609485. doi: 10.1155/2011/609485. PubMed
PMID: 21603275; PubMed Central PMCID: PMCPMC3092628.

293.

Gomes IM, Maia CJ, Santos CR. STEAP proteins: from structure to
applications in cancer therapy. Mol Cancer Res. 2012;10(5):573-87. doi:
10.1158/1541-7786.MCR-11-0281. PubMed PMID: 22522456.

294.

Grandchamp B, Hetet G, Kannengiesser C, Oudin C, Beaumont C,
Rodrigues-Ferreira S, et al. A novel type of congenital hypochromic anemia
associated with a nonsense mutation in the STEAP3/TSAP6 gene. Blood.
2011;118(25):6660-6. doi: 10.1182/blood-2011-01-329011. PubMed PMID:
22031863.

295.

Joo JI, Kim DH, Choi JW, Yun JW. Proteomic analysis for antiobesity
potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J
Proteome Res. 2010;9(6):2977-87. doi: 10.1021/pr901175w. PubMed PMID:
20359164.

296.

Ye F, Zhang H, Yang YX, Hu HD, Sze SK, Meng W, et al. Comparative
proteome analysis of 3T3-L1 adipocyte differentiation using iTRAQ-coupled
2D
LC-MS/MS.
J
Cell
Biochem.
2011;112(10):3002-14.
doi:
10.1002/jcb.23223. PubMed PMID: 21678470.

297.

Buanne P, Incerti B, Guardavaccaro D, Avvantaggiato V, Simeone A, Tirone
F. Cloning of the human interferon-related developmental regulator (IFRD1)
gene coding for the PC4 protein, a member of a novel family of
developmentally regulated genes. Genomics. 1998;51(2):233-42. doi:
10.1006/geno.1998.5260. PubMed PMID: 9722946.

298.

Vadivelu SK, Kurzbauer R, Dieplinger B, Zweyer M, Schafer R, Wernig A, et
al. Muscle regeneration and myogenic differentiation defects in mice lacking
TIS7. Mol Cell Biol. 2004;24(8):3514-25. PubMed PMID: 15060170; PubMed
Central PMCID: PMCPMC381666.

299.

Micheli L, Leonardi L, Conti F, Maresca G, Colazingari S, Mattei E, et al.
PC4/Tis7/IFRD1 stimulates skeletal muscle regeneration and is involved in
myoblast differentiation as a regulator of MyoD and NF-kappaB. J Biol
Chem. 2011;286(7):5691-707. doi: 10.1074/jbc.M110.162842. PubMed
PMID: 21127072; PubMed Central PMCID: PMCPMC3037682.

300.

Nakamura Y, Hinoi E, Iezaki T, Takada S, Hashizume S, Takahata Y, et al.
Repression of adipogenesis through promotion of Wnt/β-catenin signaling by
TIS7 up-regulated in adipocytes under hypoxia. Biochim Biophys Acta.

170

2013;1832(8):1117-28. doi: 10.1016/j.bbadis.2013.03.010. PubMed PMID:
23517917.
301.

Matsushita T, Davis FF. Studies on pseudouridylic acid synthetase from
various sources. Biochim Biophys Acta. 1971;238(2):165-73. PubMed PMID:
4936431.

302.

Breitman TR. Pseudouridulate synthetase of Escherichia coli: correlation of
its activity with utilization of pseudouridine for growth. J Bacteriol.
1970;103(1):263-4. PubMed PMID: 4912525; PubMed Central PMCID:
PMCPMC248066.

303.

Solomon LR, Breitman TR. Pseudouridylate synthetase of Escherichia coli: a
catabolite-repressible enzyme. J Bacteriol. 1971;107(2):535-42. PubMed
PMID: 4329733; PubMed Central PMCID: PMCPMC246957.

304.

Deutscher J. The mechanisms of carbon catabolite repression in bacteria.
Curr Opin Microbiol. 2008;11(2):87-93. doi: 10.1016/j.mib.2008.02.007.
PubMed PMID: 18359269.

305.

Yu DH, Fan W, Liu G, Nguy V, Chatterton JE, Long S, et al. PHTS, a novel
putative tumor suppressor, is involved in the transformation reversion of
HeLaHF cells independently of the p53 pathway. Exp Cell Res.
2006;312(6):865-76. doi: 10.1016/j.yexcr.2005.12.006. PubMed PMID:
16413018.

306.

Buisson P, Leclair MD, Jacquemont S, Podevin G, Camby C, David A, et al.
Cutaneous lipoma in children: 5 cases with Bannayan-Riley-Ruvalcaba
syndrome.
J
Pediatr
Surg.
2006;41(9):1601-3.
doi:
10.1016/j.jpedsurg.2006.05.013. PubMed PMID: 16952599.

307.

Database GHG. LYPD1 Gene - GeneCards | LYPD1 Protein | LYPD1
Antibody. 2015.

308.

Yona S, Stacey M. Adhesion-GPCRs: structure to function. Preface. Adv Exp
Med Biol. 2010;706:v-vii. PubMed PMID: 21618821.

309.

Shiratsuchi T, Nishimori H, Ichise H, Nakamura Y, Tokino T. Cloning and
characterization of BAI2 and BAI3, novel genes homologous to brain-specific
angiogenesis inhibitor 1 (BAI1). Cytogenet Cell Genet. 1997;79(1-2):103-8.
PubMed PMID: 9533023.

171

310.

Okajima D, Kudo G, Yokota H. Brain-specific angiogenesis inhibitor 2 (BAI2)
may be activated by proteolytic processing. J Recept Signal Transduct Res.
2010;30(3):143-53. doi: 10.3109/10799891003671139. PubMed PMID:
20367554.

311.

Yang TT, Suk HY, Yang X, Olabisi O, Yu RY, Durand J, et al. Role of
transcription factor NFAT in glucose and insulin homeostasis. Mol Cell Biol.
2006;26(20):7372-87. doi: 10.1128/MCB.00580-06. PubMed PMID:
16908540; PubMed Central PMCID: PMCPMC1636854.

312.

Imai T. Human carboxylesterase isozymes: catalytic properties and rational
drug design. Drug Metab Pharmacokinet. 2006;21(3):173-85. PubMed PMID:
16858120.

313.

Aguilera CM, Gomez-Llorente C, Tofe I, Gil-Campos M, Cañete R, Gil Á.
Genome-wide expression in visceral adipose tissue from obese prepubertal
children. Int J Mol Sci. 2015;16(4):7723-37. doi: 10.3390/ijms16047723.
PubMed PMID: 25856673.

314.

Jernås M, Olsson B, Arner P, Jacobson P, Sjöström L, Walley A, et al.
Regulation of carboxylesterase 1 (CES1) in human adipose tissue. Biochem
Biophys Res Commun. 2009;383(1):63-7. doi: 10.1016/j.bbrc.2009.03.120.
PubMed PMID: 19332024; PubMed Central PMCID: PMCPMC2723917.

315.

Friedrichsen M, Poulsen P, Wojtaszewski J, Hansen PR, Vaag A,
Rasmussen HB. Carboxylesterase 1 gene duplication and mRNA expression
in adipose tissue are linked to obesity and metabolic function. PLoS One.
2013;8(2):e56861. doi: 10.1371/journal.pone.0056861. PubMed PMID:
23468884; PubMed Central PMCID: PMCPMC3585247.

316.

Dominguez E, Galmozzi A, Chang JW, Hsu KL, Pawlak J, Li W, et al.
Integrated phenotypic and activity-based profiling links Ces3 to obesity and
diabetes. Nat Chem Biol. 2014;10(2):113-21. doi: 10.1038/nchembio.1429.
PubMed PMID: 24362705; PubMed Central PMCID: PMCPMC3953460.

317.

Gaikwad A, Long DJ, Stringer JL, Jaiswal AK. In vivo role of
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular
redox state and accumulation of abdominal adipose tissue. J Biol Chem.
2001;276(25):22559-64. doi: 10.1074/jbc.M101053200. PubMed PMID:
11309386.

318.

Palming J, Sjöholm K, Jernås M, Lystig TC, Gummesson A, Romeo S, et al.
The expression of NAD(P)H:quinone oxidoreductase 1 is high in human
adipose tissue, reduced by weight loss, and correlates with adiposity, insulin

172

sensitivity, and markers of liver dysfunction. J Clin Endocrinol Metab.
2007;92(6):2346-52. doi: 10.1210/jc.2006-2476. PubMed PMID: 17405841.
319.

Rothman N, Smith MT, Hayes RB, Traver RD, Hoener B, Campleman S, et
al. Benzene poisoning, a risk factor for hematological malignancy, is
associated with the NQO1 609C-->T mutation and rapid fractional excretion
of chlorzoxazone. Cancer Res. 1997;57(14):2839-42. PubMed PMID:
9230185.

320.

Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez
FJ, et al. Disruption of the DT diaphorase (NQO1) gene in mice leads to
increased menadione toxicity. J Biol Chem. 1998;273(13):7382-9. PubMed
PMID: 9516435.

321.

Schneider KS, Chan JY. Emerging role of Nrf2 in adipocytes and adipose
biology. Adv Nutr. 2013;4(1):62-6. doi: 10.3945/an.112.003103. PubMed
PMID: 23319124; PubMed Central PMCID: PMCPMC3648740.

322.

NQO1 NAD(P)H dehydrogenase, quinone 1 [Homo sapiens (human)] - Gene
- NCBI: Pubs; 2015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/.

323.

Ma C, Staudt LM. LAF-4 encodes a lymphoid nuclear protein with
transactivation potential that is homologous to AF-4, the gene fused to MLL
in t(4;11) leukemias. Blood. 1996;87(2):734-45. PubMed PMID: 8555498.

324.

Moore JM, Oliver PL, Finelli MJ, Lee S, Lickiss T, Molnár Z, et al. Laf4/Aff3, a
gene involved in intellectual disability, is required for cellular migration in the
mouse
cerebral
cortex.
PLoS
One.
2014;9(8):e105933.
doi:
10.1371/journal.pone.0105933. PubMed PMID: 25162227; PubMed Central
PMCID: PMCPMC4146563.

325.

Database GHG. AFF3 Gene - GeneCards | AFF3 Protein | AFF3 Antibody.
2015.

326.

Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T,
et al. New susceptibility loci associated with kidney disease in type 1
diabetes.
PLoS
Genet.
2012;8(9):e1002921.
doi:
10.1371/journal.pgen.1002921. PubMed PMID: 23028342; PubMed Central
PMCID: PMCPMC3447939.

327.

Maeda S, Imamura M, Kurashige M, Araki S, Suzuki D, Babazono T, et al.
Replication study for the association of 3 SNP loci identified in a genomewide association study for diabetic nephropathy in European type 1 diabetes
with diabetic nephropathy in Japanese patients with type 2 diabetes. Clin

173

Exp Nephrol. 2013;17(6):866-71. doi: 10.1007/s10157-013-0797-5. PubMed
PMID: 23543049.
328.

Yamana K, Wada H, Takahashi Y, Sato H, Kasahara Y, Kiyoki M. Molecular
cloning and characterization of CHM1L, a novel membrane molecule similar
to chondromodulin-I. Biochem Biophys Res Commun. 2001;280(4):1101-6.
doi: 10.1006/bbrc.2000.4245. PubMed PMID: 11162640.

329.

Oshima Y, Sato K, Tashiro F, Miyazaki J, Nishida K, Hiraki Y, et al. Antiangiogenic action of the C-terminal domain of tenomodulin that shares
homology with chondromodulin-I. J Cell Sci. 2004;117(Pt 13):2731-44. doi:
10.1242/jcs.01112. PubMed PMID: 15150318.

330.

Tolppanen AM, Kolehmainen M, Pulkkinen L, Uusitupa M. Tenomodulin
gene and obesity-related phenotypes. Ann Med. 2010;42(4):265-75. doi:
10.3109/07853891003801123. PubMed PMID: 20429799.

331.

Johansson LE, Danielsson AP, Parikh H, Klintenberg M, Norström F, Groop
L, et al. Differential gene expression in adipose tissue from obese human
subjects during weight loss and weight maintenance. Am J Clin Nutr.
2012;96(1):196-207. doi: 10.3945/ajcn.111.020578. PubMed PMID:
22648723.

332.

Tolppanen AM, Pulkkinen L, Kolehmainen M, Schwab U, Lindström J,
Tuomilehto J, et al. Tenomodulin is associated with obesity and diabetes
risk: the Finnish diabetes prevention study. Obesity (Silver Spring).
2007;15(5):1082-8. doi: 10.1038/oby.2007.613. PubMed PMID: 17495183.

333.

Tolppanen AM, Pulkkinen L, Herder C, Koenig W, Kolehmainen M,
Lindström J, et al. The genetic variation of the tenomodulin gene (TNMD) is
associated with serum levels of systemic immune mediators--the Finnish
Diabetes Prevention Study. Genet Med. 2008;10(7):536-44. doi:
10.1097GIM.0b013e3181772129. PubMed PMID: 18580688.

334.

Rydén M, Agustsson T, Laurencikiene J, Britton T, Sjölin E, Isaksson B, et al.
Lipolysis--not inflammation, cell death, or lipogenesis--is involved in adipose
tissue loss in cancer cachexia. Cancer. 2008;113(7):1695-704. doi:
10.1002/cncr.23802. PubMed PMID: 18704987.

335.

Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, BirnerGruenberger R, Riederer M, et al. Fat mobilization in adipose tissue is
promoted by adipose triglyceride lipase. Science. 2004;306(5700):1383-6.
doi: 10.1126/science.1100747. PubMed PMID: 15550674.

174

336.

Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, et al. Adipose
triglyceride lipase contributes to cancer-associated cachexia. Science.
2011;333(6039):233-8. doi: 10.1126/science.1198973. PubMed PMID:
21680814.

337.

Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, Rydén M, et al. Enhanced
ZAG production by subcutaneous adipose tissue is linked to weight loss in
gastrointestinal cancer patients. Br J Cancer. 2011;104(3):441-7. doi:
10.1038/sj.bjc.6606083. PubMed PMID: 21245862; PubMed Central PMCID:
PMCPMC3049573.

338.

Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J,
et al. A switch from white to brown fat increases energy expenditure in
cancer-associated cachexia. Cell Metab. 2014;20(3):433-47. doi:
10.1016/j.cmet.2014.06.011. PubMed PMID: 25043816.

339.

Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, et al. Tumourderived PTH-related protein triggers adipose tissue browning and cancer
cachexia. Nature. 2014;513(7516):100-4. doi: 10.1038/nature13528.
PubMed PMID: 25043053; PubMed Central PMCID: PMCPMC4224962.

340.

Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin
Endocrinol Metab. 2004;89(6):2548-56. doi: 10.1210/jc.2004-0395. PubMed
PMID: 15181022.

341.

Kim HJ, Yun J, Kim KH, Kim SH, Lee SC, Bae SB, et al. Pathophysiological
role of hormones and cytokines in cancer cachexia. J Korean Med Sci.
2012;27(2):128-34. doi: 10.3346/jkms.2012.27.2.128. PubMed PMID:
22323858; PubMed Central PMCID: PMCPMC3271284.

342.

Steffens S, Mach F. Adiponectin and adaptive immunity: linking the bridge
from obesity to atherogenesis. Circ Res. 2008;102(2):140-2. doi:
10.1161/CIRCRESAHA.107.170274. PubMed PMID: 18239140.

343.

Stolarczyk E, Vong CT, Perucha E, Jackson I, Cawthorne MA, Wargent ET,
et al. Improved insulin sensitivity despite increased visceral adiposity in mice
deficient for the immune cell transcription factor T-bet. Cell Metab.
2013;17(4):520-33. doi: 10.1016/j.cmet.2013.02.019. PubMed PMID:
23562076; PubMed Central PMCID: PMCPMC3685808.

344.

Red Eagle A, Chawla A. In obesity and weight loss, all roads lead to the
mighty macrophage. J Clin Invest. 2010;120(10):3437-40. doi:
10.1172/JCI44721. PubMed PMID: 20877005; PubMed Central PMCID:
PMCPMC2947244.

175

345.

Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, et al.
Weight loss and lipolysis promote a dynamic immune response in murine
adipose tissue. J Clin Invest. 2010;120(10):3466-79. doi: 10.1172/JCI42845.
PubMed PMID: 20877011; PubMed Central PMCID: PMCPMC2947229.

346.

Mayi TH, Daoudi M, Derudas B, Gross B, Bories G, Wouters K, et al. Human
adipose tissue macrophages display activation of cancer-related pathways. J
Biol Chem. 2012;287(26):21904-13. doi: 10.1074/jbc.M111.315200. PubMed
PMID: 22511784; PubMed Central PMCID: PMCPMC3381151.

347.

Tapiero H, Mathé G, Couvreur P, Tew KD. I. Arginine. Biomed
Pharmacother. 2002;56(9):439-45. PubMed PMID: 12481980.

348.

Witte MB, Barbul A. Arginine physiology and its implication for wound
healing. Wound Repair Regen. 2003;11(6):419-23. PubMed PMID:
14617280.

349.

Engel K, Höhne W, Häberle J. Mutations and polymorphisms in the human
argininosuccinate synthetase (ASS1) gene. Hum Mutat. 2009;30(3):300-7.
doi: 10.1002/humu.20847. PubMed PMID: 19006241.

350.

Kodama Y, Konishi T, Nagaoka Y, Kitai H, Aoki K. Study on Blood Ammonia
in Terminally Ill Cancer Patients. Palliative Care Research. 2015;10(1):16873.

351.

Lockwood AH, Ginsberg MD, Rhoades HM, Gutierrez MT. Cerebral glucose
metabolism after portacaval shunting in the rat. Patterns of metabolism and
implications for the pathogenesis of hepatic encephalopathy. J Clin Invest.
1986;78(1):86-95. doi: 10.1172/JCI112578. PubMed PMID: 3722388;
PubMed Central PMCID: PMCPMC329535.

352.

McKnight JR, Satterfield MC, Jobgen WS, Smith SB, Spencer TE, Meininger
CJ, et al. Beneficial effects of L-arginine on reducing obesity: potential
mechanisms and important implications for human health. Amino Acids.
2010;39(2):349-57. doi: 10.1007/s00726-010-0598-z. PubMed PMID:
20437186.

353.

Zhang J, George AL, Griggs RC, Fouad GT, Roberts J, Kwieciński H, et al.
Mutations in the human skeletal muscle chloride channel gene (CLCN1)
associated with dominant and recessive myotonia congenita. Neurology.
1996;47(4):993-8. PubMed PMID: 8857733.

354.

Howard MF, Murakami Y, Pagnamenta AT, Daumer-Haas C, Fischer B,
Hecht J, et al. Mutations in PGAP3 impair GPI-anchor maturation, causing a

176

subtype of hyperphosphatasia with mental retardation. Am J Hum Genet.
2014;94(2):278-87. doi: 10.1016/j.ajhg.2013.12.012. PubMed PMID:
24439110; PubMed Central PMCID: PMCPMC3928656.
355.

Frigerio JM, Dagorn JC, Iovanna JL. Cloning, sequencing and expression of
the L5, L21, L27a, L28, S5, S9, S10 and S29 human ribosomal protein
mRNAs. Biochim Biophys Acta. 1995;1262(1):64-8. PubMed PMID:
7772601.

356.

Maak S, Jaesert S, Neumann K, Yerle M, von Lengerken G. Isolation of
expressed sequence tags of skeletal muscle of neonatal healthy and splay
leg piglets and mapping by somatic cell hybrid analysis. Anim Genet.
2001;32(5):303-7. PubMed PMID: 11683718.

357.

Yan J, Burman A, Nichols C, Alila L, Showe LC, Showe MK, et al. Detection
of differential gene expression in brown adipose tissue of hibernating arctic
ground squirrels with mouse microarrays. Physiol Genomics.
2006;25(2):346-53. doi: 10.1152/physiolgenomics.00260.2005. PubMed
PMID: 16464973.

358.

Boll M, Daniel H, Gasnier B. The SLC36 family: proton-coupled transporters
for the absorption of selected amino acids from extracellular and intracellular
proteolysis. Pflugers Arch. 2004;447(5):776-9. doi: 10.1007/s00424-0031073-4. PubMed PMID: 12748860.

359.

Dickinson JM, Drummond MJ, Coben JR, Volpi E, Rasmussen BB. Aging
differentially affects human skeletal muscle amino acid transporter
expression when essential amino acids are ingested after exercise. Clin Nutr.
2013;32(2):273-80. doi: 10.1016/j.clnu.2012.07.009. PubMed PMID:
22889597; PubMed Central PMCID: PMCPMC3517689.

360.

Drummond MJ, Fry CS, Glynn EL, Timmerman KL, Dickinson JM, Walker
DK, et al. Skeletal muscle amino acid transporter expression is increased in
young and older adults following resistance exercise. J Appl Physiol (1985).
2011;111(1):135-42. doi: 10.1152/japplphysiol.01408.2010. PubMed PMID:
21527663; PubMed Central PMCID: PMCPMC3137547.

361.

Király R, Demény M, Fésüs L. Protein transamidation by transglutaminase 2
in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS
J. 2011;278(24):4717-39. doi: 10.1111/j.1742-4658.2011.08345.x. PubMed
PMID: 21902809.

362.

Facchiano F, Facchiano A, Facchiano AM. The role of transglutaminase-2
and its substrates in human diseases. Front Biosci. 2006;11:1758-73.
PubMed PMID: 16368554.

177

363.

Mousa A, Cui, Song A, Myneni V, Li J, Melino G, et al. Severe osteopenia,
increased bone marrow adipogenesis, and fibronectin matrix changes in
mice lacking both TG2 and FXIIIA transglutaminases. 2013. doi:
http://www.bone-abstracts.org/ba/0001/ba0001OC4.3.htm.

364.

Nakano Y, Al-Jallad HF, Mousa A, Kaartinen MT. Expression and localization
of plasma transglutaminase factor XIIIA in bone. J Histochem Cytochem.
2007;55(7):675-85. doi: 10.1369/jhc.6A7091.2007. PubMed PMID:
17341477.

365.

Jiang SS, Chen CH, Tseng KY, Tsai FY, Wang MJ, Chang IS, et al. Gene
expression profiling suggests a pathological role of human bone marrowderived mesenchymal stem cells in aging-related skeletal diseases. Aging
(Albany NY). 2011;3(7):672-84. PubMed PMID: 21808097; PubMed Central
PMCID: PMCPMC3181167.

366.

Svensson PA, Jernås M, Sjöholm K, Hoffmann JM, Nilsson BE, Hansson M,
et al. Gene expression in human brown adipose tissue. Int J Mol Med.
2011;27(2):227-32. doi: 10.3892/ijmm.2010.566. PubMed PMID: 21125211.

367.

Schofield JN, Rademacher TW. Structure and expression of the human
glycosylphosphatidylinositol phospholipase D1 (GPLD1) gene. Biochim
Biophys Acta. 2000;1494(1-2):189-94. PubMed PMID: 11072085.

368.

Scallon BJ, Fung WJ, Tsang TC, Li S, Kado-Fong H, Huang KS, et al.
Primary structure and functional activity of a phosphatidylinositol-glycanspecific phospholipase D. Science. 1991;252(5004):446-8. PubMed PMID:
2017684.

369.

Chalasani
N,
Vuppalanchi
R,
Raikwar
NS,
Deeg
MA.
Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty
liver disease: a preliminary study. J Clin Endocrinol Metab. 2006;91(6):227985. doi: 10.1210/jc.2006-0075. PubMed PMID: 16595594.

370.

Kurtz TA, Fineberg NS, Considine RV, Deeg MA. Insulin resistance is
associated with increased serum levels of glycosylphosphatidylinositolspecific phospholipase D. Metabolism. 2004;53(2):138-9. PubMed PMID:
14767861.

371.

Halprin KM, Ohkawara A. The measurement of glutathione in human
epidermis using glutathione reductase. J Invest Dermatol. 1967;48(2):14952. PubMed PMID: 6020678.

178

372.

Juronen E, Tasa G, Uusküla M, Pooga M, Mikelsaar AV. Purification,
characterization and tissue distribution of human class theta glutathione Stransferase T1-1. Biochem Mol Biol Int. 1996;39(1):21-9. PubMed PMID:
8799324.

373.

Li X, Thomason PA, Withers DJ, Scott J. Bio-informatics analysis of a gene
co-expression module in adipose tissue containing the diet-responsive gene
Nnat. BMC Syst Biol. 2010;4:175. doi: 10.1186/1752-0509-4-175. PubMed
PMID: 21187013; PubMed Central PMCID: PMCPMC3022651.

374.

Wang D, Wang N, Li N, Li H. Identification of differentially expressed proteins
in adipose tissue of divergently selected broilers. Poult Sci.
2009;88(11):2285-92. doi: 10.3382/ps.2009-00190. PubMed PMID:
19834077.

375.

Oliver CJ, Terry-Lorenzo RT, Elliott E, Bloomer WA, Li S, Brautigan DL, et al.
Targeting protein phosphatase 1 (PP1) to the actin cytoskeleton: the
neurabin I/PP1 complex regulates cell morphology. Mol Cell Biol.
2002;22(13):4690-701. PubMed PMID: 12052877; PubMed Central PMCID:
PMCPMC133892.

376.

Nakabayashi K, Makino S, Minagawa S, Smith AC, Bamforth JS, Stanier P,
et al. Genomic imprinting of PPP1R9A encoding neurabin I in skeletal
muscle and extra-embryonic tissues. J Med Genet. 2004;41(8):601-8. doi:
10.1136/jmg.2003.014142. PubMed PMID: 15286155; PubMed Central
PMCID: PMCPMC1735868.

377.

Nakanishi H, Obaishi H, Satoh A, Wada M, Mandai K, Satoh K, et al.
Neurabin: a novel neural tissue-specific actin filament-binding protein
involved in neurite formation. J Cell Biol. 1997;139(4):951-61. PubMed
PMID: 9362513; PubMed Central PMCID: PMCPMC2139968.

378.

Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, et al.
Transcriptional changes in Huntington disease identified using genome-wide
expression profiling and cross-platform analysis. Hum Mol Genet.
2010;19(8):1438-52. doi: 10.1093/hmg/ddq018. PubMed PMID: 20089533;
PubMed Central PMCID: PMCPMC2846159.

379.

Park SW, Kim J, Park JL, Ko JY, Im I, Do HS, et al. Variable allelic
expression of imprinted genes in human pluripotent stem cells during
differentiation into specialized cell types in vitro. Biochem Biophys Res
Commun. 2014;446(2):493-8. doi: 10.1016/j.bbrc.2014.02.141. PubMed
PMID: 24613840.

179

380.

Mizuno Y, Thompson TG, Guyon JR, Lidov HG, Brosius M, Imamura M, et
al. Desmuslin, an intermediate filament protein that interacts with alpha dystrobrevin and desmin. Proc Natl Acad Sci U S A. 2001;98(11):6156-61.
doi: 10.1073/pnas.111153298. PubMed PMID: 11353857; PubMed Central
PMCID: PMCPMC33438.

381.

García-Pelagio KP, Muriel J, O'Neill A, Desmond PF, Lovering RM, Lund L,
et al. Myopathic changes in murine skeletal muscle lacking synemin. Am J
Physiol Cell Physiol. 2015;308(6):C448-62. doi: 10.1152/ajpcell.00331.2014.
PubMed PMID: 25567810; PubMed Central PMCID: PMCPMC4360028.

382.

Olivé M, Goldfarb L, Dagvadorj A, Sambuughin N, Paulin D, Li Z, et al.
Expression of the intermediate filament protein synemin in myofibrillar
myopathies and other muscle diseases. Acta Neuropathol. 2003;106(1):1-7.
doi: 10.1007/s00401-003-0695-0. PubMed PMID: 12669240.

383.

Li Z, Parlakian A, Coletti D, Alonso-Martin S, Hourdé C, Joanne P, et al.
Synemin acts as a regulator of signalling molecules during skeletal muscle
hypertrophy. J Cell Sci. 2014;127(21):4589-601. doi: 10.1242/jcs.143164.
PubMed PMID: 25179606.

384.

Sun N, Huiatt TW, Paulin D, Li Z, Robson RM. Synemin interacts with the
LIM domain protein zyxin and is essential for cell adhesion and migration.
Exp Cell Res. 2010;316(3):491-505. doi: 10.1016/j.yexcr.2009.10.015.
PubMed PMID: 19853601.

385.

Bezakova G, Ruegg MA. New insights into the roles of agrin. Nat Rev Mol
Cell Biol. 2003;4(4):295-308. doi: 10.1038/nrm1074. PubMed PMID:
12671652.

386.

Zoeller JJ, McQuillan A, Whitelock J, Ho SY, Iozzo RV. A central function for
perlecan in skeletal muscle and cardiovascular development. J Cell Biol.
2008;181(2):381-94. doi: 10.1083/jcb.200708022. PubMed PMID: 18426981;
PubMed Central PMCID: PMCPMC2315682.

387.

Keller P, Vollaard NB, Gustafsson T, Gallagher IJ, Sundberg CJ, Rankinen
T, et al. A transcriptional map of the impact of endurance exercise training on
skeletal muscle phenotype. J Appl Physiol (1985). 2011;110(1):46-59. doi:
10.1152/japplphysiol.00634.2010. PubMed PMID: 20930125; PubMed
Central PMCID: PMCPMC3253010.

388.

Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG.
Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by
mutations in the desmin gene. N Engl J Med. 2000;342(11):770-80. doi:
10.1056/NEJM200003163421104. PubMed PMID: 10717012.

180

389.

Horowits R, Podolsky RJ. The positional stability of thick filaments in
activated skeletal muscle depends on sarcomere length: evidence for the
role of titin filaments. J Cell Biol. 1987;105(5):2217-23. PubMed PMID:
3680378; PubMed Central PMCID: PMCPMC2114850.

390.

Gunning PW, Schevzov G, Kee AJ, Hardeman EC. Tropomyosin isoforms:
divining rods for actin cytoskeleton function. Trends Cell Biol.
2005;15(6):333-41. doi: 10.1016/j.tcb.2005.04.007. PubMed PMID:
15953552.

391.

F G, H F, HB G, D N, JD D, JC J, et al. Current Concepts in the Role of
Mechanosensing in the Regulation of Cardiac Contractile Function. Austin
Journal of Clinical Medicine. 2014;1(3):11015.

392.

JOSEPH C. Human Anatomy AND Physiology: A Functional Approach:
Kendall Hunt Publishing; 2011 2011-06-28. 1286 p.

393.

Joyner MJ, Limberg JK. Hitting the wall: glycogen, glucose and the carotid
bodies.
J
Physiol.
2014;592(Pt
20):4413-4.
doi:
10.1113/jphysiol.2014.281790. PubMed PMID: 25320155; PubMed Central
PMCID: PMCPMC4287734.

394.

Rapoport BI. Metabolic factors limiting performance in marathon runners.
PLoS
Comput
Biol.
2010;6(10):e1000960.
doi:
10.1371/journal.pcbi.1000960. PubMed PMID: 20975938; PubMed Central
PMCID: PMCPMC2958805.

395.

McMurry J, Mary E Castellion. Fundamentals of General, Organic and
Biological Chemistry, Media Update Edition [4th Edition]. 4TH EDITION ed:
Prentice Hall; 2005.

396.

Rich PR. The molecular machinery of Keilin's respiratory chain. Biochem Soc
Trans. 2003;31(Pt 6):1095-105. doi: 10.1042/. PubMed PMID: 14641005.

397.

Albert JD, Legaspi A, Horowitz GD, Tracey KJ, Brennan MF, Lowry SF.
Peripheral tissue metabolism in man with varied disease states and similar
weight loss. J Surg Res. 1986;40(4):374-81. PubMed PMID: 3702391.

398.

Keller MA, Turchyn AV, Ralser M. Non-enzymatic glycolysis and pentose
phosphate pathway-like reactions in a plausible Archean ocean. Mol Syst
Biol. 2014;10:725. PubMed PMID: 24771084; PubMed Central PMCID:
PMCPMC4023395.

181

399.

King MW. Pentose Phosphate Pathway 2015. Available from:
http://themedicalbiochemistrypage.org/pentose-phosphate-pathway.php.

400.

Andrews R. All About Appetite Regulation, Part 1. Precision Nutrition. 2015.

